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Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced as 
by-products of normal metabolic processes in all aerobic organisms and play an 
important role in cellular signaling processes when produced at low levels. The 
antioxidant defense systems in our body guard the cells and tissues against these 
species in physiological conditions. But when there is an imbalance between the 
generation of ROS/RNS and the ability of antioxidant defense systems to remove 
them, oxidative/nitrosative damage to cellular constituents (DNA, proteins, lipids, and 
sugars) takes place, which is referred as oxidative/nitrosative stress. It is increasingly 
proposed that ROS/RNS playa key role in the development of various human 
diseases, especially as: evidence. is growing that antioxidants may prevent or delay the 
onset of these diseases. One of - the most important ROSIRNS is peroxynitrite, 
ONOO -, which is formed as' result of a major -and aggressive reaction of nitric oxide 
(NO) with superoxide( 0; ;):  
Peroxynitrite is a highly reactive'species with a half-life of approximately 1 sec. It 
may be formed under pathophysiological conditions, where both NO' and OZ - are 
produced at high rates by phagocytic cells such as macrophages, and that ONOO-is  a 
potent oxidant and nitrating agent with the potential to destroy critical cellular 
components. Peroxynitrite can alter a variety of biomolecules but possesses high 
affinity for tyrosine residues in proteins, and 3-nitrotyrosine is considered as a 
relatively specific marker of peroxynitrite-mediated damage to proteins. Reaction of 
peroxynitrite with tyrosine is a covalent modification that results in attachment of a 
nitro (—NO2) group on the aromatic ring of tyrosine residues. Nitrotyrosine formation 
is considered as a biomarker of nitrosative stress. More than 60 human disorders are 
now known to be associated with protein nitration. Indeed, the formation of protein 3-
nitrotyrosine in vivo has been shown in a number of inflammatory conditions in 
human and experimental animals. Increase in tyrosine nitration has also been 
observed in various cancers. Being an oxidizing agent, peroxynitrite also causes 
protein oxidation. The most prominent marker of protein oxidation is increase in the 
carbonyl content of proteins which is the outcome of oxidative modifications of the 
side chains of lysine, proline, arginine and threonine. Increase in protein carbonyls 
has been observed in many human diseases like diabetes, Alzheimer's, systemic lupus 
erythematosus, rheumatoid arthritis, sepsis, chronic renal failure, cancer, etc. A 
number of biological macromolecules such as proteins, phospholipids, and DNA have 
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been shown to react directly with peroxynitrite resulting in formation of various 
covalent adducts, which in turn lead to the propagation and amplification of human 
cancer. The role of peroxynitrite as a cytotoxic and mutagenic agent has been shown 
in a number of bacterial and mammalian cell culture systems. 
Human serum albumin (HSA) is the most abundant protein found in human 
plasma. HSA carries out several clearly defined physiological functions like 
maintenance of colloidal osmotic pressure, free radical scavenging, binding and 
transport of important solutes, etc. Several studies have shown that HSA is quite 
vulnerable to modification by reactive oxygen species and an elevated level of 
oxidized albumin is found in various diseases. It has been shown that peroxynitrite 
preferentially reacts with the cysteine residue of HSA and causes thiol oxidation. 
HSA is continuously exposed to oxidative stress conditions due to its abundance in 
the plasma, leading to the conformational and functional alterations of the protein 
molecule. The altered HSA may contribute to the progression of many diseases. 
Globally cancer is considered as a second ranked cause of death led only by heart 
disease. There are different causes of cancer but free radicals have emerged as one of 
the most prominent reason that can derive carcinogenesis by altering targets and 
pathways that are crucial to normal tissue homeostasis. Certain key events carried out 
by free radicals that can increase cancer risk are mutation in cancer related genes, post 
translational modifications in proteins (oxidation, nitration, acetylation, 
phosphorylation), lipid peroxydation, etc. Several experiments have revealed the role 
of free radicals in protein modifications related to carcinogenesis. 
In the present study, laboratory synthesized peroxynitrite was used to modify 
commercially available human serum albumin (HSA) and the peroxynitrite induced 
structural perturbations were analyzed by a range of physicochemical techniques Iike 
W-VIS, fluorescence, circular dichrosim (CD), FTIR spectroscopy, DSC and DLS 
measurements, HPLC and MALDI-MS analysis. Carbonyl content of native and 
peroxynitrite-modified HSA was also estimated. Besides, SOS-PAGE analysis was 
done to visualize modification in HSA. Native and peroxynitrite-modified HSA were 
also used to induce antibodies in experimental animals. The induced antibodies were 
characterized by direct binding and inhibition ELISA to detect their specificities. 
Band shift assay was performed to confirm the antigen binding specificities of these 
antibodies. To investigate the possibility of peroxynitrite-modified HSA in cancer, 
sera from patients were evaluated for their binding to native and peroxynitrite- 
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modified HSA. Direct binding and inhibition ELISA of autoantibodies and purified 
IgG of the cancer patients were probed to look into the possible presence of 
peroxynitrite-modified HSA in cancer patients. Finally, isolated HSA from normal 
healthy individuals and from cancer patients were examined for their binding with 
experimentally induced anti-peroxynitrite-modified HSA antibodies. 
Peroxynitrite treatment of HSA resulted in structural perturbations as shown by 
spectroscopic analysis. The absorbance spectroscopy result showed hyperchromicity 
in peroxynitrite-modified HSA as compared to the unmodified form, which can be 
attributed to .peroxynitrite-induced denaturation due to oxidation and nitration of 
native HSA. Nitration in peroxynitrite-modified HSA was confirmed by the 
generation of yellow colour which showed absorbance peak at 420 nm, a 
characteristic of 3-nitrotyrosine. Further confirmation of the formation of 
3-nitrotyrosine in peroxynitrite-modified HSA was evident by HPLC and MALDI-
MS analysis. SDS-PAGE showed thickening of bands in the case of peroxynitrite-
modified HSA, compared to the native protein, which may be due to the 
intramolecular cross-linking in the modified protein, leading to abnormal migration of 
the protein molecules. The cross-linking may be due to the interactions of one tyrosyl 
radical with another tyrosyl radical, generating O,O'-dityrosine covalent cross-links. 
Fluorescence spectra further confirmed the formation of dityrosine in peroxynitrite-
modified HSA. Carbonyl content is considered as a hallmark of oxidative damage to 
proteins. Almost seven fold increase in the carbonyl content of modified HSA 
suggested that peroxynitrite induced oxidation of HSA may be responsible for 
alterations in its structure and biological properties and proves that peroxynitrite is a 
strong oxidizing agent. Loss in fluorescence intensity of peroxynitrite-modified HSA, 
compared to the native protein, was observed upon excitation at 275 nm, a 
characteristic excitation wavelength for tyrosine. The loss could be ascribed to the 
destruction of tyrosine residues and/or modification of the tyrosine microenvironment 
upon peroxynitrite modification. Observed loss in fluorescence intensity, in ANS-
binding experiment, indicated that native HSA possesses a number of hydrophobic 
patches on its surface which were disrupted upon treatment with peroxynitrite. Near 
and far UV-CD spectroscopy clearly indicated structural alterations in HSA when 
subjected to peroxynitrite insult. Secondary structural perturbation was further 
confirmed by FTIR spectroscopy which showed a shift in amide I and amide II bands 
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in the peroxynitrite-modified HSA when compared with its native analogue. 
Thereafter, dynamic light scattering (DLS) measurement was done to measure the 
hydrodynamic radii (Rh) of native and peroxynitrite-modified HSA which indicated 
increased Rh value of modified HSA pointing towards unfolding of HSA molecule 
driven by the structural loss upon peroxynitrite treatment. Differential scanning 
calorimetry (DSC) analysis also indicated that the structure of HSA was destabilized 
after peroxynitrite treatment which is in agreement with the CD analysis and the 
values of AH„n/AHcal ratio showed lower stability of peroxynitrite-modified HSA 
compared to the native counterpart. 
To know the level of immunogenicity, antibodies against native and peroxynitrite-
modified HSA were induced in experimental animals. Various binding studies were 
done to know the titre and specificity of the induced antibodies. Peroxynitrite-
modified HSA was an extremely potent antigen that induced high titre and highly 
specific antibodies in experimental animal, compared to the native counterpart. The 
induced antibodies were polyspecific in nature as they, cross reacted with various 
peroxynitrite-modified conformers of different proteins and amino acids. The specific 
antigen-antibody interaction was further confirmed by band-shift assay which showed 
retarded mobility of immunogen-antibody complex. 
Thereafter, sera of the patients having cancer of different tissue origin (Iung, head 
& neck, breast, liver, urinary bladder, cervix, gall bladder and prostate) were probed 
keeping in mind the possible role of peroxynitrite-modified HSA in relation to 
carcinogenesis. This was done by screening the presence of autoantibodies in cancer 
patients that were reactive to native and peroxynitrite-modified HSA. The results 
clearly indicated that in almost all cases (but maximally in the case of lung cancer) the 
naturally occurring cancer autoantibodies preferentially recognized the epitopes 
present on peroxynitrite-modified HSA, compared to the native analog. A 
significantly higher level of nitrated proteins in serum of the lung cancer patients has 
been observed by some researchers indicating the presence of oxidative and 
nitrosative stress in those patients. Strength to the result was further provided by band 
shift assay which again showed the preferential recognition of peroxynitrite-modified 
HSA over native counterpart by the purified cancer IgG. The result indicated 
decreased intensity of free antigen (peroxynitrite-modified HSA) due to its greater 
involvement in the formation of high molecular weight species. Moreover, isolated 
HSA from the blood of cancer patients showed enhanced binding to the 
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experimentally induced anti-peroxynitrite-modified HSA IgG, indicating the 
contribution-of neo-epitopes in the generation of autoantibodies in cancer patients. In 
contrast to this, less binding of HSA, isolated from healthy individuals, to anti-
peroxynitrite-modified HSA IgG was observed. Appreciably higher binding of in 
vitro modified HSA and HSA isolated from cancer patients with experimentally 
induced anti-peroxynitrite-modified HSA IgG points towards the possible fact of 
epitope sharing between in vitro peroxynitrite-modified HSA and the HSA isolated 
from cancer patients. Thus, it can be said that exposure of HSA to peroxynitrite in 
vivo creates neo-epitopes on HSA that are recognized as non-self by the immune 
system and hence, as an antigen for autoantibody production in cancer patients. 
In view of the above findings, the results clearly demonstrate that in vitro 
modification of HSA with peroxynitrite brings about biophysical, biochemical and 
immunological alterations in this protein, which was confirmed by the generation of 
highly specific antibodies in experimental animal. Also, the results suggest that 
structurally perturbed HSA exhibits neo-epitopes which are not ordinarily present on 
the native molecule. These epitopes project the physiologic protein as `alien' for the 
immune system leading to antibody generation in cancer patients. The present study 
revealed greater binding of circulating cancer autoantibodies with peroxynitrite-
modified HSA as compared to its native form. Furthermore, drop in the antioxidant 
property of the HSA molecule, as indicated by the free radical induced hemolysis test, 
confirms that not only the structural loss but functional alterations too occur when the 
native protein gets exposed to the damaging effects of peroxynitrite. Therefore, it may 
also be proposed that reduction in the antioxidant property of peroxynitrite-modified 
HSA greatly hampers the physiological concentration of the unaltered native HSA 
which in turn leads to a decrease in the overall antioxidant level of the blood plasma. 
As it represents major and predominant circulating antioxidant in plasma, a decline in 
this function may allow different free radicals to easily damage other important 
biomolecules of the system, like DNA and some proteins, and hence affects the 
onset/progression to cancer. 
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Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced as 
by-products of normal metabolic processes in all aerobic organisms and play an 
important role in cellular signaling processes when produced at Iow levels. The 
antioxidant defense systems in our body guard the cells and tissues against these 
species in physiological conditions. But when there is an imbalance between the 
generation of ROS/RNS and the ability of antioxidant defense systems to remove 
them, oxidative/nitrosative damage to cellular constituents (DNA, proteins, lipids, and 
sugars) takes place, which is referred as oxidative/nitrosative stress. It is increasingly 
proposed that ROS/RNS play a key role in the development of various human 
diseases, especially as evidence is growing that antioxidants may prevent or delay the 
onset of these diseases. One of the most important ROS/RNS is peroxynitrite, 
ONOO-, which is formed as result of a major and aggressive reaction of nitric oxide 
(NO') with superoxide (o ). 
Peroxynitrite is a highly reactive species with a half-life of approximately 1 sec. It 
may be formed under pathophysiological conditions, where both NO' and Oz- are 
produced at high rates by phagocytic cells such as macrophages, and that ONOO-is a 
potent oxidant and nitrating agent with the potential to destroy critical cellular 
components. Peroxynitrite can alter a variety of biomolecules but possesses high 
affinity for tyrosine residues in proteins, and 3-nitrotyrosine is considered as a 
relatively specific marker of peroxynitrite-mediated damage to proteins. Reaction of 
peroxynitrite with tyrosine is a covalent modification that results in attachment of a 
nitro (—NO2) group on the aromatic ring of tyrosine residues. Nitrotyrosine formation 
is considered as a biomarker of nitrosative stress. More than 60 human disorders are 
now known to be associated with protein nitration. Indeed, the formation of protein 3-
nitrotyrosine in vivo has been shown in a number of inflammatory conditions in 
human and experimental animals. Increase in tyrosine nitration has also been 
observed in various cancers. Being an oxidizing agent, peroxynitrite also causes 
protein oxidation. The most prominent marker of protein oxidation is increase in the 
carbonyl content of proteins which is the outcome of oxidative modifications of the 
side chains of lysine, proline, arginine and threonine. Increase in protein carbonyls 
has been observed in many human diseases like diabetes, Alzheimer's, systemic lupus 
erythematosus, rheumatoid arthritis, sepsis, chronic renal failure, cancer, etc. A 
number of biological macromolecules such as proteins, phospholipids, and DNA have 
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been shown to react directly with peroxynitrite resulting in formation of various 
covalent adducts, which in turn lead to the propagation and amplification of human 
cancer. The role of peroxynitrite as a cytotoxic and mutagenic agent has been shown 
in a number of bacterial and mammalian cell culture systems. 
Human serum albumin (HSA) is the most abundant protein found in human 
plasma. HSA carries out several clearly defined physiological functions like 
maintenance of colloidal osmotic pressure, free radical scavenging, binding and 
transport of important solutes, etc. Several studies have shown that HSA is quite 
vulnerable to modification by reactive oxygen species and an elevated level of 
oxidized albumin is found in various diseases. It has been shown that peroxynitrite 
preferentially reacts with the cysteine residue of HSA and causes thiol oxidation. 
HSA is continuously exposed to oxidative stress conditions due to its abundance in 
the plasma, leading to the conformational and functional alterations of the protein 
molecule. The altered HSA may contribute to the progression of many diseases. 
Globally cancer is considered as a second ranked cause of death led only by heart 
disease. There are different causes of cancer but free radicals have emerged as one of 
the most prominent reason that can derive carcinogenesis by altering targets and 
pathways that are crucial to normal tissue homeostasis. Certain key events carried out 
by free radicals that can increase cancer risk are mutation in cancer related genes, post 
translational modifications in proteins (oxidation, nitration, acetylation, 
phosphorylation), lipid peroxydation, etc. Several experiments have revealed the role 
of free radicals in protein modifications related to carcinogenesis. 
In the present study, laboratory synthesized peroxynitrite was used to modify 
commercially available human serum albumin (HSA) and the peroxynitrite induced 
structural perturbations were analyzed by a range of physicochemical techniques like 
UV-VIS, fluorescence, circular dichrosim (CD), FTIR spectroscopy, DSC and DLS 
measurements, HPLC and MALDI-MS analysis. Carbonyl content of native and 
peroxynitrite-modified HSA was also estimated. Besides, SDS-PAGE analysis was 
done to visualize modification in HSA. Native and peroxynitrite-modified HSA were 
also used to induce antibodies in experimental animals. The induced antibodies were 
characterized by direct binding and inhibition ELISA to detect their specificities. 
Band shift assay was performed to confirm the antigen binding specificities of these 
antibodies. To investigate the possibility of peroxynitrite-modified HSA in cancer, 
sera from patients were evaluated for their binding to native and peroxynitrite- 
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modified HSA. Direct binding and inhibition ELISA of autoantibodies and purified 
IgG of the cancer patients were probed to look into the possible presence of 
peroxynitrite-modified HSA in cancer patients. Finally, isolated HSA from normal 
healthy individuals and from cancer patients were examined for their binding with 
experimentally induced anti-peroxynitrite-modified HSA antibodies. 
Peroxynitrite treatment of HSA resulted in structural perturbations as shown by 
spectroscopic analysis. The absorbance spectroscopy result showed hyperchromicity 
in peroxynitrite-modified HSA as compared to the unmodified form, which can be 
attributed to peroxynitrite-induced denaturation due to oxidation and nitration of 
native HSA. Nitration in peroxynitrite-modified HSA was confirmed by the 
generation of yellow colour which showed absorbance peak at 420 rim, a 
characteristic of 3-nitrotyrosine. - Further confirmation of the formation of 
3-nitrotyrosine in peroxynitrite-modified HSA was evident by HPLC and MALDI-
MS analysis. SDS-PAGE showed thickening of bands in the case of peroxynitrite-
modified HSA, compared to the native protein, which may be due to the 
intramolecular cross-linking in the modified protein, leading to abnormal migration of 
the protein molecules. The cross-linking may be due to the interactions of one tyrosyi-
radical with another tyrosyl radical, generating O,O'-dityrosine covalent cross-links. 
Fluorescence spectra further confirmed the formation of dityrosine in peroxynitrite-
modified HSA. Carbonyl content is considered as a hallmark of oxidative damage to 
proteins. Almost seven fold increase in the carbonyl content of modified HSA 
suggested that peroxynitrite induced oxidation of HSA may be responsible for 
alterations in its structure and biological properties and proves that peroxynitrite is a 
strong oxidizing agent. Loss in fluorescence intensity of peroxynitrite-modified HSA, 
compared to the native protein, was observed upon excitation at 275 nm, a 
characteristic excitation wavelength for tyrosine. The loss could be ascribed to the 
destruction of tyrosine residues and/or modification of the tyrosine microenvironment 
upon peroxynitrite modification. Observed loss in fluorescence intensity, in ANS- 
binding experiment, indicated that native HSA possesses a number of hydrophobic 
patches on its surface which were disrupted upon treatment with peroxynitrite. Near 
and far UV-CD spectroscopy clearly indicated structural alterations in HSA when 
subjected to peroxynitrite insult. Secondary structural perturbation was further 
confirmed by FTIR spectroscopy which showed a shift in amide I and amide II bands 
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in the peroxynitrite-modified HSA when compared with its native analogue. 
Thereafter, dynamic light scattering (DLS) measurement was done to measure the 
hydrodynamic radii (Rh) of native and peroxynitrite-modified HSA which indicated 
increased Rh value of modified HSA pointing towards unfolding of HSA molecule 
driven by the structural loss upon peroxynitrite treatment. Differential scanning 
calorimetry (DSC) analysis also indicated that the structure of HSA was destabilized 
after peroxynitrite treatment which is in agreement with the CD analysis and the 
values of AHvH/kcal ratio showed lower stability of peroxynitrite-modified HSA 
compared to the native counterpart. 
To know the level of immunogenicity, antibodies against native and peroxynitrite-
modified HSA were induced in experimental animals. Various binding studies were 
done to know the titre and specificity of the induced antibodies. Peroxynitrite-
modified HSA was an extremely potent antigen that induced high titre and highly 
specific antibodies in experimental animal, compared to the native counterpart. The 
induced antibodies were polyspecific in nature as they cross reacted with various 
peroxynitrite-modified conformers of different proteins and amino acids. The specific 
antigen-antibody interaction was further confirmed by band-shift assay which showed 
retarded mobility of immunogen-antibody complex. 
Thereafter, sera of the patients having cancer of different tissue origin (lung, head 
& neck, breast, liver, urinary bladder, cervix, gall bladder and prostate) were probed 
keeping in mind the possible role of peroxynitrite-modified HSA in relation to 
carcinogenesis. This was done by screening the presence of autoantibodies in cancer 
patients that were reactive to native and peroxynitrite-modified HSA. The results 
clearly indicated that in almost all cases (but maximally in the case of lung cancer) the 
naturally occurring cancer autoantibodies preferentially recognized the epitopes 
present on peroxynitrite-modified HSA, compared to the native analog. A 
significantly higher level of nitrated proteins in serum of the lung cancer patients has 
been observed by some researchers indicating the presence of oxidative and 
nitrosative stress in those patients. Strength to the result was further provided by band 
shift assay which again showed the preferential recognition of peroxynitrite-modified 
HSA over native counterpart by the purified cancer IgG. The result indicated 
decreased intensity of free antigen (peroxynitrite-modified HSA) due to its greater 
involvement in the formation of high molecular weight species. Moreover, isolated 
HSA from the blood of cancer patients showed enhanced binding to the 
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experimentally induced anti-peroxynitrite-modified HSA IgG, indicating the 
contribution of neo-epitopes in the generation of autoantibodies in cancer patients. In 
contrast to this, less binding of HSA, isolated from healthy individuals, to anti-
peroxynitrite-modified HSA IgG was observed. Appreciably higher binding of in 
vitro modified HSA and HSA isolated from cancer patients with experimentally 
induced anti-peroxynitrite-modified HSA IgG points towards the possible fact of 
epitope sharing between in vitro peroxynitrite-modified HSA and the HSA isolated 
from cancer patients. Thus, it can be said that exposure of HSA to peroxynitrite in 
vivo creates neo-epitopes on HSA that are recognized as non-self by the immune 
system and hence, as an antigen for autoantibody production in cancer patients. 
In view of the above findings, the results clearly demonstrate that in vitro 
modification of HSA with peroxynitrite brings about biophysical, biochemical and 
immunological alterations in this protein, which was confirmed by the generation of 
highly specific antibodies in experimental animal. Also, the results suggest that 
structurally perturbed HSA exhibits neo-epitopes which are not ordinarily present on 
he native molecule. These epitopes project the physiologic protein as alien' for the 
mmune system leading to antibody generation in cancer patients. The present study' 
vealed greater binding of circulating cancer autoantibodies with peroxynitrite-
Ddified HSA as compared to its native form. Furthermore, drop in the antioxidant 
onerty of the HSA molecule, as indicated by the free radical induced hemolysis test, 
firms that not only the structural loss but functional alterations too occur when the 
-re protein gets exposed to the damaging effects of peroxynitrite. Therefore, it may 
be proposed that reduction in the antioxidant property of peroxynitrite-modified 
greatly hampers the physiological concentration of the unaltered native HSA 
h in turn leads to a decrease in the overall antioxidant level of the blood plasma. 
represents major and predominant circulating antioxidant in plasma, a decline in 
function may allow different free radicals to easily damage other important 
olecules of the system, like DNA and some proteins, and hence affects the 
;/progression to cancer. 
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The human serum albumin has several important physiological and pharmacological 
functions. It transports metals, fatty acids, cholesterol, bile pigments, and drugs. 
Therefore, it is a multifunctional transport protein and a key element in the regulation 
of osmotic pressure and distribution of fluid between different compartments. The 
damaging role of reactive oxygen species and reactive nitrogen species in different 
biomolecules and contribution of these damaged molecules in different diseases are 
well established. Therefore, it is a thought of interest to investigate the destructive 
role of peroxynitrite in human serum albumin and its contribution in progression to 
cancer. 
Human serum albumin 
Human serum albumin (HSA) is the most abundant, nonglycosylated and 
negatively charged protein found in human plasma. It is a heart-shaped, 66 kDa single 
polypeptide and has 585 amino acid residues with 18 tyro sines, 6 methionines, one 
tryptophan (trp 214), 59 lysine, 17 disulfide bridges, and only one free cysteine 
(Cys34) which does not participate in a disulfide linkage with any external ligand. 
HSA carries out several clearly defined physiological functions like free radical 
scavenging, maintenance of colloidal osmotic pressure, binding and transport of 
important solutes, etc (Margarson and Soni, 1998). The disulphide pairings is 
predicted in the primary structure of HSA (Brown et al., 1989). In normal conditions, 
the half-life of HSA is about 20 days and its plasma concentration represents 
equilibrium not only between its synthesis in the liver and its catabolism, but also its 
transcapillary escape (Roche, et. al., 2008). 
The first crystal structure of HSA at low resolution was reported by Carter and 
co-workers in 1989 (Carter et al„ 1989; Carter and He, 1990), and its refined structure 
at 2.8 A resolution was published by the same group (He and Carter, 1992). The 
primary, secondary and tertiary structures of HSA have been well characterized. HSA 
is a helical protein with turns and extended loops, and resembles a heart shape, with 
approximate dimensions of 80x80x30 A (Fig. 1). It consists of three domains, I 
(residues 1-195), II (residues 196-383) and III (residues 384-585), which are not only 
topologically identical, as predicted from amino acid sequence comparison, but also 
very similar in three dimensional structure (Sugio et. al., 1999). It has been said from 
physicochemical studies that HSA is a flexible protein that easily changes its 
molecular shape mainly due to the relative motions of its domain structures (Carter 
1 
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Fig. 1. The structure of HSA with domains and subdomain labeled. The protein 
secondary structure is shown schematically with the sub-domains colour-
coded as follows: IA, pink; IB — light pink; IIA, green; IIB — light-green; 
IIIA, blue; IIIB — light blue; this colour scheme is maintained throughout. 
Source: Mendez, D.L., Jensen, R.A., McErloy, L.A., Pena, J.M. and Esquerra, R.M. 
(2005) Arch. Biochem. biophy. 444: 92-99. 
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and Ho, 1994). 
Functions of human serum albumin 
A large proportion of total serum antioxidant properties can be attributed to 
albumin. Previous works have shown that more than 70% of the free radical-trapping 
activity of serum is due to HSA as assayed using the free radical-induced hemolysis 
test (Bourdon and Blache, 2001). An indirect antioxidant activity of HSA comes from 
its ability to transport bilirubin, which binds with high affinity to the molecule at 
Lys240 (Jacobsen, 1978). Such HSA-bound bilirubin has been shown to act as an 
inhibitor of lipid peroxidation (Neuzil and Stocker, 1993). HSA concentrations could 
be found enhanced in sites of inflammation, for the protein to exert its multiple 
antioxidant properties (Halliwell, 1988). The physiological concentration of HSA in a 
healthy individual is 35-50 g/l. One of the most important functions of HSA is its 
ability to maintain osmotic pressure in the circulatory system (Peters, 1996). 
Transportation of a broad spectrum of molecules throughout the body is another 
important function of this macromolecule. These comprise inorganic cationic metals 
such as Cue+ and Zn2+, organic anions, metabolites, amino acids, many drug 
compounds and most prominently hydrophobic molecules like bilirubin, heroin and 
fatty. acids. Therefore, it is also called "sponge" or a "tramp steamer" of the 
circulation (Peters, 1996). The highly flexible and three domains structure of HSA 
makes this protein able to accommodate a wide range of molecules (Weber, 1975). 
While definite binding sites, known as Sudlow's site I and II, are accountable for the 
binding of most drugs, the fatty acid binding sites are scattered throughout the protein 
and engage all six sub domains, (Sudlow et. al., 1975). The reason of being an 
effective plasma buffer can be understood by its abundance in the plasma and 
presence of many charged residues on it (Doweiko and Nompleggi, 1991). 
HSA antigenicity 
A substance that induces a specific immune response is usually called an antigen; 
it is more appropriately called immunogen. Antigenicity is the ability of a molecule to 
bind specifically to the binding sites or paratopes of certain immunoglobulin 
molecules. Although all molecules that have the property of immunogenicity also 
have the property of antigenicity, but the reverse is not true. Enzymatic hydrolysis of 
HSA has shown that the protein possesses several antigenic sites with distinct 
specificities. Therefore, HSA can be considered as a good antigen. Enzymatic 
3 
digestion and cyanogen bromide (CNBr) degradation methods have been used to 
isolate different antigenic sites of HSA (Lapresle and Doyen, 1975; Doyen and 
Lapresle, 1979). So far thirteen epitopes on HSA molecule have been recognized 
(Doyen et. al., 1985), mainly due to the advent of monoclonal antibodies and 
monovalent Fab fragments. It again proves that the HSA molecule surface is antigenic. 
Free radicals -  
A free radical is an atom or group of atoms that has an unpaired electron. They are 
extremely reactive to biological molecules and will damage them. Free radicals are 
omnipresent in our body and are generated by normal physiological processes, 
including aerobic metabolism and inflammatory responses, to eradicate invading 
pathogenic microorganisms. A number of defenses have evolved in the body, both to 
protect our cells from radicals—such as antioxidant scavengers and enzymes—and to 
repair DNA damage for the reason that free radicals can also inflict cellular damage. 
An inflammatory response is initiated in infectious and non-infectious generation of 
chronic injury and irritations (Coussens and Werb, 2002; Nathan, 2002). Bioactive 
peptides from neurons, cytokines or receptor molecules constitute `Go' signals that 
sense microbes which lead to the employment of the mast cells and leukocytes to the 
injured site. Furthermore, `respiratory burst' takes place which is a subsequent release 
of free radicals from Ieukocytes, including activated macrophages. Thus, free radicals 
symbolize an important arm of host defense against a range of pathogens (Zahrt and 
Deretic, 2002). Inflammation leads to the overproduction of free radicals to a break in 
immune tolerance, increased tissue damage and altered enzyme function. Reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) are produced as by-
products of normal metabolic processes in all aerobic organisms and play an 
important role in cellular signaling processes when produced at low levels. The 
antioxidant defense systems in our body guard the cells and tissues against these 
species in physiological conditions (Halliwell and Gutteridge, 1999). But when there 
is an imbalance between the generation of ROS/RNS and the ability of antioxidant 
defense systems to remove them, oxidative/nitrosative damage to cellular constituents 
(DNA, proteins, lipids, and sugars) takes place, which is referred as 
oxidative/nitrosative stress (Sies, 1991; Halliwell and Gutteridge, 1999). So far a 
broad range of studies have been done which show that oxidative/nitrosative stress is 
responsible for a range of degenerative processes of some human diseases (Halliwell 
c 
and Gutteridge, 1999; Cutler et al., 2005). But there is a big problem with direct 
determination of these ROS/RNS in the body fluids due to there extremely short half-
life and rapid reactivity with biomolecules. For that reason, the extent of 
oxidation/nitration caused by different ROS/RNS are determined indirectly by 
measuring different biomarkers of diseases in which modified DNA, proteins, lipids, 
and sugars in biological samples are measured. But now the general concepts of free 
radical biochemistry have been changed by the passionate investigation over the past 
decade which states that free radicals too exhibit a broad range of chemical and 
physical properties and are not necessarily short lived. Similarly their biological 
properties are not always harmful. One of the best and interesting examples is nitric 
oxide, which is comparatively specific in its effects, not very reactive and serves 
significant physiological functions. 
Reactive oxygen species (ROS) 
In spite of being involved in a number of diseases, ROS are also very relevant 
mediators of several normal physiological processes. The highly reactive character of 
singlet oxygen can even be subjugated to make reactive peroxides that can serve as 
antimicrobial agents (Michel et al., 2012). Activated T lymphocytes and IL-2 attack 
macrophages and neutrophils during inflammatory response leading to the production. _ 
of high levels of OZ -, which along with other ROS tear down the engulfed bacteria 
(oxidative burst) (Lu et al., 2007). Activated ROS exerts so many deleterious effects 
on biological systems. For example; membrane damage, alters proteins structures and 
functions, Iipids denaturation, and structural harm to DNA. Numerous reactive 
oxygen species (ROS) are produced due to the mitochondrial energy metabolism 
including oxygen ions (Oz -, the primary ROS), free radicals, and peroxides 
(inorganic and organic). ROS plays a variety of functions including useful as well as 
harmful for the life. A number of facts suggest that high levels of ROS are closely 
linked to the manifestation of neuronal death in a variety of neurological disorders. 
These comprise chronic diseases such as Parkinson's disease or Alzheimer's disease 
(Guglielmotto et al., 2009), acute injury of the brain (brain trauma and cerebral 
ischemia) (Valko et al., 2007; Chen et al., 2011), and psychiatric disorders (autism, 
attention deficit hyperactivity disorder, depression, and schizophrenia) (Michel et al., 
2012). 
Fi 
Reactive nitrogen species (RNS) 
Reactive nitrogen species are becoming more and more recognized as mediators 
of damage in biological systems (Gaston et al., 1994; Mohsenin, 1994). Similar to 
ROS, RNS too are produced from the interactions of biologically generated free 
radicals to form more reactive species causing multiple biological effects. 'RNS' 
comprises of such a varied range of compounds, which have such contrasting and 
distinct characteristics that their only unifying property can be derivation from NO'. 
However, biology and biochemistry of specific RNS have been investigated by the 
advancement of the recent techniques that showed the important insights of their 
effects on normal physiology and contribution to diseases. The reactions of NO* with 
other free radicals or oxygen to produce RNS and their biological properties are 
shown in figure 2. The production of toxic and mutagenic products are the fate of 
ROS/RNS reactions causing oxidation, nitration, halogenation, and deamination of 
biomolecules of all types, including lipids, proteins, carbohydrates, and nucleic acids. 
ROS/RNS play a vital function as signaling intermediates. For instance, growth 
factors, environmental stress, and cytokines control specific cellular responses 
through redox-sensitive signaling pathways (Suzuki et al., 1997). Tyrosine nitration 
can also cause certain indirect effects on cellular signaling pathways through RNS. 
Undeniably, nitration of tyrosine by peroxynitrite leads to inhibition of tyrosine 
phosphorylation (Gow et al., 1996; Kong et al., 1996) and seems to target the 
modified proteins for breakdown. (Gow et al., 1996). ROS/RNS are directly lethal to 
the invading pathogens. Antioxidant defense mechanisms (enzymatic as well as non-
enzymatic) play a significant role to lessen the injurious effects of these species. 
AIthough many of the dominant chemical reactions of RNS and their consequences 
are still unknown. 
Radical and non-radical reactive nitrogen species consist of NO', nitrogen dioxide 
(NO2), nitrous acid (HNO2), nitrosyl cation (NO), nitrosyl anion (NO-), dinitrogen 
tetroxide (N204), dinitrogen trioxide (N203), peroxyriitrite (ONOO-),  peroxynitrous 
acid (ONOOH), alkyl peroxynitrites and nitronium cation (NO24 ). 
ROS/RNS may either be beneficial or harmful to the cells, thus, acting as a 
"double-edged sword" in cellular reactions. On one hand, ROS and RNS provoke 
damage to macromolecules such as DNA, lipids, and proteins through their capability 
to bring on biochemical alterations (Taniyama and Griendling, 2003; Wu et al., 2004). 
While on the other hand, they are so much important in many physiological functions. 
noci 
3x, 
Nitration 
-NO 
e.g. NO2-tyrosine 
uxla :tUon 	Nitrosation e.g. GSSG -N0' 
e.g. GSNO 
Fig. 2. Nitric oxide-dependent reactions that lead to the formation of RNS. Through the 
rapid reaction of NO' and OZ -, peroxynitrite (ONOOH) is formed and leads to 
oxidation, nitrosation (addition of NO') or nitration (addition of NO2). Nitric 
oxide is formed from the enzymatic action of the nitric oxide synthases (NOS) 
which under some circumstances can also produce Oz -. There are further 
potential sources of 0; - in the cell including xanthine oxidase (XOD), 
NAD(P)H oxidases (NAD(P)H ox) and respiratory complexes within the 
mitochondria (Mito). Recently it has also been shown that the enzyme 
myeloperoxidase (MPO) can cause nitration reactions using nitrite (NO2-) and its 
product hypochlozite (HOCI) as a substrate. The oxidation reactions (e.g. 
oxidation of glutathione) occur at the highest chemical yield but the nitration 
(e.g. formation of nitrotyrosine) or nitrosation (e.g. formation of S-
nitrosoglutathione) reactions are also biologically significant since they can alter 
cell signaling and generate NO' donors. 
Source: Patel, R.P., McAndrew, J., Sellak, H., White, C.R., Jo, H., Freeman, B.A., 
Darley-Usmar, V.M. (1999) Biochim. Biophys. Acta 1411: 385-400. 
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Therefore, the balance between oxygen utilization, ROS/RNS formation, and 
antioxidant activity is essential for nonnal functions of the body. 
Nitric oxide (NO') 
Nitric oxide (NO') has been considered as one of the most important breakthrough 
as a key biological molecule. Presently, the only known biological molecule being 
produced in sufficient concentrations and with the ability to react swift enough with 
superoxide to outcompete endogenous superoxide dismutase is nitric oxide (Beckman 
and Tsai, 1994). Nitric oxide plays a crucial role as a cell-signaling molecule, anti-
infective agent and, as most recently identified, an antioxidant. The metabolic 
outcome of NO' gives rise to an additional series of compounds, collectively known 
as the reactive nitrogen species (RNS), that have their own distinctive characteristics. 
Among the various free radicals, nitric oxide is in fact the most significant one 
possessing wide spectrum of pathophysiologicaI functions. Nitric oxide is. formed 
from L-arginine by the enzyme nitric oxide synthase (NOS). A number of NO' 
synthases have been identified (NOS; EC 1.13.23) including nNOS (neuronal NOS), 
eNOS (endothelial NOS), and iNOS (inducible NOS). The three forms exhibit almost 
50% identity in amino acid sequence. All three NOS isozymes exhibit considerable 
sequence homology to only one other mammalian enzyme—cytochrome P450 
reductase. Both the enzymes, nNOS (150 kDa) and eNOS (135 kDa), are constitutive 
in nature. Both are activated rapidly and are dependent on Ca}2/calmodulin for their 
activation; but, the yield of these enzymes is momentary and low—on the nanomolar 
level. Nitric oxide at this level has a comparatively long half-life and is primarily 
involved in homeostatic processes like neurotransmission, peristalsis, and blood 
pressure regulation. Neuronal NOS has been confined to the cytosol where it exists as 
a dimer under native conditions. Unlike nNOS, eNOS is membrane-bound through 
myristoylation and palmitoylation. As opposed to the constitutive enzymes, iNOS is 
the inducible type of the enzyme (130 kDa) that exists as a homodimer under native 
conditions, with tetrahydrobiopterin-dependent dimerization required for enzymatic 
activity. Inducible NOS was at first identified in macrophages. Cells continuously 
release NO' over days or weeks. iNOS may produce NO' at 4x 106 molecules/cell in 
stimulated macrophages (Lewis et al., 1995). In cases where inflammation lasts for 
months or even years, nearby cells may be exposed to considerable amounts of highly 
reactive chemical species including NO' and reactive oxygen species. Now it has been 
a 
acknowledged that many types of cells can be activated to express iNOS in the 
presence of the appropriate blend of cytokines. Recently, the role of iNOS 
in peroxynitrite-mediated protein radical formation in LPS-treated microglial BV2 
cells has been proved (Kumar et al., 2014). 
Nitric oxide plays an important role in host defense. Originally demonstrated by 
Marietta and indirectly by Hibbs, NO' is formed by macrophages as a cytotoxic agent 
in the immune or inflammatory response (Marletta et al., 1988; MarIetta, 1988; Hibbs 
et al., 1988; Moncada et al., 1991; Feldman et al., 1993). NO' may also be closely 
involved in carcinogenesis resulting from inflammation as chronic inflammation 
involving constant activation of macrophages can last for several months and 
sometimes years (Ohshima and Bartsch, 1994; Singer et al., 1996; Pavlick et al., 
2002). Hence, on the basis of essential biological roles of NO' such as vasodilation 
and neurotransmission as opposed to the fact that NO' has been shown to be 
mutagenic and genotoxic by inducing DNA damage, endogenous NO' has been 
classified as a double-edged sword with beneficial as well as harmful roles in vivo. 
Peroxynitrite 
Peroxynitrite, ONOO -, is formed as a result of a major and aggressive reaction of 
nitric oxide (NO*) with superoxide (o; -). It has a physiological half-life of 
approximately I sec, as it decomposes spontaneously to give nitrate (Fukuto and 
Ignarro, 1997). 
0; - + NO' — 	ONOO - 
Beckman and co-workers were the first to identify a possible biological 
importance of this reaction. They pointed out that peroxynitrite may be produced 
under pathophysiological conditions, where both NO* and o; -- are formed at high 
rates by phagocytic cells such as macrophages, and that ONOO - is a potent oxidant 
with the potential to destroy critical cellular components (Beckman et al., 1990). 
There is up regulation of inducible NO' synthase in activated macrophages, generating 
large NO' fluxes while concurrently producing superoxide, O;-. Both NO and Oz- 
are fairly unreactive individually, but will swiftly combine with each other to give the 
far more reactive ONOO  -. This reaction has a rate constant between 6.6 and 19x109 
M-'s-' (Kissner etal., 1997; Kissner, etal., 1998; Nauser and Koppenol, 2002), that is 
around 3-8 times greater than the rate of o; - degradation by superoxide dismutase 
E 
(SOD; k = 2.5 x 109 M-'s-1) (FieIden et aL, 1974). 'Although, peroxynitrite can alter a 
variety of biomolecules, it has high affinity for tyrosine residues in proteins. The 
specific marker of peroxynitrite-mediated damage to proteins is 3-nitrotyrosine 
(Ohshima et aL, 1990). The reaction between peroxynitrite and tyrosine residues is a 
covalent modification which results in attachment of a nitro (-NO2) group on the 
aromatic ring of tyrosine residues (Gow et. al., 2004). The formation of nitrotyrosine 
is considered as a marker for nitrosative stress. Protein nitration has been found to be 
associated with more than 60 human disorders. The presence of protein 
3-nitrotyrosine in vivo has been revealed in a number of inflammatory situations in 
human and experimental animals (Ischiropoulos, 1998). Peroxynitrite also leads to 
oxidation of sulfhydryls (Quijano, 1997). Peroxynitrite also causes protein oxidation; 
the most prominent marker of which is increase in the carbonyl content of proteins 
which results from oxidative modifications of the side chains of lysine, proline, 
arginine and threonine (Berlett et al., 1998). Increase in protein carbonyls has been 
seen in a number of diseases like diabetes) AIzheimer's, systemic lupus 
erythematosus, rheumatoid arthritis, sepsis, chronic Irenal failure, cancer, etc (Yilmaz 
et al., 2003). The reactions of peroxynitrite are  affected by local pH and 
micro environment, with hydrophobic membrane compartments support nitration and 
aqueous environments support oxidation. A present' study demonstrated that in vitro 
modification of HSA with peroxynitrite brings about biophysical and biochemical 
alterations in the protein which was confirmed by the generation of highly specific 
antibodies in experimental animal (Ahmad etal., 2013). 
When kept frozen in dark, peroxynitrite anion! is stable for weeks in aqueous 
alkaline solutions (Gmelin, 1996) as temperature and transition metal ions strongly 
influence the decay of peroxynitrite. Peroxynitrite is 36 kcal.mol--' higher in energy 
than its isomer nitrate (Koppenol et al., 1992). Peroxynitrite exhibits relative stability 
in alkaline solution and can be stored in millimolar concentrations for months at 
-80°C (Beckman et al., 1994). Tetramethylammonium is indefinitely stable and pure 
solid salt form prepared from peroxynitrite (Bohle et al., 1994). Maximum absorption 
by peroxynitrite anion is shown at 302 nm and its concentration can be known using 
an extinction coefficient of 1670 M-' crn ' (Hughes and Nicklin, 1968). About 20% of 
i 
peroxynitrite is protonated at physiological pH to peroxynitrous acid (HOONO) 
which has a pKa of 6.8 and performs a crucial role in the biological action. At 
physiological Ievels, chloride ions screen the electrostatic field that attracts 
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superoxide to the active site and thus, partially reduce the scavenging of superoxide 
by superoxide dismutase. The reduction is by a factor of 2-3 (Cudd and Fridovich, 
1982; Rigo et al., 1977), but should not have any consequence upon the radical-
radical coupling of nitric oxide and superoxide. Therefore, it is expected that the 
formation of peroxynitrite is somewhat more favorable under physiological 
environment compared to reactions conducted in phosphate buffer. 
The rate constant of the reaction of peroxynitrite anion with CO2 is 5.8x104 M1s-' 
(Lymar and Hurst, 1995; Denicola et al., 1996). An important determinant of the 
reactivity of peroxynitrite is its conformation. The reactant must be the trans rotamer. 
Carbonic anhydrase, that catalyses the reversible hydration of CO2. was used as a 
probe to show that CO2 is the reactive species (Uppu et al., 1996a). The reaction 
between peroxynitrite anion and CO2 should occur in vivo and accelerate its decay 
because the concentrations of CO2 (1.3 mM in blood plasma) and bicarbonate (12 mM 
in intracellular fluid and 25-30 mM in blood plasma) are high, (Uppu et aL, 1996a). 
Hence, it can be said that the biological actions of peroxynitrite are likely to take 
place via the intermediate nitrosodioxycarboxylate (O=NO00O2 ). Nitration 
reactions are enhanced by the reaction of peroxynitrite with CO2 but the 
hydroxylation and oxidation reactions mediated by peroxynitrous acid (ONOOH) are 
inhibited by the reaction between peroxynitrite and CO2 (Denicola et al., 1996; 
Yermilov et al., 1996; Lemercier et aL, 1997). 
It has been proposed that peroxynitrite anion-CO2 adduct can, by isomerization, 
lead to reactive intermediates like the nitronium cation, NO2 and CO3' radicals or 
nitro oxo carboxylate anion (02N-O-0O2 ) (Goldstein and Czapski, 1998). Each one 
of these species are oxidizing and nitrating agents. Superoxide formation by the 
strong oxidizing CO3' occurs via radical intermediates. The decomposition of 
peroxynitrite in acidic solutions yields nitrate as a final product, but as the pH is 
raised, it decomposes rapidly into oxygen and nitrite in a 1:2 ratio (Goldstein and 
Czapski, 1998). 
After its discovery in the year 1987, different research groups have seen the role of 
peroxynitrite in the regulation of blood pressure, and activities in kidneys, lungs, brain, 
stomach, etc. A number of studies have been done to ascertain that peroxynitrite is 
toxic mainly due to its capacity: 
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(i) to oxidize thiols and proteins having thiol and membrane lipids (Radi et al., 
1991a; Radi et al., 1991 b) and 
(ii) to cause nitration of free and protein bound phenols. 
A stable yellow protein-bound adduct identified as nitrotyrosine is formed by the 
reaction of peroxynitrite with proteins (Ischiropoulos et al., 1992). 
A two-electron oxidation reaction is the major reaction of peroxynitrite with thiols 
which leads to disulphides and considered instrumental in the peroxynitrite-mediated 
inactivation of various enzymes. The most sensitive targets in proteins are cysteins. 
At physiological pH and temperature, the apparent second-order rate constants during 
the reaction of peroxynitrite with thiols, like cysteine, glutathione and the single thiol 
group of albumin, are reported to be 1.3, 1.5 and 4.5x103 M-'s1, respectively (Radi et 
al., 199 lb, Quijano et al., 1997). SuIphhydryls are Ixidized by peroxynitrite about 103  
times quicker than does H202 under the same conditions. 
Peroxynitrite exhibits multiple facets that account for its complex chemistry that is 
strictly dependent on the environment. The ratio of OZ - to NO' is crucial in 
determining peroxynitrite reactivity. The oxidation ,and nitration reactions elicited by 
peroxynitrite are affected by excess NO' or excess o;-  (Miles et al., 1996; Wink and 
Mitchell, 1998). It is now evident that the formation of peroxynitrite in vivo plays an 
r 
important role in a wide range of pathophysiological conditions such as inflammation, 
neurodegenerative diseases, cardiovascular disorders, cancer, etc. 
Oxidizing and nitrating properties of peroxynitrite 
The effects of peroxynitrite on DNA may lead to base modification (Douki et al., 
1996) and mutations in addition to single- and dduble—strand breaks (Salgo et al., 
1995; Szabo and Ohshima, 1997). Thiyl radical formation, radical chain reactions and 
depletion of thiol pools occur when Sulfhydryls undergo one- or two-electron 
oxidation under the action of peroxynitrite (Quijano et al., 1997). Phosphorylation in 
vitro (Martin et al., 1990), which could have dramatic effects upon the regulation of 
cellular processes, is prevented by tyrosine nitration. It has been made known that a 
bolus of peroxynitrite causes apoptosis in undifferentiated PC12 cells (Este'vez et al., 
1995). Peroxynitrite oxidizing potential is sufficient enough to initiate lipid 
peroxidation reactions directly by abstracting a hydrogen atom from a polyunsaturated 
fatty acid along with the potential to cause nitration in lipids (Darley-Usmar et al., 
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1992; Rubbo, 1994). Peroxynitrite may prove a useful agent against bacteria (Zhu et. 
al., 1992) or other invading pathogens because of its cytotoxic action on them. 
However, when peroxynitrite is produced in excess, it can cause harm to normal 
tissues. The in vivo formation of 3-nitrotyrosine in proteins has previously been 
shown in a number of inflammatory situations in humans and experimental animals 
(Ischiropoulos, 1998). 
Peroxynitrite scavengers and neutralizers 
Several molecules are capable of reacting directly with peroxynitrite, with 
peroxynitrite-derived radicals or with both. To probe the roles of peroxynitrite, 
endogenous molecules as well as exogenous compounds have been used. 
Metalloporphyrins, _ which have been found to react rapidly with peroxynitrite, 
represent promising drug candidates. 
Peroxiredoxins possess a fast reacting (peroxidatic) thiol in their active site. They 
belong to a ubiquitous family of peroxidases in prokaryotes and eukaryotes. 
Peroxynitrite are readily and catalytically reduced to nitrite by bacterial and parasitic 
peroxiredoxins through the reaction of the peroxidatic cysteine (k --1 X 106 M-'ssl ). 
Human peroxiredoxin-V has been demonstrated to serve as a peroxynitrite/ 
thioredoxin oxido-reductase. It reduces peroxynitrite with a rate constant of 7x 107 
Nils ' — a high value for peroxynitrite as well as for peroxide-thiol reactions in 
common (Dubuisson et al., 2004; Rhee et al., 2005). 
Uric acid, which is considered as a physiological modulator of peroxynitrite 
reactivity, reacts slowly with peroxynitrite but readily scavenges peroxynitrite derived 
radicals. It has been used in a variety of studies and has reputable useful effects in 
animal models of inflammation and reperfusion injury (Kooy et al., 1994; Lanone et 
al., 2002; Scott et al., 2002; Whiteman et al., 2002; Szabo, 2003; Robinson et al., 
2004; Scott et al., 2005). Peroxynitrite-mediated toxicity has been shown to be 
reduced by simple thiol-based antioxidants, such as mercaptoalkylguanidines, N-
acetylcysteine and dihydrolipoic acid and also reduction in 3-nitrotyrosine 
immunoreactivity in various pathophysiological conditions (Szabo et al., 1997; 
Zingarelli et al., 1997; Ploner et al., 2001; Szabo, 2003; Lancel et al., 2004; 
Moochhala et al., 2005). 
Caffeic Acid Phenethyl Ester (CAPE), an active component of honeybee products, 
shows antioxidant, anti-inflammatory, and immunomodulatory activities. It has been 
13 
} 
shown that CAPE successfully suppresses the inflammatory response that lead to cell 
damage and, potentially, cell death through inhibition of the production of cytotoxic 
molecules such as nitric oxide and peroxynitrite (Ka'ssim et al., 2014). 
} 
The properties of ebselen (as well as other selenocompounds) as peroxynitrite 
scavengers have been summarized by Klotz and Sies, 2003. Ebselen has shown to be 
having protective effects in various models of inflammation and reperfusion injury 
I 
(Sugiura et aL, 1999; Daiber et al., 2000; Noiri et al., 2001). Some of these actions 
are possibly associated with its ability to neutralize peroxynitrite. Ebselen also 
improves endothelial function in diabetic blood vessels and kidneys (Gealekman et 
aL, 2004); this is in agreement with the pathological role of peroxynitrite in the 
disease. Selenoprotein P and glutathione peroxidase 'are selenium-containing proteins 
with known inhibitory effects on peroxynitrite-mediated reactions (Sies et al., 1997; 
Arteel et al., 1998). In vitro study has shown that the reduction of peroxynitrite to 
nitrite can be achieved by glutathione peroxidase, however, its protective role in vivo 
remains to be established. Inhibitory effects on peroxynitrite-mediated reactions are 
also exerted by selenocysteine, selenomethionine and selenite (Briviba et al., 1996; 
Jacob et aL, 1998). It has been shown that besides jthiol- and selenium-containing 
compounds, the inhibition of peroxynitrite-dependent 'oxidation and nitration can also 
be achieved by organo-tellurium derivatives in vitro (Sies et al., 1997; Arteel et al., 
1998; Jacob etal., 1998). 
Several marketed drugs, which in most cases do not react directly with 
peroxynitrite but with its secondary radicals, have been demonstrated to have 
peroxynitrite scavenging activities. For example, i peroxynitrite-induced matrix 
metalloproteinase activation and related cardiotoxicity has been proven to be reduced 
by acetaminophen (Rork et al., 2006)_ Nebivolol has been made known to diminish 
endothelial peroxynitrite production in humans (Mason et al., 2005). Drugs with 
established in vitro peroxynitrite-scavenging pro erties include pindolol, zileuton,  
deprenyl, hydralazine, simvastatin, edaravone, propofol; penicillamine, rasagiline and 
1,4-dihydropyridine calcium antagonists (Cabassi et aL, 2001; Coffey et al., 2001; 
Maruyama et aL, 2002; Acquaviva et aL, 2004; Althaus et al., 1994; Lopez-Alarcon 
et al., 2004; Trujillo et al., 2004; Banno et al., 2005; Daiber et al., 2005; Fernandes et 
aL, 2005; Selley, 2005). It remains to be determined that how and to what extent, the 
antioxidant effect of these compounds may contribute to :their therapeutic actions. 
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Various molecules present in natural or dietary products, such as carotenoids, 
polyphenol oligomers and epicatechin, have proved to effectively guard cells from the 
damaging role of peroxynitrite (Arteel et al., 1999; Arteel and Sies, 1999; Panasenko 
et al., 2000; Schroeder et aL, 2003). They tend to react slowly with peroxynitrite itself 
and so react with other reactive species instead, including peroxynitrite derived 
radicals. 
For most compounds with peroxynitrite scavenging potential in vitro, the rate 
constants of their reactions are low and their action may be attributed to reaction with 
the secondary radicals (for example, OH', NO2, co-).  Their therapeutic prospective 
as peroxynitrite neutralizing agents is low because it is improbable that most classical 
scavengers would successfully react as peroxynitrite scavengers in vivo. 
Peroxynitrite-induced cytotoxicity 
The oxidizing and nitrating effects of peroxynitrite remain in check due to 
endogenous antioxidant defense systems which regulate the formation of peroxynitrite 
under normal physiological conditions (Radi et al., 2002a; Radi et aL, 2002b; Trujillo 
et al., 2008). However, a I00-fold increase in peroxynitrite formation takes place by a 
10-fold increase in superoxide and nitric oxide levels as proved by researchers. The 
reaction of peroxynitrite is strictly time dependent. Even a moderate flux of it over a 
long time period leads to an extensive oxidation and potential damage to different 
cellular components, which in turn results in dysfunction in critical cellular processes, 
interference of cell signaling pathways and the initiation of cell death through both 
apoptosis and necrosis (Virag et al., 2003). Peroxynitrite has highly pH-dependent 
oxidant reactivity and both peroxynitrite anion (ONOO -) and peroxynitrous acid 
(ONOOH) can take part directly in one- and two- electron oxidation reactions with 
various biomolecules (Fig. 3). A rapid reaction of peroxyitrite with carbon dioxide is 
considered as a primary reaction of peroxynitrite in biological systems which occur in 
equilibrium with physiological levels of bicarbonate anion. This reaction results in the 
production of carbonate (CO; -) and nitrogen dioxide (NO2') radicals (yield -.35%), 
which are one-electron oxidants (Radi et al., 2001). As a result of diffusion-controlled 
radical-radical termination reactions of nitrogen dioxide with biomolecules, there is 
formation of nitrated compounds. In addition, ONOOH can undergo homolytic fission 
to generate one-electron oxidants, hydroxyl (OH) and NO2 radicals (with a 30% 
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Fig. 3. Biochemistry of peroxynitrite: reaction targets and fate. Peroxynitrite anion 
(ONOO -) is in equilibrium with peroxynitrous acid (ONOOH; pKa = 6.8) and either 
one can undergo direct reactions with biomolecules as indicated (a and b). A 
fundamental reaction of ONOO- in biological systems is its fast reaction with carbon 
dioxide (in equilibrium with physiological levels of bicarbonate anion; c), which 
leads to the formation of carbonate (Co -) and nitrogen dioxide (NO2) radicals 
(yield approximating 35%), which are good one-electron oxidants (d) that can readily 
oxidize amino acids such as cysteine and tyrosine to yield the corresponding cysteinyl 
and tyrosyl radicals. In addition, NO2 can undergo diffusion-controlled termination 
reactions with biomolecule-derived radicals, resulting in nitrated compounds (d). 
Alternatively, ONOOH can undergo homotytic ;fission to generate one-electron 
oxidants hydroxyl (OH) and NO2 radicals (with a 3(1% yield; e). However, this 
reaction is slow in biological systems compared with the other reactions of ONOO-
and ONOOH and therefore is a modest component of the in vivo reactivity of 
peroxynitrite in aqueous compartments. However, ONOOH readily crosses lipid 
bilayers (f) and its decomposition to OW and NO2 radicals seems to become relevant 
in hydrophobic phases to initiate lipid peroxidation and lipid and protein nitration 
processes (g). Moreover, ONOOH in the membranes may undergo direct reactions 
with metal centres such as heroin or membrane associated thiols. 
Source: Szabo, C., Ischiropoulos, H. and Radi, D. (2007) Nature (London) 6: 662-
680. 
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yield). But this reaction is a modest component of the in vivo reactivity of 
peroxynitrite as it is slow compared with other reactions of ONOO - and ONOOH in 
biological systems. In hydrophobic phases the proton-catalysed decomposition of 
ONOO - to form OH and NO2' radicals may become relevant, leading to the initiation 
of lipid peroxidation processes (Radi et al., 1991 a; Bartesaghi, el al., 2006). 
Peroxynitrite as a trigger of cell death 
Because of the huge number of biochemical alterations and positive-feedback 
cycles that peroxynitrite can elicit, it is not astonishing that peroxynitrite can provoke 
cell death. Necrotic-type cell death occurs on exposure to high concentrations of 
peroxynitrite which takes place due to acute and severe cellular energetic 
derangements (Szabo, 2003; Virag et aL, 2003; Jagtap and Szabo, 2005). On the 
contrary, lower concentrations of peroxynitrite cause delayed, programmed, 
apoptotic-type cell death. The thioI-dependent antioxidant detoxification pathways are 
responsible to tolerate the low levels of peroxynitrite that are continuously formed 
under basal conditions but the problem come into existence when the formation of 
peroxynitrite is increased compared to the tolerating power of these detoxification 
pathways and the result is cell dysfunction and death. The peroxynitrite-induced 
apoptotic cell oxidant/free-radical-mediated apoptosis is chiefly dependent on the 
activation of death, comparable to other forms of caspases 3, 2, 8 and 9 (CASP3, 
CASP2, CASP8, CASP9) (Virag et al., 1998; Zhuang and Simon, 2000; Shacka et aL, 
2006; Vicente et al., 2006). The release of cytochrome c and other proteins from the 
intermembrane space is triggered by peroxynitrite. This subsequently triggers various 
molecular events that culminate in cell death. The release of cytochrome c may be due 
to the opening of mitochondrial permeability transition pore, and may be to a certain 
extent accountable for the inhibition of mitochondrial respiration which is induced by 
ischaemia, high calcium and oxidants (Estevez et al., 1998; Borutaite et al., 1999; 
Richter et al., 1999). An early step of intracellular calcium release (Virag et al., 
1999), that is probably mediated by the stimulation of calcium release from the 
endoplasmic reticulum, might be caused by peroxynitrite-mediated early stress 
responses (Dickhout et al., 2005; Redondo et al., 2005). The consequent cytotoxicity 
seems to be because of calpain activation. Many of the subsequent cytotoxic 
processes can be prevented by chelation of calcium during this early step (Virag et al., 
1999). 
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Both, cell death promoting and protective signaling pathways are involved in cell 
death mediated by peroxynitrite. Some of the regulatory mechanisms have been 
characterized in detail by Estevez and colleagues I in PC 12 cells. Activation of the 
MLKJp38/JNK (mixed lineage kinase/p38/c-jun N-terminal kinase) pathway by 
peroxynitrite appears to be linked with BCL2-associated X protein (BAX) translocation, 
cytochrome c release and caspase activation. Changes in levels of cytosolic and 
mitochondrial JNK may also contribute. It may occur dependently or independently of 
BAX translocation. Inactivation of the PI3K/AKT (phosphoinositide 3-kinase/) 
pathway was demonstrated in experimental system. This has a part in the 
translocation of BAX and activation of the intrinsic apoptotic pathway. The AKT and 
the p38 pathways take place independent of each other, or the inactivation of 
PI3K/AKT occurs upstream ofp38/JNK activation (Shacka et al., 2006) (Fig. 4). 
Mitochondria have significant roles in the process of peroxynitrite-mediated cell 
death (both apoptotic and necrotic). The release of apoptosis-inducing factor (AIF) 
from the mitochondria is stimulated by peroxynitriteI as shown by some recent studies. 
AIF release subsequently triggers DNA fragmentation processes (dependent and 
independent of caspase activation, respectively) (Zhang et al., 2002). The 
peroxynitrite-induced DNA single-strand breakage and consequent PARP activation, 
which are categorized in nuclear processes; work, in a complex manner with the 
mitochondrial cell-death processes. For instance) mitochondrial AIF release is 
controlled by nuclear processes governed by poly (ADP-ribose) polymerase (PARP) 
(Dawson and Dawson, 2004; Beller et al., 2006). 
The respective anti-apoptotic or neurotrophic actions of thioredoxin' and nerve 
growth factor (NGF) can be transformed into powerful pro-apoptotic actions by direct 
reactions of peroxynitrite with these proteins (Pehar'et al., 2006; Tao et al., 2006). In 
general, there is safe elimination of apoptotic cells by professional phagocytes and 
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other cells capable of phagocytosis. Nonetheless, when peroxynitrite-damaged cells 
die by necrosis, their content is released into the extracellular environment. Under 
these conditions, additional inflammatory responses, Which include a positive 
feedback cycle of further peroxynitrite generation, are triggered by intracellular 
factors, including high mobility group protein BI (HMGB 1) (Sappington et al., 2002; 
Ulloa and Messner, 2006). Peroxynitrite-modif ed DNA sequences or tyrosine-
nitrated modified proteins can encourage the increased autoantibodies production 
(Dixit et al., 2005; Ohmori and Kanayama, 2005). 
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Fig. 4. Mechanisms of cell death induced by peroxynitrite. Peroxynitrite can induce both 
cellular apoptosis and necrosis depending on production rates, endogenous 
antioxidant levels and exposure time. Apoptosis involves mitochondrial signalling 
that can arise from intramitochondrial oxidation and nitration reactions in crucial 
targets such as protein components of the permeability transition pore and 
cardiolipin, which facilitate cytochrome c (Cyt c) release and apoptosome 
activation. Alternatively, apoptosis could be mediated by secondary activation of 
cytosolic mitogen activated protein (MAP) kinases that result in the phosphorylation 
of p38 and INK (c-jun N-terminal kinase), which in turn promote the translocation 
of the pro-apoptotic protein SAX (BCL2-associated X protein) to mitochondria. 
High levels of peroxynitrite lead to necrosis in part through activation of the poly 
(ADP-ribose) polymerase (PARP) pathway secondary to DNA damage; excessive 
activation of PARP leads to the depletion of cellular NAD and ATP stores, which 
results in the loss of redox regulation and energy collapse and subsequent necrotic 
cell death. ATP depletion can be also secondary to peroxynitrite-dependent 
inactivation of mitochondrial electron transport complexes I and II and of the ATP 
synthase (complex V). Peroxynitrite-dependent nitration of mitochondrial proteins 
such as manganese superoxide dismutase (MnSOD) and cytochrome c serves to 
amplify oxidative damage through either decreased antioxidant activity (nitro-
MnSOD) or enhanced peroxidase activity (nitro-cytochrome c). BCL2, B-cell 
CLL/lymphoma 2; MLK, mixed lineage kinase. 
Source: Szabo, C., Ischiropoulos, H. and Radi, D. (2007) Nature (London) 6: 662— 
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Reaction of peroxynitrite with different biontolecules 
Peroxynitrite is a potent oxidizing and nitrating agent and can damage a wide 
range of biological macromolecules. Many biomolecules are oxidized and/or nitrated 
by peroxynitrite-derived radicals, including tyrosine residues, thiols, DNA and 
unsaturated fatty acid containing phospholipids. 
(i) Reaction of peroxynitrite with proteins 
One of the main targeted macromolecules of the cell is protein. Peroxvnitrite can 
be considered as a major destructive oxidant produced in vivo that is likely to 
responsible for much of the cytotoxicity generally attributed to nitric oxide. After it is 
formed. peroxynitrite reacts gradually with most biological molecules to be 
moderately selective in the types of biological molecules that it attacks. Tyrosine 
nitration can potentially affect various protein functions which can be catalyzed by 
superoxide dismutase and other metalloproteins. Structural proteins are among the 
most plentiful proteins in a cell and only a relatively few need to be modified to 
disrupt their normal structural assembly and disassembly. Hence, their modification 
may be a particularly important pathological target of nitration (Beckman, 1996). 
Reaction of peroxynitrite with proteins may occur either directly or indirectly by 
the production of other damaging species that may lead to oxidation and nitration of 
proteins. The nitration of tyrosines can also be catalyzed by reaction of transition 
metals with peroxynitrite (Beckman et al., 1992; Ischiropoulos et al., 1992). 
Peroxynitrite and a metal catalyst will nitrate tyrosine at neutral pH, a crucial marker 
of peroxynitrite formation in vivo (Beckman et al., 1994). Metal-catalyzed 
peroxynitrite nitration, which is quite efficient process, is most likely to be a 
significant source of nitrotyrosine formation. Neutrophil derived myeloperoxidase 
also reacts with peroxynitrite at a rate of about 106 M-'s-I (Floris cat al., 199 3) and 
results in nitration of proteins even in the existence of its better recognized substrates 
hydrogen peroxide and chloride (Sampson et al., 1995). The rate of nitration is 
usually elevated in the presence of transition metal ions or certain metalloproteins 
(e.g. CuZnSOD), while peroxynitrite causes nitration to tyrosine residues alone or 
protein bound tyrosine residues (Ischiropoulos et al., 1992; Beckman et al., 1992; 
Beckman et al., 1994; Pryor and Squadrito, 1995; Van der Vliet et al., 1995; 
Ischiropoulos et al., 1995). Nitrotyrosine involves a carbon-nitrogen bond which is 
difficult to remove chemically, thus it is a stable adduct which needs 70-80 kcal.moL' 
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energy to break this bond. Some of the proteins modified and inactivated by nitration 
include Mn-SOD (MacMillan-Crow et al., 1998; MacMillan-Crow and Thompson, 
1999), tyrosine phosphatases (Takakura et al., 1999), cytochrome P450 2B 1 (Roberts 
et al., 1998), and ribonucleotide reductase (Guittet et al., 2000). Few of the enzymes 
are also inactivated by oxidation of critical cysteine residues involved in the catalytic 
mechanism. These include yeast alcohol dehydrogenase (Crow et al., 1995) and 
glyceraldehyde-3-phosphate dehydrogenase (Mohr et al_, 1994; Souza and Radi, 
1998). Thiolates [4Fe-4S] in clusters are also vulnerable to peroxynitrite assault 
(Keyer and Imlay, 1997). By the use of immunohistochemical techniques in vivo, a 
number of proteins including neurofilament-L (Crow et al., 1997; Strong et al., 1998), 
Mn-SOD (MacMillan-Crow et al., 1996), and the sarcoplasmic reticulum Ca-ATPase 
(SERCA2a) have been found to contain 3-nitrotyrosine, most likely as a consequence 
of their exposure to peroxynitrite (Viner et al., 1996). 
Peroxynitrite causes hydroxylation of phenylalanine at the three positions of the 
aromatic ring (Van der Vliet et al., 1994) and at ortho and para positions of salicylic 
acid (Kaur et al., 1997). Though their yields were low, but have been observed in 
vitro. This peroxynitrite induced hydroxylation reaction may be explained by HO' 
formation if peroxynitrous acid undergoes homolysis. Maximally 40% of 
peroxynitrite is converted into this activated oxidizing species as demonstrated that a 
maximum of 40% oxidation takes place with rising concentrations of the substrates 
(Goldstein et al., 1996). Copper, zinc superoxide dismutase reacts with peroxynitrite 
to form a complex that selectively nitrates other proteins (Ischiropoulos et al., 1992). 
Reactions of peroxynitrite with transition metal containing proteins 
Among the fastest known reactions for peroxynitrite is its direct reaction with the 
proteins containing transition metal centers (Alvarez and Radi, 2003). Hence, 
peroxynitrite can cause modification of proteins containing a heme prosthetic group; 
such as hemoglobin (Boccini and Herold, 2004), myoglobin (Herold et al., 2003), or 
cytochrome c (Thomson et al., 1995) by oxidizing ferrous heme into the 
corresponding ferric form. By oxidative modification of the heme group of inducible 
nitric oxide synthase (iNOS), peroxynitrite can cause its inactivation (Huhmer et al., 
1997). This might serve as a negative feedback regulation of peroxynitrite production 
under inflammatory conditions. Inactivation of proteins involved in various critical 
metabolic pathways, like mitochondrial aconitase (Castro et al., 1994) and 
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oshogluconate dehydratase (Keyer and Imlay, 1997), occurs - on reaction of 
peroxynitrite with their iron-sulfur clusters. In the same way, reaction of peroxynitrite 
with Zn21 sulfur motifs of endothelial nitric oxide synthase (eNOS) (Zou et al., 2004) 
and alcohol dehydrogenase (Crow et al., 1995) causes their inactivation. 
Reaction of peroxynitrite with cysteine 
Reaction of peroxynitrite with several amino acids causes alteration in protein 
structure and function. Peroxynitrite causes thiol oxidation upon reaction with 
cysteine (Radi et al., 1991b). This results in inactivation of many enzymes of cellular 
energetic processes; for examples; glyceraldehyde-3-phosphate dehydrogenase (Souza 
and Radi, 1998; Buchczyk et al., 2003), creatine kinase (Konorev et al., 1998), 
complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), complex 
III (cytochrome c reductase) as well as complex V (ATP synthase) of the 
mitochondria) respiratory chain (Radi et al., 1994, Radi et al., 2002a; Radi et al., 
2002b). Moreover, tyrosine nitration also causes inactivation of these enzymes. The 
amount of intracellular glutathione largely determines the susceptibility of cells to 
peroxynitrite toxicity. Decline in glutathione level augments peroxynitrite toxicity and 
tissue injury during circulatory shock (Cuzzocrea et al., 1998; Cuzzocrea et al., 1999). 
Such a correlation has also been recognized in some neurodegenerative diseases such 
as Parkinson's disease and amyotrophic lateral sclerosis (Marshall et al., 1999; Vargas 
et al., 2006). 
Reactions of peroxynitrite with tryptophan, methionine and histidine 
Peroxynitrite causes oxidation of methionine to form methionine sulfoxide and to 
a smaller extent ethylene and dimethyldisulfide (Alvarez and Radi, 2003). Because of 
methionine oxidation, inhibition of alpha-l-antiproteinase consequences in its 
inability to inactivate proteases, most notably elastase (Whiteman and Halliwell, 
1996). Tryptophan oxidation is also carried out by' peroxynitrite to form N-
foranylkynurenine, oxindole, hydropyrroloindole and nitrotryptophan, though the 
significance of these products is yet to be understood (Alvarez and Radi, 2003; 
Yamakura and Ikeda, 2006). Histidine is modified by peroxynitrite through a radical 
mechanism, forming a histidinyl radical. This mechanism is concerned in the 
inactivation of Cu—Zn superoxide dismutase by peroxynitrite (Alvarez et al., 2004; 
Yamakura et al., 2005; Yamakura and Ikeda, 2006). 
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Reactions of peroxynitrite with tyrosine 
Nitration of tyrosine by peroxynitrite is a covalent alteration which causes addition 
of a nitro (—NO2) group adjacent to the hydroxyl group on the aromatic ring of 
tyrosine residues (Gow et al., 2004). The nitrotyrosination leads to generation of new 
epitopes, alterations in enzymes catalytic activities, distorted cytoskeletal organization 
and impaired cell signal transduction (Virag and Szabo, 2000). Radical mechanism 
occurs for the tyrosine nitration in which a hydrogen atom is first abstracted from 
tyrosine to form a tyrosyl radical that readily combines with nitrogen dioxide radical 
to produce 3-nitrotyrosine. In a secondary reaction the formation of dityrosine may 
take place if nitrotyrosine combines with another tyrosyl radical (Beckman, 1996; 
Beckman et al., 1996; Ischiropoulos, 2003; Radi, 2004). Nitrogen dioxide radicals 
most probably come from reaction of peroxynitrite with CO2 producing CO; - and 
NOZ radicals (Turko and Murad, 2002; Alvarez and Radi, 2003; Radi, 2004). 
However, they may also come from homolysis of peroxynitrite to form hydroxyl and 
nitrogen dioxide radicals (like HO and NO2). Another mechanism of tyrosine-
nitration, in presence of hydrogen peroxide, depends upon the generation of the 
nitrogen dioxide radical from several heme-peroxidases (mainly myeloperoxidase and 
eosinophil peroxidase) (Van der Vliet et al., 1997; Wu et al., 1999; Gaut et al., 
2001). This may act as a recycling process to reuse products generated from 
superoxide and NO'. Hence nitrotyrosine formation must be regarded as a marker of 
"nitrosative" stress. 
It has been confirmed by proteomic analyses that nitration is a highly selective 
process that is confined to specific tyrosine residues on an astonishingly small number 
of proteins (Aulak et al., 2001; Gow et al., 2004; Kanski et al., 2005a; Kanski et al., 
2005b). There are few factors that determine the nitration of tyrosine residues which 
include exposure of the aromatic ring to the surface of the protein, the position of the 
tyrosine on a loop structure, its connection with a neighboring negative charge and 
absence of proximal cysteins (Souza et al., 1999). Hydrophobic environment may also 
favor tyrosine nitration considering that peroxynitrous acid can readily pass all the 
way through lipid membranes (Turko and Murad, 2002; Bartesaghi et al., 2006). 
Protein carbonyl 
Protein carbonyls are the chemically stable biomarkers of oxidative stress and are 
thus widely used. Compared to other oxidized products, they circulate for longer time 
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in the blood (Pantke and Volk, 1999). One more thing which reflects its wide use is 
that it is possible to keep the assay sample at —80 °C for at least 10 years (Stadtman 
and Levine, 2003). The direct oxidation of amino acid residues, mainly lysine, 
arginine, threonine, and proline results in protein carbonyl formation. They can also 
be generated by secondary reaction with the primary oxidation products of sugars and 
lipids (Berlett and Stadman, 1997; Levine, 2002; Dalle-Donne et al., 2006). Carbonyl 
formation may lead to the alterations in structure. and functions of proteins. Free 
radicals and oxidants are commonly generated during normal metabolism (Tobias et 
al., 2007). This can even be a sign of normal aging or a characteristic of pathologic 
processes (Bailey, 2003; Fubini and Hubbard, 2003; Klaunig and Kamendulis, 2004; 
Emerit et al., 2004). This holds true for both, reactive oxygen species and reactive 
nitrogen species. The peroxynitrite anion (ONOO -) is an extremely reactive molecule 
(Gow et al., 1996; Souza et al., 1999; Stadtman, 2001; Castegna et al., 2003) that has 
short diffusion distance in biological tissue (Ischiropoulos and Al-Mehdi, 1995). 
Oxidative cleavage of proteins, by either the a-oxidation pathway or by oxidation of 
glutamyl side chains, can also produce protein carbonyl derivatives. This leads to the 
generation of a peptide in which the N-terminal amino acid is blocked by an a-
ketoacyl derivative (Berlett and Stadman, 1997). Because protein carbonyl is a stable 
product of oxidative damage, its use as a biomarker of oxidation product is more 
advantageous. Protein carbonyl accumulation has been observed in Alzheimer's 
disease, diabetes (CerieIlo, 2008), inflammatory bowel disease, systemic lupus 
erythematosus, rheumatoid diseases, sepsis, chronic renal failure, respiratory distress 
syndrome (Dalle-Dome et al., 2003; Ghafourifar et al., 2008), cancer (Yilmaz et al., 
2003) etc. 
(ii) Reaction of peroxynitrite with lipids 
The property of peroxynitrite to trigger Iipid peroxidation in membranes, 
liposomes and lipoproteins by abstracting a hydrogen atom from polyunsaturated fatty 
acids represents a major aspect of peroxynitrite-dependent cytotoxicity (Radi et al., 
1991a). The products that are being formed include lipid hydroperoxyradicals, 
conjugated dienes, and aldehydes (Denicola and Radi, 2005). These radicals then 
attack neighboring polyunsatturated fatty acids, producing additional radicals which 
propagate free radical reactions and eventually deterioration of membrane lipids (Radi 
et al., 1991 a; Hogg and Kalyanaraman, 1999) which leads to alteration in membrane 
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permeability and fluidity (Smith et al., 1999). Peroxynitrite may be a key player in 
inflammatory diseases of the nervous system by initiating peroxidation of myelin 
lipids that leads to demyelination (Shi et al., 1999; Smith et al., 1999; Van der Veen 
and Roberts, 1998). It also has the potential to cause oxidation of low-density 
lipoprotein (LDL) (Leeuwenburgh et aL, 1997; Trostchansky et aL, 2003). The 
binding of Peroxynitrite—modified LDL to scavenger receptors occurs with high 
affinity leading to the accumulation of oxidized cholesteryl esters and foam cells 
which are basic molecules of atherogenesis (Graham et aL, 1993; Hogg et aL, 1993; 
Guy et al., 2001). Peroxynitrite may interact with membrane lipids leading to several 
nitrated lipids that can work as potential biological mediators of signal transduction 
under physiological and pathological circumstances (Baker et aL, 2004). 
(iii) Reactions of peroxynitrite with DNA 
Reactive nitrogen species mediate their oxidative and nitrative chemistry mainly 
by peroxynitrite with added contributions from NO2 (Burney et al., 1999; Shafirovich 
et al., 2001). Besides DNA strand breaks, peroxynitrite reacts principally with dG in 
DNA to result in a variety of modifications including 8-nitrodG and 8-oxodG. 8-
oxodG is at least 1000-times more vulnerable to further oxidation by peroxynitrite 
than dG itself. Exposure of DNA to peroxynitrite in vitro can result in both sugar and 
base damage (Kennedy et al., 1997; Tretyakova et al., 2000). Predominantly, 
deoxyribose oxidation (i.e., strand breaks and oxidized abasic sites) is caused by 
peroxynitrite (Tretyakova et aL, 2000). 8-oxoguanine, which is the major product of 
guanine oxidation, upon further reaction with peroxynitrite yields cyanuric acid and 
oxazolone (Niles et al., 2006). The formation of 8-oxoG was controversial initially. 
Its absence was reported by many groups that used high peroxynitrite concentrations 
(Ohshima and Bartsch, 1994). However, others demonstrated it in experiments with 
lower treatment levels and more sensitive analytical methods (Kennedy et al., 1997). 
The cause behind this discrepancy became obvious after demonstration that 8-oxodG 
was at least 1000-fold more reactive than the parent dG (Uppu et al., 1996b). This 
observation is entirely consistent with the fact that oxidation of 8-oxodG is 
thermodynamically more encouraging than oxidation of dG. This led to the hypothesis 
that 8-oxodG in DNA could be a target for peroxynitrite, and finally, guanine 
oxidation by peroxynitrite ends in guanine fragmentation, a significant step towards 
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mutagenesis and carcinogenesis (Burney et al., 1999; Niles et al., 2006). Therefore, 
damage is more likely to occur at dG out of the four natural DNA bases. 
Opening of the sugar ring and generation of DNA strand breaks may occur if 
peroxynitrite attacks the sugar—phosphate backbone by abstracting a hydrogen atom 
from the deoxyribose moiety (Burney et al., 1999; Niles et al., 2006). DNA single 
strand breaks represent the obligatory trigger for the activation of the nuclear enzyme 
PARP. Thus, their formations represent a critical aspect of peroxynitrite-mediated 
cytotoxicity, a pathway ultimately related to the induction of cell death and tissue 
inflammation. (Szabo et al., 1996; Pacher and Szabo, 2008). Activation of DNA 
repair enzymes occurs on oxidative modifications in DNA, this may cause rapid 
decline of intracellular energy. This in turn will cause endonuclease-mediated DNA 
fragmentation, the chief mechanism that leads to DNA-damage (Cui et al., 2000). 
Direct or indirect role of peroxynitrite in human diseases 
Peroxynitrite production has been recognized' in a number of inflammatory 
conditions. Peroxynitrite is a more powerful oxidant and cytotoxic mediator than 
nitric oxide or superoxide alone as suggested by few present evidences (Crow and 
Beckman, 1995; Szabo, 1996). 
A study showed that peroxynitrite is produced in human pancreatic islet cells 
incubated with pro inflammatory cytokines, and peroxynitrite production was 
associated with /3-cell destruction. ` Moreover, the findings provided proof, that 
peroxynitrite is a mediator of cytokine-induced #-cell damage. This study showed that 
peroxynitrite generation determines cytokine-induced human islet fl-cell destruction 
(Lakey, 2001). 
Another recent study shows the involvement of peroxynitrite induced damage and 
its component, protein nitration, in the development of diabetic peripheral neuropathy. 
But the study also indicated that both structural and functional changes of chronic 
diabetic peripheral neuropathy can be reversed, and provide underlying principle for 
the development of a new generation of antioxidants and peroxynitrite decomposition 
catalysts, for treatment of diabetic peripheral neuropathy (Stavniichuk et al., 2014). 
The hypothesis that peroxynitrite production past the body's defense contributes to 
myocardial and vascular dysfunction during ischemia and reperfiision, myocarditis, 
chronic heart failure and other cardiovascular pathologies has been the center of 
rigorous research during the last many years. There are several mechanisms, including 
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triggering apoptosis and/or PARP-dependent cell death in endothelium (Mihm et al., 
2000; Dickhout et al., 2005) and vascular smooth muscle cells (Li et. al., 2003; Li et 
al., 2004b) by inducing up-regulation of adhesion molecules in endothelial cells, 
endothelial glycocalyx disruption, enhancing neutrophils adhesion (Pacher e£ at, 
2007), inhibiting voltage-gated K+ K(v) and Cat —activated K+ channels in coronary 
arterioles (Liu et al., 2002; Li et al., 2004a) and vascular prostacyclin synthase 
(Pacher et al., 2007), by which peroxynitrite may contribute to vascular 
pathophysiology. Besides, clinically applicable concentrations of 3-nitrotyrosine lead 
to concentration-dependent destruction of acetylcholine-induced, endothelium-
dependent vascular relaxation and may induce DNA damage in vascular endothelial 
cells (Mihm et al., 2000; Zou et al., 2002). 
In the state of shock, there are four main mechanisms underlying the toxicity of 
peroxynitrite. They consist of lipid peroxidation, reduction of antioxidant reserves 
(especially reduced GSH), oxidation/nitration of proteins (especially mitochondrial 
proteins) and ultimately, induction of DNA damage causing the activation of poly 
(ADP-ribose) polymerase (Gonsette, 2008). Apart from direct cytotoxic effects of 
peroxynitrite such as peroxidation of lipids, proteins and DNA, peroxynitrite also 
occupies an important place in a positive feedback loop of inflammatory injury. This 
activates pro-inflammatory signaling and triggers the recruitment of phagocytes 
within injured tissues, which further leads to combination of nitric oxide with 
superoxide to form peroxynitrite, which will progressively strengthen the initial 
inflammatory reactions. These findings suggest that reduction of peroxynitrite or its 
precursors might have a significant therapeutic role in clinical circulatory shock. A 
multitude of biological effects can occur on exposure of biological systems to 
peroxynitrite leading to adverse effects on the viability and function of cells (Table 1). 
Cancer 
Globally cancer is still considered as one of the greater killer diseases to the 
society in spite of good advancements for its diagnosis and treatment (Kotnis et al, 
2005). The percentage of death by cancer in USA and India are about 23 and 7%, 
respectively. It is a point of attention that in near future the number of cancer patients 
will increase as a result of increase in life expectancy, increase in the proportion of 
elderly population, size of population and due to absence of any mass screening 
programmes. It is expected that globally out of 15.0 million new cancer cases that will 
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Table I 
Selected biological effects of peroxynitrite 
Action Representative examples Mechanism Consequence 
Antioxidant 'Copper, zinc and 'Oxidation, 'Deleterious positive- 
enzyme manganese superoxide nitration feedback cycles 
inhibition dismutase, glutathione of injury, due to the 
reductase, glutaredoxin diminished ability 
of the cell to protect 
against oxidant 
and free-radical 
damage 
'Neuronal injury  
Antioxidant •Glutathione, cysteine 'Oxidation 'Deleterious positive- 
depletion feedback cycles 
of injury, due to the 
diminished ability 
of the cell to protect 
against oxidant 
and free-radical 
damage 
'Neuronal injury 
Cytosolic •Glyceraldehyde-3- 'Oxidation of 'Cellular functional 
enzyme phosphate cysteine impairment 
Inhibition dehydrogenase, tyrosine residues, •Inhibition of 
hydroxylase, creatine nitration tyrosine hydroxylase, 
kinase, tyrosine impaired dopamine 
phosphatases, aconitase production in 
dopaminergic 
neurons (for 
example, 
in Parkinson's 
disease)  
Protein •cc-synuclein and 'Oxidation, •Lewy-body 
aggregation microtubuleassociated tau nitration formation, 
protein modifications in neurodegeneration 
the CNS 
Impairment of 'Conversion of 'Oxidation •Impairment of BH4- 
enzyme tetrahydrobiopterin (BH4) mediated 
cofactors to the quinonoid enzymes (most 
5,6-dihydrobiopterin notably NOS 
and subsequently uncoupling) 
7,8-dihydrobiopterin 'Further destruction 
•Conversion of NADH to of BH4 via 
NAD} and superoxide NOSdependent 
formation of 
peroxynitrite 
'Imbalance in 
cellular pyrimidine 
nucleotide levels 
•Inhibition of NAD- 
dependent enzymes 
'Positive-feedback 
cycle of cytotoxic 
oxidant gration 
Modification •Prostacylin synthase, •Nitration, 'Inhibition of 
of mediator fibroblast growth factor, oxidation, prostaglandin 
pathways and interleukin 8, interleukin generally leading formation, 
cellular 10 to impaired imbalance of pro- 
signalling •Modifications of function (except and 
molecules cyclooxygenase activity nitration of antiinflammatoiy 
interleukin 10 mediator pathways 
enhances its anti- 
inflammatory 
effect) 
•Substrate or 
inactivator 	of 
cyclooxygenase 
depending on 
concentrations 
Upregulation •Endothelial cells, •NFxB activation, -Enhanced 
of neutrophils PARP activation inflammatory 
adhesion responses 
receptors 
Surfactant 'Human and bovine 'Oxidation, •Impaired pulmonary 
protein surfactants nitration defence 
damage 
Calcium •Myocytes, neurons, •Dysfunctional 'Alterations in 
Dysregulation immune cells calcium pumps myocardial and 
and impaired skeletal muscle 
overall cell contractility 
energetics 'Cellular energetic 
'Nitration of dysfunction, 
SERCA in vitro promotion of cell 
and in vivo death (necrosis, 
a o tosis 
Lipid 'Formation of 'Oxidation, 'Nitration of fatty 
peroxidation malondialdehyde, nitrosation, acids may lead to 
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NOS, nitric oxide synthase; SERCA, sarco/endoplasmic reticulum Ca'+-ATP-ase. EGF, 
epidermal growth factor; ERK, extracellular signal-regulated kinase; IRS I, insulin 
receptor substrate 1; JNK, c jun N-terminal kinase; MAP, mitogen-activated protein; 
MMP, matrix metalloproteinase; NFi B, nuclear factor-KB; PARP, poly(ADP-ribase) 
polyinerase; SCOT, succinyl-CoA:3-oxoacid CoA transferase (also known as OXCTI); 
SERCA, sarco/endoplasmic reticulum Cat+-ATP-ase; STAT3, signal transducer and 
activator of transcription 3. 
Source: Szabo, C., IschiropouIos, H. and Radi, D. (2007) Nature (London) 6: 662-
680. 
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be diagnosed by 2020, 12.0 million cancer patients will die by this deadly disease 
(Brayand and Moller, 2006). According to the study done in India, it is expected that 
the number of new Tobacco Related Cancers (TRC) incidence in males would rise 
from 276,316 cases (0.276 million) in 2011 to 448,276 cases (0.448 million) in 2026. 
TRC accounted for nearly 46-48% of all cancers seen amongst men. On the other 
hand, it is 16-18% in females. On considering both the sexes, the incidence due to 
TRC would rise from 383,407 cases (0.383 million) to 622,502 (0.623 million) cases. 
Cancer appears to be a significant public health problem, with an estimated 1.19 
million cases in 2011 and 1.86 million cases in 2026, in India (D'Souza et al., 2013). 
Figure 5 shows data of cancer patients that was compiled from 2004 to 2010 in India. 
Today, millions of people are living with cancer or have had cancer. Cancer starts 
when cells in a part of the body start to grow out of control. There are many kinds of 
cancer, but they all start because of out-of-control growth -of abnormal cells. 
Therefore it can be said that carcinogenesis is the malignant transformation of a cell 
or group of cells (Farber and Cameron, 1980; Potter, 1983; Farber, 1984). Almost 
every tissue in the body can spawn malignancies; some even yield several types, with 
each cancer having unique features. The genes implicated in the malignancy are often 
modified forms of the human genes. The activation of the proto-oncogenes into 
oncogenes, the product of which when altered contribute to malignancy. Mutation can 
also convert proto-oncogenes into carcinogenic oncogenes. 
Cancer has a multifactorial etiology including both genetic and environmental 
factors (Gourley et al., 1992). The cancer incidence by genetic factors is less eye-
catching and more difficult to identify (Clemens, 1991). Different environmental 
factors are responsible for maximum percentage of all human cancers among which, 
tobacco consumption in different forms is the main cause of cancer of lung, larynx, 
mouth, pharynx, bladder, pancreas, and probably kidney (WHO, 1983). It has been 
seen that smoking cigarette leads to the depletion of antioxidants and increase in 
number of neutrophils in lung resulting in overall increase in the level of free radicals. 
Excessive consumption of tobacco results in increase generation of free radicals and 
brings out immunosuppression (Enwonwu and Meeks, 1995). On the other hand, 
consumption of alcohol is associated with cancer of oesophagus, Iiver and rectum 
(Kabat et al., 1986; Eskelson et al., 1993). Sometimes, dietary factors such as food 
additives, high fat diets, etc., have also been related to cancer (Ames, 1983). There are 
31 
1400000 
1200000 Ptedicted 
1000000 Incidentcases 
case 	■ 11 OIN 
■Females 
800000 ■ Total 
600000 - 
v 
400000 
200000 
0 
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32 
certain viruses that are associated with hepatocellular carcinoma (HCC) as Hepatitis B 
and C (Blumberg et al., 1975). It has been estimated that around 40% of all HCCs 
cases worldwide occur in Hepatitis B virus (HBV)-infected individuals. Labors 
working in different industries are also prone to different cancers due to their 
exposure, called occupational exposure, to benzene, arsenic, cadmium, chromium, etc. 
(Kasai and Nishimura, 1984; Frenkel, 1992; Kolachna et al., 1993). Environmental 
factors are also responsible for carcinogenesis like sunlight, radiations, pesticides and 
medications. (Ananthaswamy and Pierceall, 1990; Liehr, 1997). In India the first three 
leading cancer sites are breast, cervix and lung (Satyanarayana and Asthana, 2008). 
Reactive oxygen species (ROS) generated by most of the exogenous carcinogens 
are the key players of different cancers. (Frenkel, 1992; Leanderson, 1993; Feig et al., 
1994; Erhardt et al., 1997). Therefore, exogenously as well as endogenously produced 
ROS are known to be the main causative agents in the initiation and promotion of 
multistage carcinogenesis (Totter, 1980; Ames, 1989; Toyokuni et al., 1994; Sadani 
and Nadkarni, 1996). 
Cancer: The radical causes 
The initiation of an inflammatory response is generated by infectious and non-
infectious chronic injuries (Coussens and Werb, 2002; Nathan, 2002). The., 
inflammatory response leads to the recruitment of mast cells and leukocytes to the 
damaged site. In answer to the inflammatory response, `respiratory burst' takes place 
which occurs with an increased uptake of oxygen that Ieads to the discharge of free radicals 
from leukocytes, including activated macrophages. This phenomenon sometimes 
may damage otherwise healthy neighboring epithelial and stromal cells. Due to this 
phenomenon alterations in the targets and pathways that are crucial to normal tissue 
homeostasis may take place which in turn can drive carcinogenesis (Christen et al., 
1999; Coussens and Werb, 2002). About one in four of all cancer cases worldwide are 
due to chronic infection and associated inflammation (Ames et al., 1995; Coussens 
and Werb, 2002). DNA, RNA, proteins and lipids are the main targets of free radicals 
in biological system. Certain key events that the free radicals carry out are mutation in 
cancer-related genes; post translational modifications in proteins, like oxidation, 
nitration, acetylation, phosphorylation; lipid peroxydation, etc. Transgenic and 
knockout animal models have been used to demonstrate the role of free radicals in 
carcinogenesis. The eventual effect of free radicals is multifaceted and depends on 
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their local concentration, the micro environment and the genetic milieu of the 
individuals (Hussain et al., 2003). 
Carcinogenesis due to DNA damage and protein modifications by free radicals 
In vitro studies have shown the role of free radical damaged DNA and modified 
proteins in carcinogenesis. One of the earliest studies proved that hydrogen peroxide 
(H202), in the presence of a peroxidation activator, causes chromosomal fragmentation 
(Phillips, 1956). Since then, many experiments have revealed the role of other free 
radicals in DNA damage and protein modifications (Wiseman and Halliwell, 1996; 
Marshall et al., 2000; Marnett, 2000; Aulak et al., 2001). Hydroxyl radical (OH), 
which causes oxidative DNA damage, is highly reactive in vitro, but in vivo, the 
significance of OH' to DNA damage, however, remains unclear because it has a very short 
half-life, and, therefore, has to be formed directly adjacent to DNA to induce damage 
(Pryor, 1986). By contrast, - ONOO -, which causes both oxidation and nitration of 
DNA bases can diffuse within cells (Radi, 1998), and so might be of meticulous 
concern during chronic inflammation. Oz - and H202 are two other toxic species, but 
their toxicity is thought to be due to their metal ion-catalyzed conversion into highly 
reactive OH' (Halliwell and Gutteridge, 1989; Halliwell and Aruoma, 1991). The 
modifications caused by OH' result into a unique and extensive pattern in DNA and 
nucleoprotein, including modified bases and DNA protein crosslinks (Oleinick et al., 1987; 
von Sonntag, 1987; Dizdaroglu, 1991; Halliwell and Aruorna, 1991). The fommation of such 
lesions in DNA may be promutagenic and may be a key player in carcinogenesis (Halliwell 
and Gutteridge, 1989; Breimer, 1990; Floyd, 1990; Halliwell and Aruoma, 1991). 
Not only DNA but proteins are also at high risk of modifications by different free 
radicals, both structurally and functionally. For example, proteins such as DNA-repair 
enzymes, those concerned in signal transduction, apoptotic modulators, p53 protein, 
etc., can be modified by the effects of various free radicals which in turn produce 
certain structural and functional alterations leading to carcinogenesis. There is a 
balance between the production of free radicals, which are generated as a result of 
different endogenous cellular processes, and their check by the delicately balanced 
antioxidant enzyme machinery. But if this balance gets disturbed it may cause oxidative 
damage to the biomolecules including DNA and proteins. Therefore, the key reasons 
associated with carcinogenesis by free radicals include DNA damage, protein 
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modification and alterations in the transcriptional activation and/or repression of genes 
that are accountable for cellular homeostasis (Hussain et al., 2003) (Fig. 6). 
Objectives of the study 
Human serum albumin (HSA) is the most abundant protein in circulation. 
Antibodies against HSA have been reported in various diseases, but it is not clear how 
this protein becomes antigenic. While, damaging role of various RNSIROS on HSA 
has been reported in various diseases. Reactive nitrogen species, like peroxynitrite, 
are generated both through chemical reactions in the environment and from 
metabolism of nitrogen and oxygen inside the cell. It is therefore thought of interest to 
investigate the effect of peroxynitrite on HSA and to probe the level of nitration of 
circulating body's proteins by using antibodies generated against peroxynitrite 
modified HSA through cross-reactive immunochemical studies. In the present study, 
commercially available HSA was modified by peroxynitrite and the structural changes 
were monitored by ultraviolet, fluorescence, circular dichroism (CD), FT-IR 
spectroscopy, differential scattering calorimetry (DSC), dynamic light scattering 
(DLS) studies, MALDI-MS, HPLC and SDS-polyacrylamide gel electrophoresis. 
Oxidative damage to HSA, upon modification with peroxynitrite, was ascertained by 
determining carbonyl content of the protein. The antigenicity of native and 
peroxynitrite-modified HSA was probed by inducing antibodies in female rabbits. The 
specificity of induced antibodies was evaluated by competition ELISA and band shift 
assay. In order to assess the possible role of peroxynitrite-modified HSA in the 
etiology of cancer, sera from patients were investigated for the presence of 
autoantibodies reactive to native and peroxynitrite-modified HSA. Furthermore, the 
experimentally induced antibodies were used as an immunochemical probe to 
determine the presence of peroxynitrite-modified HSA isolated from cancer patients. 
The extent of peroxynitrite-modified HSA may be usetbl for assessing the risk for 
cancer. 
35 
Stimulate apoptosis 
Inhibit cell cycle 
Stimulate repair 
Inhibit apoptosis 
Stimulate cev cycle 
Inhibit repair 
Jr 
Free radicals 
:b rE
ification 
DNA daranage 	" o 	proteins' 
and mutation • Aodulators. 	r~r repression 
• 
• Mnzymes -«ng M e 
Increased 	Decreased 
carcinogenesis 	 carcinogenesis 
Inhibit apoptosis 	Simulate apoptosis 
Stimulate cell cycle I 	I ibitcell cycle 
Iriibit repair 	 timulate repair 
Fig. 6. Chronic inflammation and production of free radicals regulate multiple 
cellular processes. Free radicals, released at the site of inflammation, not 
only damage DNA, but also modify cancer-related proteins and regulate 
transcription. Often, if the insult continues over a prolonged period of time, 
the scales are tipped in favor of increased tumorigenesis, with DNA damage 
and mutation, an inhibition of apoptosis, a stimulation of the cell 
cycle/proliferation and an inhibition of DNA repair. 
Source: Hussain, S.P., Hofseth, L.J. and Harris, C.C. (2003) Nat. Rev. Cancer. 3: 
276-285. 
36 

MATERIALS 
Chemicals 
Human serum albumin (HSA), 3-nitrotyrosine, anti-human/anti-rabbit lgG-
alkaline phosphatase conjugate, p-nitrophenyl phosphate, tween-20, coomassie 
brilliant blue (G-250 & R-250), sodium dodecyl sulphate, Freund's complete and 
incomplete adjuvants, agarose, bisacrylamide, 1-anilinonaphthalene-8-sulfonic acid 
(ANS) and Protein-A agarose were purchased from Sigma Chemical Company, USA. 
Milex syringe filters (0.22 µM) were purchased from Millipore 'Inc., USA. Folin-
Ciocalteau reagent was purchased from Centre for Biochemical Technology, New 
Delhi. Silver nitrate, formaldehyde, methanol, glacial acetic acid, isopropanol, sodium 
chloride, sodium carbonate, sodium bicarbonate, magnesium chloride, potassium 
chloride, guanidinium chloride, sodium hydroxide, and hydrogen peroxide were 
obtained from Qualigens, India. Flat bottom polysorp ELISA modules were purchased 
from NUNC, Denmark. Acrylamide, ammonium persulphate, bisacrylamide, 
N,N, N',N'-tertramethylethylenediamine (TEMED) were from Bio-Rad Laboratories 
USA. All other reagents/chemicals were of the highest analytical grade available. 
Equipments 
Hitachi U-2910 UV-VIS Spectrophotorneter (Tokyo, Japan), 
Spectrofluorophotometer RF-5301PC (Shimadzu, Japan), Tensor 37 FT-IR 
spectrometer (Bruker), Bio-Rad iMarkTM Microplate Reader (USA), Kubota-6500 
High Speed Refrigerated Centrifuge (Tokyo, Japan), Desk top Microfiige (Remi, 
India), Bio-Rad Molecular Imager® Gel DocTM XR System (USA), Electrophoresis 
Power Supply (Boitech, India), PAGE Assembly (Genei, Bangalore, India), Agarose 
Gel Electrophoresis Unit (Pharmacia, Sweden), Uni Bloc AUX 220 Digital Balance 
(Shimadzu, Japan), Elico pH meter, HPLC system consisted of a Hewlett-Packard 
Series 1050 device (Agilent, Geneva, Switzerland) with UV detector equipped with a 
reversed-phase C18 column, Jasco spectropolarimeter (J-815) equipped with a Jasco 
Peltier-type temperature controller (PTC-424S/15), VP-DSC microcalorimeter 
(MicroCal, Northampton, MA), DynaPro-TC 04 dynamic light scattering equipment 
(Protein Solutions, Wyatt Technology, Santa Barbara, CA) equipped with a 
temperature-controlled microsampler and AB SCIEX TOF/TOFTI 5800 
(Framingham, MA, USA) were the major equipments used in this study. 
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Collection and processing of blood samples 
Informed consents from patients as well as healthy subjects were obtained before 
taking serum samples. Sera of pre-treated cancer patients (n = 80) having cancer of 
different tissue origin (lung, n = 16; head and neck, n = 15; breast, n = 12; liver, n = 9; 
urinary bladder, n = 8; cervix, n = 7; gall bladder, n = 7; prostate, n 6) with proven 
histopathological diagnosis attending the medicine outdoor clinic or those admitted in 
the medicine ward of the Jawaharlal Nehru Medical College and Hospital (JNMCH), 
Aligarh Muslim University (AMU), Aligarh, India, were collected. Total numbers of 
male and female patients were 49 and 31, respectively, with a mean age of 40±20 
years. Sera from healthy individuals (n = 30), with a mean age of 35±15, served as 
negative control. The bioethical committee did not find anything 
objectionable/unethical vis-a-vis human subjects in this research study. Therefore, the 
present research work was awarded ethical clearance certificate. All the serum 
samples were heated at 56°C for 30 min to inactivate complement proteins and stored 
at --20°C with 0.2% sodium azide. 
METHODS 
Determination of protein concentration 
Protein concentration was estimated by the method of Lowry et al., 1951. 
Protein estimation by Lowry method 
Protein estimation by this method utilizes alkali (to keep the pH high), Cue+ ions 
(to chelate proteins) and tartarate (to keep the Cue+ ions in the solution at high pH). 
a) Folin-Ciocalteau reagent 
The Folin-Ciocalteau reagent was diluted 1:4 with distilled water before use. 
b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as under. 
i. 2% sodium carbonate in 0.1 M sodium hydroxide. 
ii. 1% copper sulphate in distilled water. 
iii. 2% sodium potassium tartarate. 
The working reagent was prepared fresh by mixing components i, ii and iii in 
100:1:1 ratio. 
c) Procedure 
Varying amounts of protein in 1.0 ml of volume were mixed with 5.0 ml of 
freshly prepared alkaline copper reagent and incubated at room temperature for 10 
W 
min. One ml of working Folin-Ciocalteau reagent was added followed by 30 min 
incubation at room temperature. The absorbance was monitored at 660 nm. Protein 
content of the unknown sample was determined from the standard plot of human 
serum albumin (Fig. 7). 
The determination of HSA concentration was also done spectrophotometrically 
using a molar extinction coefficient of 35,219 M-1cm 1 at 280 nm (Tabassum et al., 
2012). 
Laboratory synthesis of peroxynitrite 
Peroxynitrite was synthesized by rapid quenched flow process (Beckman et al., 
1996). Briefly, solutions of sodium nitrite (0.6 M in 50 mM sodium phosphate buffer, 
pH 7.4), hydrogen peroxide (0.6 N in 0.7 N HCl) and sodium hydroxide (1.2 M in 
distilled water) were prepared and chilled at 0°C for few minutes prior to use. The 
schematic representation of laboratory wares that were assembled to synthesize 
peroxynitrite is shown in Figure 8. A flow rate of 10 ml/min was adjusted to get more 
concentrated solution of peroxynitrite. The peroxynitrite was collected in 1.2 M 
NaOH and kept at –20°C. The concentration of stored peroxynitrite was assessed 
every time it was used; by recording absorbance at 302 nm and using molar extinction 
coefficient of 1670 M' cm  1 (Hughes and Nicklin, 1968) (Fig. 9). 
Modification of HSA by peroxynitrite 
Commercially available HSA was dissolved in phosphate-buffered saline (10 mM 
sodium phosphate, pH 7.4, containing 150 mM NaCl) and the modification was 
carried out by incubating 5 µM of HSA with 60, 125, 250, 500 and 750 gM 
peroxynitrite at 37°C for 3 h. The approximate pH of the incubation mixture was in 
the range of 10-11. 
Polyacrylamide gel electrophoresis (PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to the method of Laemmli (1970) using slab gel electrophoresis 
apparatus. Slight modifications were made in the original protocol only to improve 
the separation and visualization of bands. The following stock solutions were 
prepared. 
(i) Acrylamide--bisacrylamide (30:0.8): — A stock solution was prepared by 
dissolving 30 gm of acrylamide and 0.8 gm bis-acrylamide in distilled water 
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n 
Fig. 8. Assembly for laboratory synthesis of peroxynitrite. The system was 
operated under vacuum and the bypass tube was initially directed to the 
waste bottle. Once a steady flow was observed the tube was manually twisted 
to collect the peroxynitrite. Barring waste container, all flasks were covered 
with ice. 
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Fig. 9. Absorbance spectrum of peroxynitrite synthesized by rapid quenched 
flow process using sodium nitrite and acidified hydrogen peroxide. 
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to a final volume of 100 ml. 
(ii) Resolving gel buffer: -- A stock solution was prepared by dissolving 36.3 gin 
Tris base in 48.0 ml of IN HCI. The contents were mixed, pH adjusted to 8.8 
and the final volume brought to 100 ml with distilled water. 
(iii) Electrode buffer:— 3.03 gm Tris and 14.4 gm glycine were dissolved in 
distilled water and pH was adjusted to 8.3. Thereafter, SDS (1.0 g) was added 
and the volume was made up to one litre. 
(iv) Procedure for making polyacrylamide gel:— Thoroughly cleaned glass 
plates, separated by 1.5 mm thick spacer, were sealed from bottom and sides 
with 1% agarose. The resolving gel mixture (10%) was prepared by mixing the 
components and poured into the space between the glass plates and allowed to 
solidify. Protein samples mixed with sample dye (10% glycerol, 2% SDS, 0.5 M 
Tris pH 6.8 and 0.002% bromophenol blue) were placed into wells and 
electrophoresis was carried out for 3 to 8 hr at 50-80V (depending on the need). 
The electrophoresed proteins were visualized by staining with silver nitrate. 
Recipe for 10% resolving gel:—Following solutions were mixed and 
immediately poured between the glass plates. 
Component 	 Volume 
Acrylamide -- bisacrylamide 	3.3 ml 
Resolving gel buffer 	 2.5 ml 
Distilled water 	 4.0 ml 
10% SDS 	 0.1 ml 
1.5% ammonium persulphate 	0.1 ml 
TEMED 	 4.0 p.l 
SDS-PAGE under non-reducing conditions 
Native and peroxynitrite-modified HSA samples were subjected to electrophoresis 
on 10% polyacrylamide gel. The samples were mixed with one-tenth volume of 
sample dye and electrophoresed at 80 V for 3-4 hr in Tris-glycine (pH 8.3) buffer 
containing SDS. Protein bands were visualized by staining with silver nitrate. 
Silver nitrate staining of polyacrylamide gel 
The procedure described by Merril ei al., (1981) was followed for silver staining. 
Soon after electrophoresis, the protein bands were fixed by rapidly immersing the gel 
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in a mixture, containing 40% methanol and 13.5% formaldehyde, for 15 min with 
occasional shaking. The gel was then washed with distilled water twice and 
transferred to 0.02% sodium thiosulphate (Na2S2O3) solution and incubated for 2 min. 
Again, the gel was rinsed twice with distilled water. This was followed by treatment 
with 0.1% AgNO3 solution for 20 min. The gel was washed with distilled water 
briefly and then immersed in a developer solution (3% sodium carbonate solution 
containing 0.5% formaldehyde and 0.02% Na2S2O3)'for 15 min or until the gel was 
properly stained. The reaction was stopped by transferring the gel to a stopper 
solution (25% isopropanol solution containing 10% glacial acetic acid) and left for 5 
min. The gel was finally stored in distilled water. 
UV-VIS measurements of native and peroxynitrite-modified HSA 
The absorption spectra of native and peroxynitrite—modified HSA were recorded 
on Hitachi U-2910 UV-VIS Spectrophotometer in the wavelength range of 250-500 
nm using quartz cuvette of 1 cm path length. The increase in absorbance was 
calculated using the following equation. 
A native sam le — A modWed sample hyperchromicity = 	p 	p  
'A 
x 100 
1155 sample 
Fluorescence measurements of native and peroxynitrite—modified HSA 
FIuorescence emission was recorded on Spectrofluorophotometer RF-5301PC. 
Fluorescence of tyrosine residues of native (control) and peroxynitrite-modified HSA 
were monitored in the wavelength range of 300-400 nm after exciting the samples at 
275 nm, specific wavelength for tyrosine residues. Loss in emission intensity was 
computed using the following formula: 
i 
loss of FL — Flltative sample — Flmodifed sample X 100 
FT native sample 
Effective protein hydrophobicity 
Binding of ANS to native and peroxynitrite-modified HSA was evaluated in terms 
of fluorescence. The ANS fluorescence is affected by exposure or masking of 
hydrophobic patches in proteins. A fresh stock solution of ANS was prepared in 
i 
distilled water and its concentration was determined ;spectrophotometrically using a 
molar extinction coefficient of 5000 M 1cm 1 at 350 nm (Rabbani et al., 2011). The 
molar ratio of protein and ANS was 1:10 and emission spectra were recorded in the 
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range of 400-600 nm using an excitation wavelength of 380 nm. Decrease in 
fluorescence intensity (Fl) was calculated as follows: 
°ti loss of Fl — FI "„`Ve  Sample — FI I°odified sample X 100 
FT nativesample 
Determination of reactive carbonyls in peroxynitrite-modified HSA 
Peroxynitrite mediated oxidation of HSA resulted in alteration in the side chain of 
certain amino acid residues duo to generation of 2,4-dinitrophenylhydrazine (DNPH) 
reactive carbonyls. Spectrophotometric assay using DNPH reagent can give a 
quantitative estimate of carbonyl groups in proteins. In this study, protein carbonyls 
were assayed according to the method of Levine et al., (1994) with slight 
modifications. Briefly, native and peroxynitrite—modified HSA were precipitated with 
10% (v/v) ice-cold trichloroacetic acid (TCA). After 10 min incubation at 4°C, the 
samples were centrifuged at 11,000 x g for 3 min. The pellet thus obtained was re-
suspended in 0.5 ml of 10 mM DNPH dissolved in 2M HCI. The assay tubes were 
then placed in a sample holder and continuously vortexed at room temperature for, 
1 hr and precipitated with 0.5 ml of 20% (v/v) TCA followed by centrifugation at 
11,000 x g for 3 min. The pellet was washed with 1 ml of 1:1 mixture of ethanol—
ethyl acetate (v/v) to get rid of any extra DNPH reagent. Samples were incubated for 
10 min at room temperature and then centrifuged at 11,000 x g for 5 min. The 
supernatant was discarded and the pellet was washed twice with ethanol-ethyl acetate 
mixture. The protein pellet was finally suspended in I ml of 6 M guanidinium 
chloride dissolved in 2 mM potassium phosphate buffer (pH 2.3, adjusted with 
trifluoroacetic acid). The samples were incubated at 37°C for 15-30 min for complete 
dissolution of proteins. Samples having difficulties going into solution were briefly 
sonicated and incubated at an elevated temperature, up to 70°C. All samples were 
then centrifuged to remove any insoluble material from suspension. The concentration 
of DNPH was determined by measuring absorbance at 360 nm against guanidinium 
chloride (as blank) using the molar extinction coefficient of 22,000 M-'cm '. Finally, 
the carbonyl content in native and peroxynitrite-modified HSA was expressed as 
numole/mg protein. 
Estimation of dityrosine 
The dityrosine content of peroxynitrite-modified HSA was determined 
spectrophotometrically using a molar extinction coefficient of 4000 MM`cm ' at 330 
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nm (Ischiropoulos and Al-Mehdi, 1995). Dityrosine formation was also confirmed by 
fluorescence spectra after exciting native and peroxynitrite-modified HSA at 330 nm 
and measuring emission in the range of 350-450 nm. 
Nitrotyrosine determination 
The concentration of nitrotyrosine in peroxynitrite-modified HSA was determined 
by measuring the absorbance at 420 nm using a molar extinction coefficient of 4300 
M 1 cm-1  (Beckman etal., 1992). 
Circular dichroism (CD) measurements of native and peroxynitrite—modified 
HSA 
CD measurements were carried out on a Jasco spectropolarimeter (J-815) 
equipped with a Jasco Peltier-type temperature controller (PTC-424S/15). The 
instrument was calibrated with D-10-camphorsulphonic acid. Spectra were taken in a 
cell of 1 and 10 mm path length and protein concentrations used were 4.5 and 12 p.M 
for far and near-UV CD, respectively. The results were expressed as mean residue 
ellipticity (MRE) in deg cm2 dmol"' which is defined as: 
MRE =  Oobs (m deg) 
lOxnxCxI 
where Boas  is the CD in milli-degree, it is the number of amino acid residues (585-1 = 
584),1 is the path length of the cell, and C is the molar concentration of protein. 
Helical. content was calculated from the MRE values at 222 nun using the 
following equation (Chen et al., 1972): 
%a helix= MRE222nm — 2,340 x 100 
30,300 
Fourier transform infrared (FT-IR) spectroscopy of native and peroxynitrite-
modified HSA 
Lyophilized samples of native and peroxynitrite-modified HSA were analyzed on 
FT-IR spectrometer. Briefly, pellets were prepared by mixing lyophilized samples 
with potassium bromide, KBr, (to absorb remaining moisture, if any) under 5-6 T 
pressure (produced by carver press) and then subjected to spectral recording on a 
Tensor 37 FTIR spectrometer (Bruker). 
Dynamic light scattering (DLS) measurements 
DLS measurements were carried out at 830 nm by using DynaPro-TC-04 
dynamic Iight scattering equipment (Protein Solutions, Wyatt Technology, Santa 
Barbara, CA) equipped with a temperature-controlled microsampler. Before 
measurement, all the solutions were spun at 10,000 rpm for 10 min and filtered 
through a microfilter (Whatman International, Maidstone, UK) with an average pore 
size of 0.22 .tin directly into a 12 p.l black quartz cell and the protein concentration of 
native and peroxynitrite-modified HSA was 18 µM. Measured size was presented as 
the average value of 20 runs. All data were analysised by using Dynamics 6.10.0.10 
software at optimized resolution. The mean hydrodynamic radius and polydispersity 
were estimated on the basis of an autocorrelation analysis of scattered light intensity 
data based on translational diffusion coefficient (D) by the Stokes-Einstein equation: 
R 	
kT 
n — 6 Dxs°c 
w 
where, R1, is the hydrodynamic radius, k is the Boltzman's constant, T is the absolute 
temperature, i is the viscosity of water and DC  is translational diffusion coefficient 
of water at 25°C. 
Differential scanning calorimetry (DSC) 
Thermal denaturation experiments were conducted on a VP-DSC 
microcalorimeter (MicroCaI, Northampton, MA). The DSC scans were run between 
20 and 90°C at a rate of I.0°C/min. The experiments were performed using 18 pM 
HSA. The respective reference scan was run under identical DSC set up conditions 
and was subtracted from each sample scan. The heat capacity curves (Cp), midpoint 
temperature (Tm ), calorimetric enthalpy (6,Hcai) and van't Hoff enthalpy (AH„H) were 
analyzed using Origin 7.0 software. 
Protein 3-nitrotyrosine determination by High Performance Liquid 
Chromatography (HPLC) 
Pronase digested samples of native as well as peroxynitrite-modified HSA were 
subjected to HPLC analysis for nitrotyrosine determination by the HPLC system 
consisting of a Hewlett-Packard Series 1050 device (Agilent, Geneva, Switzerland) 
with UV detector equipped with a reversed-phase C18 column (4.6mmx150 mm, 
Nova-Pak, USA). The retention time of standard 3-nitrotyrosine was taken as 
reference. Briefly, the enzyme pronase protease was first dialyzed against 0.1 M 
sodium acetate buffer, pH 7.2 and added to protein samples kept in 20 mM Tris 
buffer, pH 7.4 and then the assay tubes were heated to 50°C for 16 h to hydrolyze 
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protein. The pronase:HSA ratio was 1:5 (w/w). The enzymatic digestion was stopped 
by freezing followed by lyophilization. Prior to HPLC analysis, all samples and 
solvents were filtered with Millipore 0.22 µm syringe filters. The filtered samples 
were diluted 1:2 with eluant buffer (0.5 M potassium phosphate, pH 3.0 containing 
10% methanol) before injecting into column. The flow rate was set at 0.6 ml/min. All 
samples were measured in triplicates. 
Protein 3-nitrotyrosine determination by Matrix-assisted laser desorption/ 
ionization-mass spectrometry (MALDI-MS) 
Pronase digested samples of HSA (native as well as peroxynitrite-modified) were 
subjected to MALDI-MS analysis for nitrotyrosine determination using AB SC1EX 
TOF/TOFTM 5800 SYSTEM. 3-nitrotyrosine. was used as a standard. For MALDI-MS 
analysis, pronase digested native and peroxynitrite-modified HSA as well as standard 
3-nitrotyrosine samples were directly applied onto the stainless-steel MALDI target 
sample plate with 0.1% TFA saturated with a-cyano-4-hydroxycinnamic acid, which 
is used as a matrix, and air-dried for 10 min before introduction into the mass 
spectrometer for obtaining MALDI-MS profiles. In each case, I µl of sample solution 
was mixed with 2 µl matrix, and 1 pL was deposited on the MALDI target. Mass 
spectra were acquired in the mass range between 100 and 1000 Da but a selected 
range was shown in the result. The instrument was operated in the positive reflector 
mode. All ions measured by MS were in the LM+H]+ form. 
Free radical-induced hemolysis test 
This test was performed to check the antioxidant property of native as well as 
peroxynitrite-modified HSA using the standard procedure with slight modification 
(Bourdon et al., 1999). For this test, blood was taken from healthy human male 
subject using 10% (v/v) buffered sodium citrate as anticoagulant. The RBC were 
separated from plasma by centrifugation at 800 x g for 10 min at 37°C and washed 
with five volumes of phosphate buffer saline (PBS, pH 7.4). Subsequently, pellets of 
erythrocytes were used to prepare 10% (vlv) erythrocyte suspension in phosphate 
buffer saline (pH 7.4). Oxidative hemolysis was started by adding 100 mM of peroxyl 
radical initiator AAPH t2, 2' azobis (2-amidinopropane) dihydrochloride] in 500µl of 
RBC suspension mixed with 0.5 mg/ml of native or peroxynitrite-modified HSA. A 
control sample, having AAPH only, was taken for reference. The free radical 
generation by AAPH was started by thermal shock by heating the samples to 37°C. 
The final volume of the reaction mixtures was 2 ml. Reading was taken after every 30 
min by taking 0.02 ml of the sample in 1.0 ml of PBS. After 10-60 sec centrifugation 
at 3000 x g, an aliquot (0.2 ml) of the supernatant was taken in microtitre plate and 
read at 540 nm. 
Isolation of HSA from cancer patients as well as healthy individuals 
HSA was isolated according to the method described earlier (Tayyab and Qasim, 
1990). HSA was isolated from the plasma of normal individuals and cancer patients. 
Briefly plasma separated from the normal healthy individuals and patients was 
brought to 2.26 M in ammonium sulphate by adding requisite volume of 4 M 
ammonium sulphate solution pH 7.0_ The mixture was kept for 12 hr at room 
temperature and then carefully diluted with water with frequent addition of 0.5 N 
H2SO4 such that the final concentration of ammonium sulphate was reduced to 1.9 M 
and pH to 4.2. After incubating it for 12 hr at room temperature, the precipitate was 
collected by centrifugation at 3000 x g for 30 min. It was washed 3 times with 2.2 M 
ammonium sulphate, pH 4.2 and then dissolved in 0,06 M sodium phosphate buffer 
pH 7.4 containing 0.08 M NaCl. The protein precipitation thus obtained, i.e. albumin, 
was extensively dialyzed against 6 litres of 0.06 M sodium phosphate buffer pH 7.4 
and stored at 4°C. Thereafter, a column of Sephacryl S-200 HR (60 x 1.5 cm) was-
packed and equilibrated with 0.06 M sodium phosphate buffer pH 7.0. The void 
volume of the column was determined by passing blue dextran (5 mg/ml) and was 
found to be 54 ml. Each dialyzed sample was loaded on top of the column and eluted 
with 0.06 M sodium phosphate buffer pH 7.4 at a flow rate of 15-20 mllh in 3 ml 
fractions. Protein in each fraction was monitored by the method of lowry et al., 
(1951). 
Immunization of animals 
Healthy, random bred female New Zealand white rabbits (1-1.5 Kg) were 
separately challenged with 200 ug each of HSA and its peroxynitrite-modified 
counterpart, as described previously (Dixit et al., 2005). The immunogen was 
emulsified with equal volume of Freund's complete adjuvant (first injection). 
Intramuscular injections were given at multiple sites. Subsequent injections of 
respective immunogens were given in Freund's incomplete adjuvant at weekly 
intervals. During the course of immunization each animal received a total of 1200 µg 
of immunogen. One week after the last dose, marginal ear veins of immunized 
animals were punctured and blood was carefully collected. Pre-immune blood was 
collected before immunization from all animals. Sera were separated and 
decompleinented by heating at 56°C for 30 min and stored at --20°C with 0.1% 
sodium azide as a preservative. 
Isolation of IgG by Protein A-agrose column 
IgG from rabbit sera was isolated by affinity chromatography on Protein A-
agarose affinity column (Ahmad et al., 2011). Protein-A (from Staphylococcus 
aureus) binds to IgG from most mammalian species through unique histidine residues 
present in Fc region of the molecule. The column was pre-equilibrated with PBS and 
0.3 ml serum was applied on it. The wash through was recycled 2-3 times and 
unbound material was removed by extensive washing with PBS. The bound IgG was 
eluted with 0.58% (v/v) acetic acid in 0.85% (w/v) sodium chloride and collected in 
tubes containing 1.0 ml of 1.0 M Tris—HCI, pH 8.5. Three ml fractions were collected 
and their absorbance was read at 278 nm. The IgG concentration was determined 
considering 1.4 OD278 = 1.0 mg IgG/ml. The homogeneity of isolated IgG was 
checked on 10% SDS—PAGE. The isolated IgG was dialyzed against PBS and stored 
at —20°C with 0.1% sodium azide as a preservative. 
Immunological detection of antibodies 
Pre-immune and immune sera were tested for antibodies against native and 
peroxynitrite-modified HSA by enzyme linked immunosorbent assay (ELISA) and gel 
retardation assay. Furthermore, sera of cancer patients were processed in a similar 
way. 
Reagents for ELISA: Following reagents were used in ELISA; 
[i], Protein coating buffer: 15 mM sodium carbonate, 35 mM sodium bicarbonate, 
pH 9.6. 
[ii]. Tris-ba fered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4. 
[iii]. Tris-buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM 
NaCl, 2.68 mM KC1, pH 7.4, containing 500 .i1 Tween-20 per litre. 
[iv]. Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6, containing 2 mM magnesium chloride. 
[v]. Substrate: 500 µg p-nitrophenyl phosphate per ml of above carbonate-
bicarbonate buffer. 
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Direct binding ELISA 
ELISA was performed on flat bottom polystyrene plates as described earlier (All 
and Alam, 2002). Polystyrene PolySorp immunoplates were coated with 100 }il of 
native or peroxynitrite-modified HSA (10 µg/ml) in antigen coating buffer. The plates 
were incubated for 2 h at 37°C and overnight at 4°C. Each sample was assayed in 
duplicate and half of the plate, devoid of antigen coating, served as control. The wells 
of the test plates were washed three times with TBS-T (20 mM Tris, 2.68 mM KCI, 
150 mM NaCl, pH 7.4, containing 0.05% Tween-20) and unoccupied sites were 
blocked with 150 µl of 1.5-2.5% fat-free skimmed milk in TBS (10 mM Tris, 150 
mM NaCI, pH 7.4) for 4-6 h at 37°C. After incubation, the plates were washed 5-6 
times with TBS-T. Test serum, serially diluted in TBS-T, was added to each well (100 
pllwell) and reincubated for 2 h at37°C and then overnight at 4°C. After incubation, 
the plates were washed three times with TBS-T and bound antibodies were assayed 
with anti-rabbit alkaline phosphatase conjugate in TBS. After 2 h incubation, the 
plates were again washed three times with TBS-T and twice with distilled water and 
then coated with p-nitrophenylphosphate (substrate). Absorbance (A) in each well 
was monitored at 405 nm on an automatic microplate reader. Results were expressed 
as mean of Atest--A°011rul. 
Competition ELISA 
The antigenic specificity of antibodies was determined by competition ELISA 
(Habib et al., 2005). The plates were coated with 100 VI of antigen (native or 
peroxynitrite-modified HSA, 10 pg/ml) for 2 h at 37°C and overnight at 4°C. Varying 
amounts of inhibitors (0-20 pglml) were mixed with a constant amount of antiserum 
or affinity purified IgG. The mixtures were incubated at 37°C for 2 h and overnight at 
4°C. The immune complex thus formed was coated in the wells instead of serum. The 
remaining steps were the same as mentioned above in direct binding ELISA. Percent 
inhibition was calculated using the equation: 
Percent inhibition = 1 —  A'"hiblied  x 100 
Arrninrited 
Gel retardation assay 
Antigen-antibody specificity was analyzed by mobility shift assay in 
polyacrylamide gel (Khan et at., 2007). Immune complex was prepared by incubating 
constant amount of antigen (native and peroxynitrite-modified HSA) with varying 
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amounts of anti-peroxynitrite-modified HSA antibodies for 2 h at 37°C and overnight 
at 4°C. The reaction mixture was brought to room temperature and mixed with one-
tenth volume of 0.002% bromophenol blue dissolved in a mixture of 0.5 M Tris (pH 
6.8), 2% SDS and 10% glycerol. The samples were applied into the wells of 10% 
polyacrylamide gel and electrophoresed at 80 V for 3-4 h in Tris-glycine buffer 
(pH 8.3) containing SDS. Bands were visualized by staining with silver nitrate. 
Statistical analysis 
Data are presented as mean ± standard deviation (±SD). Statistical significance of 
data was determined by Student's t test and a p value of <0.05 was considered as 
significant. 
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Physicochemica[ characterization of native and peroxynitrite-modified HSA 
The evaluation of the peroxynitrite induced structural/conformational changes in 
commercially available HSA were done by ultraviolet, fluorescence, circular 
dichroism and FT-IR spectroscopy, SDS-PAGE, DSC, DLS, HPLC, MALDI-MS 
analysis and determination of carbonyl content. 
Ultraviolet absorption spectroscopy of native and peroxynitrite-modified HSA 
A constant amount of HSA was incubated with the varying concentration of 
peroxynitrite just to know the optimum concentration of the modifying agent giving 
maximum damage in protein. Native HSA showed an absorbance peak at 278 nm 
which exhibited hyperchromicities upon modification by different concentrations of 
peroxynitrite (Fig. 10). Repeated experiments exhibited little difference between the 
hyperchromi cities induced by 500 and 750 pM peroxynitrite. Therefore, HSA 
modified with 500 jiM peroxynittite was used in further studies. The absorbance 
profile of peroxynitrite-modified HSA also showed peak at 420 nm, which is a 
characteristic peak of 3-nitrotyrosine (Fig. 10, inset). Furthermore, the generation of 
yellow colour in samples of peroxynitrite-modified HSA (with absorption peak at 420 
nm) also reflects the formation of nitrotyrosine. The nitrotyrosine content in modified 
HSA was calculated to be 29.6 ± 2.3 nmollmg protein. Absorbance at 280 nm and 
percent hyperchromicity values of native and peroxynitrite-modified HSA are 
summarized in Table II. 
SDS-polyacrylamide gel electrophoresis of native and peroxynitrite-modified 
HSA 
Native and peroxynitrite-modified HSA were subjected to polyacrylamide gel 
electrophoresis under non reducing conditions and the migration pattern of the bands 
was analyzed by silver staining (Fig. 11). Native and peroxynitrite-modified HSA 
samples (10 jig each) were loaded into the wells of 10% polyacrylamide gel. Native 
HSA moved as compact single band while HSA, modified with increasing 
concentrations of peroxynitrite, showed thickening of bands as compared to the native 
protein. Since, HSA modified with 500 gM peroxynitrite (lane 5) showed maximum 
band width. Therefore, this concentration of peroxynitrite was used for all other 
studies. It is quite clear that peroxynitrite induced modification has produced 
significant structural changes in HSA. 
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Fig. 10. Absorbance spectra of native HSA (-A-) and HSA modified by 60 pM 
(-d-), 125 pM (-s-), 250 pM (-o-), 500 gM (-e-) and 750 µM (-o-) 
peroxynitrite. Inset shows absorbance profile of standard 3-nitrotyrosine. 
The spectra are the average of three determinations. 
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Table TI  
Absorbance data of native and peroxynitrite-modified HSA 
Sample 	 UV absorbance# 	Percent hyperchromicity 
Native HSA 	 0.164 	 — 
Peroxynitrite-modified HSA 	0.179 	 9.14 
(60 jiM) 
Peroxynitrite-modified HSA 	0.199 	 2I.34 
(125 AM) 
Peroxynitrite-modified HSA 	0.226 	 37.80 
(250 AM) 
Peroxynitrite-modified HSA 	0.235 	 43.29 
(500 KM) 
Peroxynitrite-modified HSA 	0.239 	 45.70 
(750 AM) 
# Va1ue at 278 nm. 
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Fig. 11. SDS-polyacrylamide gel electrophoresis of HSA under 
non-reducing conditions. Protein samples (10 g in each 
lane) were loaded on gel. Electrophoresis was performed 
on 10% SDS—PAGE for 4 h at 80 V. Lanes: (1) Native 
HSA; (2-5) HSA modified with 60, 125, 250 and 500 iiM 
peroxynitrite. 
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Estimation of dityrosine 
The formation of dityrosine was confirmed from fluorescence spectroscopy by 
exciting the samples at 330 nm, specific for dityrosine, and recording the peak 
between 350-500 nm. A prominent emission peak at 401 nm in the case of 
peroxynitrite-modified HSA was seen, which was completely absent in native protein 
(Fig. 12). The dityrosine concentration of peroxynitrite-modified HSA was measured 
by absorbance spectroscopy which was found to be 112.7 ± 3.1 nmol/mg protein. 
Fluorescence characteristic of native and peroxynitrite.-modified USA 
Changes in the overall tertiary structure of proteins can be inferred by variations 
in fluorescence intensities and the wavelengths of emission maxima (71,). The 
intrinsic fluorescence probes of proteins are aromatic amino acids viz., tryptophan, 
tyrosine and phenylalanine. Peroxynitrite-modified HSA showed 79% loss in 
fluorescence intensity and a blue shift of 34 nm as compared to its native form when 
excited at 275 nm, which is considered as a specific excitation wavelength for 
tyrosine residues (Fig. 13). 
Measurement of hydrophobic surface accessibility by ANS binding experiment 
The conformational changes in HSA after peroxynitrite treatment, compared to 
the native analogue, and measurement of its hydrophobic surface accessibility were 
studied by ANS binding experiment. ANS is an extrinsic probe which can bind to 
apolar sites on proteins. It gives high fluorescence emission upon binding to 
hydrophobic regions, but does not fluoresce when present free in solution or in 
denatured protein solution (Rabbani et al., 2012). Compared to the native protein, 
peroxynitrite-modified HSA showed 88.2% loss in fluorescence intensity (Fig. 14). 
Determination of protein-bound carbonyl groups 
Carbonyl content is the most commonly used marker of protein oxidation and its 
accumulation has been observed in many human diseases (Beal, 2002). The typical 
markers of protein oxidation are carbonyls of lysine, arginine, threonine and proline 
residues which are detected after their derivatization with 2,4-dinitrophenyl 
hydrazine. The reaction forms a stable 2,4-dinitrophenyl hydrazone which is 
measured spectrophotometrically at 360 nm. The carbonyl contents of native and 
peroxynitrite-modified HSA were found to be 3.1 ± 0.4 and 20.24 ± 1.2 nmol/mg 
protein, respectively (Fig. 15). This corresponds to almost seven fold increase in 
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Fig. 12. FIuorescence emission spectra of native (-A-) and peroxynitrite-modified 
HSA (-A-) at excitation wavelength of 330 rim for dityrosine. The spectra 
are the average of three determinations. 
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Fig. 13. Fluorescence emission spectra of native (- A-) and peroxynitrite-modified 
HSA (-A-) at excitation wavelength of 275 nm for tyrosine residues. The 
spectra are the average of three determinations. 
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Fig. 14. Fluorescence emission spectra of native (-A-) and peroxynitrite-modified 
HSA (-A-) at excitation wavelength of 380 nrn for ANS binding. The 
spectra are the average of three determinations. 
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Fig. 15. Carbonyl content of native and peroxynitrite-modified HSA. The bars 
show average carbonyl content (±SD) of three independent assays. 
carbonyl level as compared to the native HSA. 
CD profile of native and peroxynitrite-modified HSA 
The secondary structure of HSA was monitored by far-UV CD experiment. The 
amide chromophores of the peptide bonds in proteins give CD spectra in far-UV 
range (200-250). The spectra showed a decrease in percent helicity of HSA upon 
peroxynitrite modification. The CD spectra of HS exhibited two minima, at 208 and 
222 nm, which is typical for a-helical structure (Fig. 16A). After calculations, it was 
found that the a-helix content was 64% in native HSA while it was 45% in the case of 
peroxynitrite-modified counterpart. 
The tertiary structure of proteins is inferred by near-UV CD spectra which are 
sensitive to the environment of aromatic side chains and have contributions from 
disulfide bonds (Kelly and Price, 1997). The native HSA showed a broad band at 
around 275 nm, which is specific for tyrosine residue. However, this band was less 
pronounced in the case of peroxynitrite-modified HSA, which shows that tyrosine 
residue(s) is/are modified by the effect of peroxynitrite. Moreover, the value of 268 
nm peak, specific for phenylalanine, was observed to be decreased in case of 
peroxynitrite-modified HSA as compared to native HSA. The disulphide bond gives 
peak at around 255 nm which got shifted in case of peroxynitrite-modified HSA (Fig. 
16B). 
FT-IR studies on native and peroxynitrite-modified HSA 
The changes in the secondary structure of HSA, inferred by far-UV CD spectra, 
were further confirmed by FTIR spectroscopy, a powerful technique used to 
determine the secondary structures of proteins. Bands originating due to amide I and 
amide II vibrations of native as well as its counterpart modified form were analyzed. 
The amide I band, which arises due to C=O stretching, is particularly important in the 
secondary structure studies (Tian et al., 2004). Upon peroxynitrite modification of 
HSA, the amide I band was shifted from 1656 to 1638 cm 1 while a shoulder of amide 
II band, which arises due to CN stretching and NH bending, shifted from 1553 to 
1546 cm-1 (Fig. 17). 
Dynamic light scattering (DLS) measurements 
A DLS measurement was performed to see the changes in hydrodynamic radii 
(Rh) of native and peroxynitrite-modified HSA (Fig. 18). We observed a broadening 
in histogram in the case of peroxynitrite-modified HSA. The hydrodynamic radius 
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Fig. 16. Far-UV (A) and Near-UV (B) CD spectra of native (- A-) and peroxynitrite- 
modified HSA (-A-). The spectra are the average of three determinations. 
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Fig. 17. FT-IR spectra of (A) native and (B) peroxynitrite-modified HSA. 
The spectra are the average of three determinations. 
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Fig. 18. Dynamic light scattering of native HSA (A) and peroxynitrite-modified HSA 
(B). Determination of hydrodynamic radii (Rh) of HSA was done in absence 
and presence of peroxynitrite. The histograms are the average of three 
determinations. 
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(Rh) of native HSA was found to be 4.2 nm which is in agreement with the previous 
observations (Ahmad et al., 2012), while the Rh, value of peroxynitrite-modified HSA, 
4.7 nm, was found to be greater than the native protein. Characterization of native and 
peroxynitrite-modified HSA has been shown in Table III. 
Differential scanning calorimetry (DSC) studies 
DSC experiment was performed to compare the thermal transition characteristics 
of HSA in absence and presence of peroxynitrite. On the basis of deconvolution 
results, the existence of two endothermic peaks was observed for the native and 
peroxynitrite-modified HSA (Fig. 19). The native protein showed a peak (T,l, 
58.03±0.21°C) and a broad shoulder in the temperature range of 65-75°C (T,n 
69.58±0.088°C). Peroxynitrite-modified HSA showed the thermogram shift towards 
lower temperature, compared to the native HSA. The peroxynitrite-modified HSA has 
a first peak at around 53.08±0.032°C in addition to the second peak (T,n = 
63.45±0.21°C), which too was lowered by peroxynitrite treatment. The ratio of 
OH„HIAHcal is one of the most important parameters of a transition process which can 
be obtained via DSC analysis. According to the calculated data obtained from 
OH„H'AHcat ratio of first transition (R'), the peroxynitrite-modified HSA gave higher 
value than the native HSA. A greater than I ratio of AHvx/AHcat reflects two things, 
self-association between domains and enhancement of internal forces between the 
domains. With regards to the calculated ration , of second transition, R2, a greater 
difference in T,n and a lowest value of AH„H/AHcal ratio 0.15±0.01 was observed for 
peroxynitrite-modified HSA compared to the native protein (Table IV). 
Determination of protein 3-nitrotyrosine by HPLC 
To analyze the formation of 3-nitrotyrsoine in peroxynitrite-modified HSA, 
we subjected standard 3-nitrotyrosine; pronase digested native and peroxynitrite-
modified HSA to HPLC examination. But !before probing the presence of 
3-nitrotyrosine in peroxynitrite-modified HSA, HPLC profile of commercially 
available 3-nitrotyrosine was taken as a reference which was eluted at 13.5 min (Fig. 
20A). Moreover, peroxynitrite-modified HSA was subjected to HPLC analysis. We 
observed a peak at a retention time close to 13.25 min (Fig. 20C) which was matched 
with the retention time of standard 3-nitrotyrosine. In contrast to this result, native 
HSA did not give any peak at around 13.5 min (Fig. 20B) when subjected to the 
Table III 
Characterization of native and peroxynitrite-modified HSA 
Parameters 	 Native HSA 	Peroxynitrite-modified HSA 
Absorbance (at 278 nm) 0.164 0.235 
Fluorescence intensity, Fl 114.77 22.25 
275) 
ANS binding, FI 107.84 12.75 
a(Xe;;= 380) 
Carbonyl content 3.1 f 0.4 20.24 ± 1.2b 
(nmol mg 1 protein) 
Nitrotyrosine conc. - 29.6 ± 2.3 c 
(nmoI.mg 1` protein) 
Dityrosine conc. - 112.7±3.lc  
(nmoLmg ' protein) 
Far-UV CD 
dMRE 222 nm —21606 —15971 
ea—helix (%) 64 45 
Near-UV CD 
dMRE 275 nm —1263 —1072 
FTIR, peak positions 
(Amide I, cm 1) 1656 1638 
(Amide II, cm-1) 1553 1546 
Hydrodynamic radius (Rh) 4.2 4.7 
(in mu) 
a7,x = excitation wavelength. 
6p < 0.001 versus native HSA. 
p < 0.001 
` fMRE value in deg cm' drool-1. 
`a—helix (%) calculated by Chen et ad. method 
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Fig. 19. Differential scanning calorimetry (DSC) profiles of native (—) 
and peroxynitrite-modified HSA ("""),I Samples were prepared in 
20 mM sodium phosphate buffer, pH 7.4. The spectra are the 
average of three determinations. 
Table IV 
Thermodynamic parameters for the thermal unfolding of native and 
peroxynitrite-modified HSA measured by DSC 
Transition 	Parameters Native HSA 	 Modified HSA 
15` transition 
T." 58.03±0.21 
AH' 110.0±0.856 
AHVH 92.59±0.512 
R' 0.84±0.01 
2°3 transition 
Tm 69.58±0.088 
AHcai 61.4±0.940 
AHVH 63.44±0.989 
R2 1.03±0.02 
R' or R2 9H H/L.Hcai 
TR, is expressed in °C 
AH is expressed in kcal/mol 
53.08±0.032 
61.75±0.978 
82.93±0.642 
1.34±0.03 
63.45±0.21 
334.5±1.05 
52.46±1.25 
0.15±0.01 
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Fig. 20. HPLC chromatogram of standard 3-nitrotyrosine (A), pronase 
treated native (B) and peroxynitrite-modified HSA (C). The 
spectra are the average of three determinations. 
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HPLC analysis in the same experimental conditions. 
Determination of protein 3-nitrotyrosine by MALDI-MS analysis 
The MALDI-MS analysis was done to verify the formation of 3-nitrotyrosine in 
HSA after peroxynitrite treatment. Only desired m/z has been shown in figure 21. The 
MALDI-MS analysis of standard 3-nitrotyrosine, taken as a reference, revealed a 
major ion with m/z of 227, which is consistent with the predicted mass for 
3-nitrotyrosine (Fig. 21A). The native HSA did not give any mass at mlz 227 of 
nitrotyrosine (Fig. 21B), in contrary to the peroxynitrite-modified protein, which 
showed mass at m/z 227 (Fig. 21 C). 
Free radical-induced hemolysis test 
Free radical induced hemolysis test was performed to determine the effects of 
peroxynitrite on antioxidant property of HSA. AAPH [2, 2' azobis (2-
amidinopropane) dihydrochloride] was used to mimic the in vivo condition of 
oxidative stress, i.e., generation of free radicals in time dependant manner. As shown 
in figure 22A, we observed different Iag phases (protective phases) for the different 
incubation conditions of RBCs and the lengthiest lag phase was observed when native 
HSA was there in the RBCs suspension. Hemolysis was almost negligible when 
RBCs suspension was in PBS only. But maximum percent hemolysis, in a time 
dependent manner, was seen when RBCs suspension was incubated merely in the 
presence of AAPH, which served as control, showed shortest lag phase. Compared to 
the native HSA, hemolysis was more when incubation was done in the presence of 
peroxynitrite-modified HSA in addition to the AAPH. The 50% of maximal 
hemolysis time (HT50 in hour) for native HSA, peroxynitrite-modified HSA and for 
control were 4.5 h, 3.6 h and 3.15 h, respectively (Fig. 22B). 
Immunogenicity of native and peroxynitrite-modified HSA 
To check the immunogenicity of native and peroxynitrite-modified HSA, female 
rabbits were immunized with the respective antigens. After booster dose the antisera 
of animals were collected and assayed by direct binding and competition ELISA on 
polysorp ELISA plates coated with the respective immunogens. 
The direct binding ELISA result showed antibody titre of >1:12800 in 
peroxynitrite-modified form (Fig. 23B) as compared to <1:6400 titre obtained in the 
case of native HSA (Fig. 23A). This clearly indicates that peroxynitrite modification 
of HSA has made the protein an even more potent immunogen. Preimmune serum 
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Fig. 21. MALDI-MS spectra of (A) standard 3 -nitrotyrosine; pronase treated 
(B) Native HSA and (C) peroxynitrite-modified HSA. The instrument 
was operated in the positive reflector mode. All ions measured by MS 
were in the [M+Hj{ form. 
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Fig. 22. Free radical-induced blood hemolysis test for measuring antioxidant 
property of native and peroxynitrite-modified HSA. Hemolysis was 
monitored spectrophotometrically at 540 nm using microplate reader. 
(A) Curves illustrating the antioxidant effects of native (—A—)  and 
peroxynitrite-modified HSA (—A—), compared with control (—u—). 
Different lag phases can be easily observed in the given figure. Cell 
suspension only in PBS, pH 7.4, was also taken (—❑—). (B) Histogram 
showing 50% of the maximal hemolysis time (HT50 in hour) of native 
and peroxynitrite-modified HSA compared to control. 
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Fig. 23. Level of induced antibodies against native and peroxynitrite-modified 
HSA. Direct binding ELISA of (A) native HSA and (B) peroxynitrite-
modified HSA with pre-immune (-A-); and immune (-A-) sera. 
ELISA plate was coated with the respective antigens (10 4g/mI). 
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when used as control showed negligible binding with either immunogen under 
identical experimental conditions. 
Competitive inhibition ELISA was done to detect the specificity of experimentally 
induced antibodies against peroxynitrite-modified HSA. An inhibition of 52.9±1.7% 
was observed at 20 1.cg/m1 when native HSA was used as an inhibitor of anti-
peroxynitrite-modified-HSA antibodies (Fig. 24A), while it was 81.4±3.2% when 
peroxynitrite-HSA was use as an inhibitor at a concentration of 20 pg/ml (Fig. 24B). 
Fifty percent inhibition was achieved at a concentration of 4.5 pg/ml when inhibitor 
was peroxynitrite-modified HSA, while it was 10.9 µg/ml for native HSA. 
Purification and characterization of serum IgG 
Protein A-agarose affinity chromatography on a Protein-A Agarose column was 
used to isolate IgG from preimmune and immune rabbit antisera of native and 
peroxynitrite-modified HSA. The purified IgG eluted as a single symmetrical peak 
and its purity was confirmed by the presence of a single homogeneous band by SDS-
PAGE under non-reducing conditions (Fig. 25). 
To evaluate the amount required for antigen saturation, IgG purified from 
preimmune and immune serum were subjected to direct binding immunoassay on 
ELISA plates coated with native and peroxynitrite-modified HSA. The purified anti-
peroxynitrite-modified-HSA IgG and anti-native-HSA IgG showed strong binding 
with their respective immunogens as determined by direct binding ELISA. However, 
pre-immune IgG showed negligible binding under identical conditions. Saturation for 
native and peroxynitrite- modified HSA was obtained at 80 and 40 jig/ml of IgG, 
respectively. 
Competitive ELISA was performed to check the specificity of anti-peroxynitrite-
modified HSA IgG towards native and peroxynitrite-modifed HSA. An inhibition of 
83.2±2.1% in the antibody binding was achieved when peroxynitrite-modified HSA 
was employed as an inhibitor. Fifty percent inhibition was achieved at an inhibitor 
(peroxynitrite-modified HSA) concentration of 3.9 µg/ml. Inhibition of native HSA 
showed 55.3±1.9% inhibition in antibody binding at 20 jig/nil (Fig. 26). 
Cross reactivity of anti-peroxynitrite-modified HSA IgG 
Furthermore, cross-reactivity of anti-peroxynitrite-modified HSA IgG with 
different inhibitors was checked to confirm that the induced antibodies were highly 
specific for peroxynitrite-modified HSA. Heterogeneity was observed in induced 
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Fig. 24. Inhibition of binding of preimmune (-A-) and immune (-A-) anti-
peroxynitrite-modified HSA antibodies by (A) native HSA and (B) 
peroxynitrite-modified HSA. 
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Fig. 25. Elution profile of anti-peroxynitrite-modified-HSA IgG on Protein A-
Agarose affinity column. Inset: SDS-PAGE of purified IgGG on 10% 
polyacrylamide gel. Similar pattern has been obtained for anti-native-
HSA IgG. 
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Fig. 26. Inhibition ELISA of anti-peroxynitrite-modified-HSA IgG. The inhibitors 
were native HSA (-A-) and peroxynitrite-modified HSA (- A -). The 
ELISA plate was coated with peroxynitrite-modified HSA (10 jig/ml). 
antibodies which exhibited heterogeneity in recognizing various inhibitors at 
maximum inhibitor concentration of 20 pg/mI in all the cases. 
Cross-reactivity of anti-peroxynitrite-modified HSA IgG with native and 
peroxynitrite-modified HSA has been shown in figure 26. 
Peroxynitrite-modified IgG and native IgG when used as inhibtors, caused 
64.4±3.2% and 42.3±2.4% inhibition respectively in the binding of anti-peroxynitrite-
modified HSA IgG to the peroxynitrite-modified HSA and 5.2 µg/ml of peroxynitrite-
modified IgG was required to achieve fifty percent inhibition, (Fig. 27). It shows that 
the induced antibodies were preferentially recognizing the peroxynitrite-modified 
epitopes on IgG. 
Peroxynitrite-modified H2A histone showed inhibition of 59.4±2.6%. In contrast, 
native H2A histone caused inhibition of 37.2±1.8% (Fig. 28). The amount required 
for 50% inhibition in antibody activity was 7 µg/ml in case of peroxynitrite-modified 
H2A histone. 
Peroxynitrite-modified tyrosine and native tyrosine caused 65±3.6% and 
32.6±2.2% inhibition respectively, when used as inhibitors of anti-peroxynitrite-
modified HSA IgG biding to peroxynitrite-modified HSA (Fig. 29). The amount of 
peroxynitrite-modified tyrosine for 50% inhibition was 6.9 pg/ml. 
Inhibition with peroxynitrite-modified tryptophan and native tryptophan; and 
peroxynitrite-modified phenylalanine and native phenylalanine were observed to be 
34.4±2.5% and 17*2.2% (Fig. 30); 22.6±2.9% and 15.2±1.9%, respectively (Fig. 31). 
Table V shows the antigen binding specificity of anti-peroxynitrite-modified-HSA 
IgG. The binding study reflects that peroxynitrite induced damage to different 
proteins and amino acids share common epitopes_ 
Cross reactivity of anti-HSA IgG 
To check the cross reactivity of anti-HSA IgG with different antigens, competition 
ELISA was performed. We observed a maximum inhibition of 65.3±2.3% when the 
inhibitor was native HSA for anti-HSA IgG and the concentration required for 50% 
inhibition in antibody binding was 7 gg/ml. The induced anti-HSA IgG showed a 
maximum inhibition of 52.112.1% in the case of peroxynitrite-modified HSA. The 
concentration of peroxynitrite-modified HSA required for 50% inhibition of antibody 
binding was 18 p.g/mI (Fig. 32). 
Native and peroxynitrite-modified IgG showed maximum inhibition of 42.3±3.1 % 
and 36.1±2.4%, respectively, when used as inhibitors in the binding of anti-HSA IgG 
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Fig. 27. Inhibition ELISA of anti-peroxynitrite-modified-HSA IgG binding to 
peroxynitrite-modified HSA by inhibitors: native IgG (-A-) and 
peroxynitrite-modified IgG (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 28. Inhibition ELISA of anti-peroxynitrite-modified-HSA IgG binding to 
peroxynitrite-modified HSA by inhibitors: native H2A histone (-0-) and 
peroxynitrite-modified H2A histone (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10.ig/mI). 
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Fig. 29. Inhibition ELISA of anti-peroxynitrite-modified-HSA IgG binding to 
peroxynitrite-modified HSA by inhibitors: native tyrosine (-A-) and 
peroxynitrite-modified tyrosine (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10 gg/ml). 
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Fig. 30. Inhibition ELISA of anti-neroxynitrite-modified-HSA IgG binding to 
peroxynitrite-modified HSA by inhibitors: native typtophan (-A-) and 
peroxynitrite-modified typtophan (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 31. Inhibition ELISA of anti-peroxynitrite-modified-HSA IgG binding to 
peroxynitrite-modified HSA by inhibitors: native phenylalanine (-©-) 
and peroxynitrite-modified phenylalanine ( A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/ml). 
Table V 
Cross-reactivity of anti peroxynitrite-modified HSA IgG with different inhibitors 
Inhibitors Maximum % 
inhibition at 20 pglml 
Concentration for 
50% inhibition 
(}ig/m1) 
Peroxynitrite-modified HSA 83.2±2.1 3.9 
Native HSA 55.3±1.9 - 
Peroxynitrite-modified IgG 64.4±3.2 5.2 
Native IgG 42.3±2.4 - 
Peroxynitrite-modified H2A histone 59.4±2.6 7 
Native H2A histone 37.2±1.8 - 
Peroxynitrite-modified tyrosine 65±3.6 6.9 
Native tyrosine 32.6±2.2 - 
Peroxynitrite-modified tryptophan 34.4±2.5 - 
Native tryptophan 17±1.5 - 
Peroxynitrite-modified phenylalanine 22.6±2.9 - 
Native phenylalanine 15.2±1.6 - 
Each well of the ELISA plate was coated with peroxynitrite-modified HSA 
(10 tg/ml). 
0 
10 
4N 
0 30 
si 40 
•= 50 
60 
a. 70 
100 
0.01 	0.1 	1 	10 	100 
Inhibitor concentration (pglml) 
Fig. 32. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA 
plate was coated with native HSA (10 gg/m1). 
to HSA (Fig. 33). 
Native H2A histone caused inhibition of 40.2±2.8%, whereas peroxynititre-
modified H2A histone showed inhibition of 35.3±2.6% (Fig. 34). 
Tyrosine and its peroxynitrite-modif ed conformer showed inhibition of 
38.2±3.2% and 29.1±1.8%, respectively (Fig. 35). An inhibition of 32±2.4% was 
observed when the inhibitor was tryptophan whereas its peroxynitrite counterpart 
showed an inhibition of 26.3±1.8% (Fig. 36). 
Furthermore, a negligible inhibition of 25.2±2.9% was seen with phenylalanine 
whereas it was merely 20.6±1.2% with its peroxynitrite form when used as an 
inhibitor (Fig. 37). The binding characteristics data of anti-HSA IgG, as determined 
by inhibition ELISA, has been summarizing in Table VI. The data shows that 
unmodified inhibitors are preferentially bound by the experimentally produced 
antibodies (anti-HSA-IgG) as compared to their peroxynitrite-modified counterparts. 
Band shift assay 
Band shift assay was performed to visualize the specificity of antibodies and to 
confirm the interaction of native and peroxynitrite-modified HSA with the isolated 
IgG. The antigen—antibody complexes were prepared by incubating a constant amount 
of native/peroxynitrite-modified HSA with increasing concentrations of anti-
peroxynitrite-modified-HSA IgG and then electrophoresing these immune complexes 
on 10% SDS—PAGE. The gel pattern showed that with increasing -amount of anti-
peroxynitrite-modified-HSA IgG, incubated with constant amount of peroxynitrite-
modified HSA, there was corresponding increase in the formation of high molecular 
mass immune complexes (Fig. 38B). The free antigen intensity was gradually 
decreased showing its greater involvement in the formation of immune complexes. 
However, there was slight shifting in the mobility when native HSA was used instead 
of peroxynitrite-modified HSA under identical experimental conditions (Fig. 38A). 
Studies on sera of cancer patients 
All 80 serum samples of patients of both the sexes, having cancer of different 
tissue origin, were collected from medicine outdoor clinic and/or those admitted in the 
medicine ward of the Department of Radiotherapy, J. N. Medical college, Aligarh 
Muslim University, India. All the patients satisfied the criteria of having confirmed 
cancer. Sera from 50 age and sex matched normal, healthy individuals served as 
control. Direct binding ELISA was performed to check the level of binding of 
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Fig. 33. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native IgG (-A-) and peroxynitrite-modified IgG (- A -). The ELISA plate 
was coated with native HSA (10 gg/m1). 
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Fig. 34. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native H2A histone (-A-) and peroxynitrite-modified H2A histone (-,-). 
The ELISA plate was coated with native HSA (10 µg/rnl). 
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Fig. 35. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native tyrosine (-A-) and peroxynitrite-modified tyrosine (-A-). The 
ELISA plate was coated with native HSA (10 pglml). 
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Fig. 36. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native tryptophan (-0-) and peroxynitrite-modified tryptophan (-A-). The 
ELISA plate was coated with native HSA (10 g/ml). 
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Fig. 37. Inhibition ELISA of anti-HSA IgG binding to native HSA by inhibitors: 
native phenylalanine (-0-) and peroxynitrite-modified phenylalanine (-A-). 
The ELISA plate was coated with native HSA (10 gg/ml). 
92 
Table VI 
Cross-reactivity of anti-HSA IgG with different inhibitors 
Inhibitors 	 Maximum % inhibition 	Concentration for SO% 
at 20 µg/ml 	 inhibition (pg/ml) 
Native HSA 65.3±2.3 	 7 
Peroxynitrite-modified HSA 52.1±2.1 	 18 
Native IgG 42.3±3.1 	 - 
Peroxynitrite-modified IgG 36.1±2.4 	 - 
Native H2A histone 40.2±2.8 	 - 
Peroxynitrite-modified H2A histone 35.3±2.6 	 - 
Native tyrosine 38.2±3.2 	 - 
Peroxynitrite-modified tyrosine 29.1±1.8 	 - 
Native tryptophan 32±2.4 	 - 
Peroxynitrite-modified tryptophan 26.3±1.8 	 - 
Native phenylalanine 25.2±2.9 	 - 
Peroxynitrite-modified 20.6±1.2 	 - 
phenylalanine 
Each well of the ELISA plate was coated with native HSA (10 µg/ml). 
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Fig. 38. Band shift assay of'anti-peroxynitrite-modified-HSA IgG 
binding to (A) native NSA and (B) peroxynitrite-
modified USA. Electrophoresis was performed on 10% 
SDS—PAGE for 4 h at 80 V. (A) Native HSA (10 µu) 
was incubated with 0, 10. 20. 30. 40 and 50 µs, anti-
peroxynitrite-modified-HSA IgG. respectively (lanes 1-
6) for 2 h at 37°C and overnight at 4°C. (B) 
Peroxynitrite-modified USA (10 .Lg) was incubated with 
0. 10. 20. 30. 40 and 50 jig anti-peroxynitrite-modiiied-
HSA lgG respectively (lanes 1-6) under identical 
conditions. 
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peroxynitrite-modified HSA and native HSA to cancer autoantibodies at 1:100 serum 
dilution (p<0.05). We observed that almost all sera recognized peroxynitrite-modified 
HSA up to certain extent but lung cancer sera showed maximum binding with the 
antigen (Fig. 39-46). We did not observe any appreciable binding with the sera of 
normal subjects. 
Thereafter, competitive binding ELISA was performed to assess the specific 
binding characteristics of autoantibodies of cancer sera by using native HSA and 
peroxynitrite-modified HSA as inhibitors. The ELISA plate was coated with 
peroxynitrite-modified HSA. Peroxynitrite-modified HSA reflected higher inhibition 
in the binding of cancer autoantibodies over native HSA (Fig 47-54). The inhibition 
data have been summarized in Table VII. 
Purification of cancer IgG 
For further studies, screening of the serum samples showing higher percent 
inhibition in competition ELISA was done to isolate IgG. To isolate IgG from healthy 
individuals and cancer patients, Protein-A Agarose column was used. The purified 
IgG eluted in a single symmetrical peak and to check the purity, when isolated IgG 
was subjected to SDS-PAGE under non-reducing condition, it showed a single 
homogenous band. Figure 55 is showing elution profile of IgG of lung cancer patient 
on Protein A-Agarose affinity column and inset shows SDS-PAGE of purified IgG on 
10% polyacrylamide gel. Similar pattern has been obtained for all other isolated IgG. 
Inhibition ELISA of cancer IgG with native and peroxynitrite-modified HSA 
Competitive binding ELISA was performed to assess the specific binding 
characteristics of isolated IgG by using native HSA and peroxynitrite-modified HSA 
as inhibitors. The ELISA plate was coated with peroxynitrite-modified HSA. 
Peroxynitrite-modified HSA reflected higher inhibition in the binding of IgG isolated 
from cancer patients over native HSA. Maximum percent inhibition (79.4±3.3) was 
observed in the case of lung cancer IgG, followed by head & neck cancer (61.1±4.5) 
and so on (Fig. 56-63; data summarized in table VIII). In contrast to the above results, 
less inhibition was observed when native HSA was used as an antigen in the same 
experimental conditions. Serum antibodies from normal healthy individuals showed 
percent inhibitions of 12.1±2.4 and 14.2±3.2 when native HSA and peroxynitrite-
modified HSA, respectively, were used as inhibitors. 
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Fig. 39. Direct binding ELISA of lung cancer sera to native (n) and peroxynitrite-
modified HSA (m). Normal human sera (NHS) served as negative control. 
Bars representing NHS show mean absorbance values±SD for binding of 
NHS. The ELISA plate was coated with the respective antigens (10 µg/ml). 
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Fig. 40. Direct binding ELISA of head and neck cancer sera to native (o) and 
peroxynitrite-modified HSA (R). Normal human sera (NHS) served as 
negative control. Bars representing NHS show mean absorbance values±SD 
for binding of NHS. The ELISA plate was coated with the respective 
antigens (10 jig/ml). 
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Fig. 41. Direct binding ELISA of breast cancer sera to native (o) and peroxynitrite-
modified HSA (n). Normal human sera (NHS) served as negative control. 
Bars representing NHS show mean absorbance values±SD for binding of 
NHS. The ELISA plate was coated with the respective antigens (10 
µg/ml). 
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Fig. 42. Direct binding ELISA of liver cancer sera to native (o) and peroxynitrite-
modified HSA (a). Normal human sera (NHS) served as negative control. 
Bars representing NHS show mean absorbance values±SD for binding of 
NHS. The ELISA plate was coated with the respective antigens (10 
µglml). 
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Fig. 43. Direct binding ELISA of urinary bladder cancer sera to native (o) and 
peroxynitrite-modified HSA (n). Normal human sera (NHS) served as 
negative control. Bars representing NHS show mean absorbance 
values±SD for binding of NHS. The ELISA plate was coated with the 
respective antigens (10 µg/ml). 
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Fig. 44. Direct binding ELISA of cervix cancer sera to native (o) and peroxynitrite-
modified HSA (n). Normal human sera (NHS) served as negative control. 
Bars representing NHS show mean absorbance values±SD for binding of 
NHS. The ELISA plate was coated with the respective antigens (10 
Kg/ml). 
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Fig. 45. Direct binding ELISA of gall bladder cancer sera to native (❑) and 
peroxynitrite-modified HSA (u). Normal human sera (NHS) served as 
negative control. Bars representing NHS show mean absorbance 
values±SD for binding of NHS. The ELISA plate was coated with the 
respective antigens (10 gg/ml). 
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Fig. 46. Direct binding ELISA of prostate cancer sera to native (❑) and 
peroxynitrite-modified HSA (n). Normal human sera (NHS) served as 
negative control. Bars representing NHS show mean absorbance 
values±SD for binding of NHS. The ELISA plate was coated with the 
respective antigens (10 }ig/ml). 
103 
a 
10 
0 30 
.~ 40 
50 
c v 60 
L 
°. 
 
a. 70 
100 
0.01 	0.1 	1 	10 	100 
Inhibitor concentration (pglml) 
Fig. 47. Inhibition of serum autoantibodies in lung cancer patients by native HSA 
(-A-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 }tg/m1_). 
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Fig. 48. Inhibition of serum autoantibodies in head and neck cancer patients by 
native HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA 
plate was coated with peroxynitrite-modified HSA (10 µg/m1). 
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Fig. 49. Inhibition of serum autoantibodies in breast cancer patients by native 
HSA (-A-) and peroxynitrite-modified HSA (-A -). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/m1). 
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Fig. 50. Inhibition of serum autoantibodies in liver cancer patients by native HSA 
(-A-) and peroxynitrite-modified HSA (- A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/mi). 
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Fig. 51. Inhibition of serum autoantibodies in urinary bladder cancer patients by 
native HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA 
plate was coated with peroxynitrite-modified HSA (10 p.g/ml). 
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Fig. 52. Inhibition of serum autoantibodies in cervix cancer patients by native 
HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 53. Inhibition of serum autoantibodies in gall I bladder cancer patients by 
native HSA (-0-) and peroxynitrite-modified HSA (-A-). The ELISA 
plate was coated with peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 54. Inhibition of serum autoantibodies in prostate cancer patients by native 
HSA (-A-) and peroxynitrite-modified HSA (- 4k-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/m1). 
Table VII 
Competitive inhibition of circulating antibodies in cancer sera with native and 
peroxynitrite-modified HSA 
Cancer sera 	 Maximum percent inhibition at 20 pg/ml 
Native HSA 	 Modified HSA 
Lung 24.1±4.3 
Head & Neck 21.6±5.9 
Breast 25.1±3.7 
Liver 20.7±4.9 
Urinary Bladder 18.0±4.3 
Cervix 14.4±4.1 
Gall Bladder 14.7±3.8 
Prostate 16.2±3.9 
68.2±9.4 
56.3±7.2 
51.4±6.2 
45.916.3 
35.1±5.6 
27.8±5.8 
24.4±4.7 
23.5±5.5 
Each well of the ELISA plate was coated with peroxynitrite-modified HSA 
(10 ug/m1). 
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Fig. 55. Elution profile of IgG isolated from cancer patients on Protein A-
Agarose affinity column. Inset: SDS-PAGE of purified IgG on 100/0 
polyacrylamide gel. Similar pattern has been obtained for IgG isolated 
from normal human sera. 
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Fig. 56. Inhibition of isolated IgG from lung cancer patients by native HSA (-A-) 
and peroxynitrite-modified HSA (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10 µg/m1). 
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Fig. 57. Inhibition of isolated IgG from head and neck cancer patients by native 
HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 58. Inhibition of isolated IgG from breast cancer patients by native HSA (-A-) 
and peroxynitrite-modified HSA (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 }tg/m1). 
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Fig. 59. Inhibition of isolated IgG from liver cancer patients by native HSA (-A-) 
and peroxynitrite-modified HSA (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10 p.g/ml). 
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Fig. 60. Inhibition of isolated IgG from urinary bladder cancer patients by native 
HSA (-A-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 gg/ml). 
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. 61. Inhibition of isolated IgG from cervix cancer patients by native HSA 
(-A-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 62. Inhibition, of isolated IgG from gall bladder cancer patients by native 
HSA (-0-) and peroxynitrite-modified HSA (-A-). The ELISA plate was 
coated with peroxynitrite-modified HSA (10 gg/url). 
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Fig. 63. Inhibition of isolated IgG from prostate cancer patients by native HSA 
(-A-) and peroxynitrite-modified HSA (- A -). The ELISA plate was 
coated with peroxynitrite-inodified HSA (10 µg/ml). 
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Table VIII 
Competitive inhibition of IgG isolated from cancer sera with native and 
peroxynitrite-modified HSA 
Cancer sera Maximum percent inhibition at 20 µg/mi 
Native HSA 	 Modified HSA 
Lung 32.4±4.7 79.4±8.7 
Head & Neck 28.4±5.2 61.1±7.3 
Breast 26.3±4.9 55.3±5.8 
Liver 25.5±4.7 52.9±6.9 
Urinary Bladder 19.0±3.9 38.5±5.6 
Cervix 18.2±3.6 32.9±5.1 
Gall Bladder 18.1±4.7 28.5±5.5 
Prostate 17.0±4.5 26.4±4.7 
Each well of the ELISA plate was coated with peroxynitrite-modified HSA 
(10 µg/ml). 
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Band shift 
Band shift assay was performed to visualize the interaction of native HSA and 
peroxynitrite-modified HSA with IgG isolated from cancer sera: It was done to 
confirm the possible presence of peroxynitrite modified HSA in cancer patients. The 
antigen—antibody complexes were prepared by incubating a constant amount of 
native/peroxynitrite-modified HSA with increasing concentrations of patient's IgG 
and then electrophoresing these immune complexes on 10% SDS—PAGE. The gel 
pattern showed that with increasing amount of IgG, incubated with constant amount 
of peroxynitrite-modified HSA, there was corresponding increase in the formation of 
high molecular weight immune complexes (Fig. 64A). As compared to the modified 
form, native HSA, when used as an antigen for the formation of antigen-antibody 
complex, exhibited decreased mobility shift (Fig. 64B). 
Determination of protein carbonyl contents in cancer sera 
Protein carbonyls are a generic marker of protein oxidation that are generated by 
multiple radicals, excited state species, and singlet oxygen (as a result of the 
secondary reactions). Protein-bound carbonyls have been shown in numerous human 
diseases. The carbonyl contents of the cancer patients sera (three from each group 
showing higher binding in direct binding ELISA) as well as of the normal healthy sera 
(n=5) were determined and it was observed that average serum protein carbonyl 
contents were significantly (p<0.001) increased in cancer patients as compared to the 
healthy individuals. Maximum carbonyl content was seen in the case of lung cancer 
patients followed by other cancers of different tissue origin (Fig. 65; Table IX). 
Isolation of HSA from cancer patients and normal healthy individuals 
Sera of normal healthy individuals (n=10) as well as of selected cancer patients, 
having cancer of different tissue origin and showing higher percent inhibition in 
competition ELISA, were used to isolate HSA. Absorbance at 280 nm was monitored 
and polyacrylamide gel electrophoresis was performed to know the purity of isolated 
HSA and it was found that the purified HSA was eluted in a single symmetrical peak 
on Sephacryl S-200 HR column, (Fig. 66). SDS-PAGE profile showed a single 
homogenous band of the purified HSA (inset). Thereafter, isolated HSA of healthy 
individuals and patients were used for the further antigen-antibody interaction studies. 
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Fig. 64. Band shift assay of affinity purified lung cancer IgG with 
native and peroxynitrite-nnodified HSA. Electrophoresis was 
performed on 10% SDS—PAGE for 4 h at 80 V. 
(A) Peroxynitrite-modified HSA (10 µg) was incubated with 0, 
10, 20, 30, 40, 50 and 60 pg of cancer IgG, respectively (lanes 
1-7) for 2 hat 37°C and overnight at 4°C. (B) Native IISA (ID 
µg) was incubated with 0. 10, 20, 30, 40. 50 and 60 pg of 
cancer IgG, respectively (lanes 1-7) under identical conditions. 
0 
O 5  
Q 
Cf 
E 4 
0 
E c 3 
c 
c 2 
0 1 
h. 
0 
Fig. 65. Average carbonyl content of normal human sera (NHS) and cancer sera. Each 
bar shows the mean±SD of the analyzed samples. 
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Table IX 
Carbonyl content of cancer sera and normal healthy sera 
Sera Average carbonyl content (±SD) 
Lung 4.82±0.2 
Head & Neck 4.25±0.4 
Breast 3.81±0.6 
Liver 3.52±0.4 
Urinary Bladder 3.82±0.2 
Cervix 2.72±0.3 
Gall Bladder 2.81±0.5 
Prostate 2.47±0.4 
Normal human sera 1.95±0.2 
Carbonyl content was determined by the method of Levine et al., 1994. 
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Fig. 66. Elution profile of HSA isolated from the sera of lung cancer patients on 
Sephacryl S-200 HR column. Electrophoresis was performed on 10% 
SDS—PAGE for 4 h at 80 V to check the purity and homogeneity of the 
isolated HSA (inset). Similar elution profile and gel pattern was 
observed for other purified HSA. 
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Probing of peroxynitrite induced modification in USA in cancer patients using 
experimentally induced anti-peroxynitrite-modified-HSA IgG 
To probe the presence of HSA modified by peroxynitrite in cancer patients, 
competition ELISA was performed using experimentally induced anti-peroxynitrite-
modified-HSA IgG. The ELISA plate was coated with peroxynitrite;modified-HSA 
(10 pg/ml) for both native as well as modified assays. The isolated HSA (0-20 pg/ml) 
from cancer and normal subjects were used as inhibitors in the binding of 
peroxynitrite-modified HSA to anti-peroxynitrite-modified-HSA IgG in competitive 
binding ELISA. The ELISA results showed that percent inhibition was higher when 
patient's HSA was used as an inhibitor, while HSA of the healthy subjects, when used 
as an inhibitor, showed significantly lesser recognition of anti-peroxynitrite-modified-
HSA IgG (Fig. 67-74). Table X shows the competitive inhibition of experimentally 
induced anti-peroxynitrite-modified-HSA IgG with HSA isolated from normal healthy 
subjects and cancer patients. 
128 
M 
10 
20 
0 30 
40 
.~ 50 
w60 
C) 
a 70 
:t 
100 
0.01 	 0.1 	 1 	 10 	 100 
Inhibitor concentration (pgfmi) 
Fig. 67. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-0-) and 
from lung cancer patients (- A -). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 jig/ml). 
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Fig. 68. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-A-) and 
from head and neck cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 }ig/ml). 
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Fig. 69. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-A-) and 
from breast cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 70. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-A-) and 
from liver cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 gg/ml). 
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1. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-A-) and 
from urinary bladder cancer patients (-A-). The ELISA plate was coated 
with peroxynitrite-modified HSA (10 pg/ml). 
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Fig. 72. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from -normal healthy individuals (-A-) and 
from cervix cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 µg/ml). 
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Fig. 73. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-0-) and 
from gall bladder cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 tg/m1). 
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Fig. 74. Inhibition of anti-peroxynitrite-modified-HSA IgG binding to peroxynitrite-
modified HSA by HSA isolated from normal healthy individuals (-A-) and 
from prostate cancer patients (-A-). The ELISA plate was coated with 
peroxynitrite-modified HSA (10 µg/ml). 
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Table X 
Competitive inhibition of experimentally induced anti-peroxynitrite-modified- 
HSA IgG with HSA isolated from normal healthy individuals and cancer 
patients 
Cancer 	 Maximum percent inhibition at 20 pg/ml 
Normal healthy 	 Cancer 
individual's HSA patient's HSA 
Lung (4) 	 26.7±3.2 	 65.4±7.3 
Head & Neck (4) 	25.4±3.8 	 56.6±7.6 
Breast (3) 	 27.1±4.1 	 49.7±6.2 
Liver (3) 	 25.2±3.7 	 45.0±5.1 
Urinary Bladder (3) 	22.7±3.9 	 36.8±6.4 
Cervix (3) 	 24.8±3.5 	 30.1±4.9 
Gall BIadder (3) 	 21.4±4.1 	 28.6±5.3 
Prostate (3) 	 21.5±4.2 	 24.1±5.6 
9 Each well of the ELISA plate was coated with peroxynitrite-modified HSA 
(10 1g/ml). 
Values in the parentheses show the number of sera used to isolate HSA from 
each group. 
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It is increasingly proposed that reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) play a key role in various human disease developments, especially as 
evidence is growing that antioxidants may prevent or delay the onset of those 
diseases. During oxidative burst triggered by inflammation, the cells of 
immunoregulatory network produce both nitric oxide and superoxide. These two free 
radicals can combine to produce peroxynitrite which has become the area of deep 
concern right from the date of its discovery due to its fast and damaging effects on 
different biomolecules. Peroxynitrite is a powerful oxidant and nitrating agent which 
can oxidize thiols and/or nitrate DNA, proteins and lipids. One of the most important 
effects of peroxynitrite is nitration of tyrosine residues and oxidation of proteins. 
Tyrosine nitration can profoundly alter protein function indicating that this reaction 
may be fundamentally related to oxidative cell injury. The formation of 3-
nitrotyrosine in vivo in various pathological conditions has been well established (Kuo 
et al., 2000) and it is for this reason 3-nitrotyrosine is considered to be a relatively 
specific marker of nitrosative damage mediated by peroxynitrite. Reaction of 
peroxynitrite with tyrosine is a covalent modification that results in attachment of a 
nitro (—NO2) group on the aromatic ring of tyrosine residues. Increase in tyrosine 
nitration has been observed in various cancers (Maeda and Akaike, 1998; Pignatelli et 
al., 2001). In addition to nitration, peroxynitrite is also a potent oxidizing agent and 
can oxidize a variety of biomolecules including proteins. A number of biological 
macromolecules such as proteins, phospholipids, and DNA have been shown to react 
directly with peroxynitrite resulting in various covalent adduct formation, which in 
turn Iead to the propagation and amplification of human cancer (Ischiropoulos and 
Beckman, 2003). The role of peroxynitrite as a cytotoxic and mutagenic agent has 
been shown in a number of bacterial and mammalian cell culture systems (Gal and 
Wogan, 1996; Zhuang and Wogan, 1997; Zhuang et al., 1998; Zhuang etal., 2000) 
Human serum albumin (HSA), a heart-shaped, nonglycosylated polypeptide of 
585 amino acid residues, is the most abundant protein found in human plasma. HSA 
carries out several clearly defined physiological functions (Margarson and Soni, 
1998) like maintenance of colloidal osmotic pressure, free radical scavenging, binding 
and transport of important solutes, etc. One of the most important and protective 
functions of HSA is its antioxidant property which if gets altered may lead to many 
diseases. Due to its abundance in plasma, HSA is continuously exposed to oxidative 
stress, which can alter the conformation and function of this molecule, resulting in 
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modification of its biological properties (Oettl and Stauber, 2007) and hence its 
contribution to the progression to different diseases. It has been well documented that 
HSA is quite vulnerable to oxidizing and nitrating agents and its abundance in human 
plasma makes this protein an attractive candidate for biomarker studies (Anderson 
and Anderson, 2002). Various studies have shown the elevated levels of oxidized 
albumin in patients with various diseases (Era et al., 1995). Therefore, 
characterization of peroxynitrite induced structural and immunological modification 
in HSA assumes significance. 
Many studies have shown the potent role of ROS/RNS in various human diseases 
including cancer development (Oshima and Bartsch, 1994), which can be 
delayed/prevented by the use of anti-oxidants. It is documented that tyrosine nitration 
gets increased in the case of lung cancer patients (Masri et al., 2005). Loss of 
biological functions by the effects of free radicals has been shown in a number of 
proteins, e.g., fibrinogen loses its ability to form a solid clot (Shacter et al., 1995). 
Direct damages to the proteins are not the only deleterious effects of the free radicals, 
but, sometimes the free radical damaged protein can contribute to secondary damage 
to other biomolecules, e.g., a loss in replicating fidelity in the DNA polymerases has 
been observed after inactivation of DNA repair enzymes by the free radical 
(Halliwell, 1978; Ramotar and Demple, 1993). Damaging role of peroxynitrite on 
different biological macromolecules has been shown in a number of 
pathophysiological conditions. 
The present study was carried out with the characterization of native and 
peroxynitrite-modified HSA by various physicochemical techniques. But before using 
the samples for various studies, extensive dialysis was performed for both the samples 
i.e., native and peroxynitrite-modified HSA. The absorbance spectroscopy results 
indicated that hyperchromicities at 278 nm with the increasing concentrations of 
peroxynitrite could be attributed to peroxynitrite-induced denaturation due to 
oxidation and nitration of native HSA. Nitration in peroxynitrite-modified HSA was 
further confirmed by the generation of yellow colour which showed peak at 420 nm. 
The nitrotyrosine estimation was done to confirm that the generation of nitrotyrosine 
takes place when native HSA is projected to the nitration causing effect of 
peroxynitrite. It is quite clear from the results that peroxynitrite-modification caused 
concentration dependent generation of nitrotyrosine and consequent alteration in the 
native structure of HSA. 
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Thereafter, SDS-PAGE results reiterated that when native and peroxynitrite-modified 
HSA was subjected to non-reducing polyacrylarnide gel electrophoresis under 
denaturing conditions, native HSA moved as a compact single band while HSA, 
modified with increasing concentrations of peroxynitrite, showed gradual thickening 
of bands as compared to the native protein. It is quite clear that peroxynitrite induced 
modification (nitration and oxidation) has produced significant structural changes in 
HSA. The gradual thickening of the bands, as compared to the native HSA, may be 
due to the intramolecular cross-linking in the modified protein, which might lead to 
abnormal migration of the protein molecules. The cross-linking may be formed due to 
the interactions of one tyrosyl radical with another tyrosyl radical, generating O,O`-
dityrosine covalent cross-links (Khan et al., 2009). Cross-linking and oligomerization 
have also been reported during nitration of several other proteins (Lundblad and 
Noyes, 1984). 
Fluorescence spectra further confirmed the formation of dityrosine. A prominent 
emission peak at 401 nm in case of peroxynitrite-modified HSA, when excited at 330 
nm, was seen which was completely absent in the native protein indicating that 
dityrosine is being formed in peroxynitrite treated HSA. This result, along with the 
SDS-PAGE analysis, confirmed the formation of O,O'-dityrosine covalent cross-links 
upon peroxynitrite modification of HSA. This may be the reaction of one tyrosyl 
radical generated by peroxynitrite with another tyrosyl radical of HSA molecule 
(Ischiropoulos, and Al-Mehdi, 1995). 
Overall structural changes were further monitored by fluorescence spectra of 
peroxynitrite-modified HSA in comparison with its native analogue. The intrinsic 
fluorescence probes of proteins are aromatic amino acids tryptophan, tyrosine and 
phenylalanine. The aim was to monitor the structural change at tyrosine residues due 
to the fact that peroxynitrite converts tyrosine to 3-nitrotyrosine. Loss in fluorescence 
intensity of peroxynitrite-modified HSA was observed compared to the native protein 
when they were excited at 275 nm, a characteristic excitation wavelength for tyrosine. 
The loss could be ascribed to the destruction of tyrosine residues and/or modification 
of the tyrosine microenvironment upon peroxynitrite modification. Furthermore, a 
blue shift of 34 nm in peroxynitrite-modified HSA when excited at 275 nm, compared 
to its native counterpart, indicated that the chromophore of protein was exposed to a 
more hydrophobic environment (Mir et al., 2010). 
Measurement of hydrophobic surface accessibility by ANS binding experiment was 
done to see the conformational changes in HSA when it was projected to the 
damaging role of peroxynitrite. Observed loss in fluorescence intensity indicating that 
native HSA possesses a number of hydrophobic patches on its surface which were 
disrupted upon treatment with peroxynitrite. The peroxynitrite induced structural 
perturbations in HSA molecule led to the loss of ANS binding sites (Ahmad et al., 
2005). 
The most commonly used marker of protein oxidation is carbonyl content 
(Shacter, 2000). When proteins are projected to the oxidizing agents, carbonyl group 
appears as a consequence of oxidative modifications of the side chains of lysine, 
proline, arginine and threonine (Berlett et al., 1998). The reaction products are 
chemically stable which are measured spectrophotometrically at 360 nm. Almost 
seven fold increase in •the carbonyl - content of modified HSA suggested that 
peroxynitrite induced oxidation of HSA may • be responsible for alterations in its 
structural and biological properties and proves that peroxynitrite is a strong oxidizing 
agent. 
Far-UV CD spectra can be used to rapidly estimate the secondary structure of a 
protein. Negative peaks near 208 and 222 nm are characteristic of a helical protein 
(Chen et al., 1972). A very significant decrease in the a-helical content of 
peroxynitrite-modified HSA compared to the native protein showed that HSA 
undergoes certain conformational changes in the presence of peroxynitrite. 
Furthermore, changes in the tertiary structure were estimated by near-UV CD spectra 
which are sensitive to the environment of aromatic side chains and closeness of 
packing of the aromatic residues (Kelly and Price, 1997). An additional evidence for 
structural instability can be obtained from the near-UV CD spectra. Looking carefully 
on the near-UV CD spectra of both native as well as peroxynitrite-modified HSA, we 
observed that the peak specific for tyrosine residues, 275 nm, became less pronounced 
in peroxynitrite-modified HSA compared to the native analogue which shows that 
tyrosine residue(s) is/are modified by peroxynitrite. The modification in tyrosine 
residue(s) might be responsible in altering the tertiary structure of HSA and hence, 
may cause alterations in its physiological functions. 
Secondary structural perturbations in HSA were further confirmed by Fourier 
Transform Infrared Spectroscopy (FT-IR). Infrared spectroscopy is considered as one 
of the oldest and well established experimental techniques for the study of secondary 
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structure of polypeptides and proteins by measurement of wavelength and intensity of 
the absorption of IR radiation by a sample. Amide I band is the most sensitive spectral 
region to the protein secondary structural components (1700-1600 cin H ), which is 
due almost exclusively to the C=O stretching vibrations of the peptide linkages. In 
contrast to the amide I counterpart, amide II band derives mainly from in-plane NH 
bending and from the CN stretching vibration, showing much less protein 
conformational sensitivity (Krimm and Bandekar, I986). In our result, a shift in the 
peaks of both amide I and amide II bands were observed but it was more pronounced 
in the case of amide I. It is clear from these results that amide I is more sensitive than 
amide II towards peroxynitrite modification. The observed shifting in amide I and 
amide II bands is a clear proof of secondary structure perturbation and fully supports 
the observations of far-UV CD spectra. 
The next step in characterization was to measure the size of HSA with and without 
peroxynitrite modification. Keeping this in mind, dynamic light scattering (DLS) 
measurement was done to determine the hydrodynamic radii of native and 
peroxynitrite-modified HSA. Increased Rh value obtained by DLS measurement was 
pointing towards unfolding of HSA molecule driven by the structural loss upon 
peroxynitrite treatment. The result indicates that upon interaction with peroxynitrite, 
HSA undergoes certain conformational changes. The increase in Rh suggests that 
peroxynitrite probably causes relaxation in hydrophobic forces of intradomain of HSA 
and may cause unfolding of the overall secondary and tertiary structure of this protein 
which is in agreement with the previous results. 
Differential scanning calorimetry (DSC) is a thermo-analytical technique of direct 
application to protein studies as it can measure a key stability parameter, the 
unfolding temperature, orTm , of a protein. With DSC the T,,, is measured as the 
transition midpoint between the protein in a native and an unfolded state. Therefore, 
DSC was performed to compare the thermal transition characteristics in absence and 
presence of peroxynitrite. Predicting the DSC result, a lower T,„ value of 
peroxynitrite-modified HSA compared to the native form clearly indicated that the 
structure of HSA got destabilized after peroxynitrite treatment which is in agreement 
with the CD analysis. The unfolding of proteins lead to more than one endothermic 
peak that reflect the unfolding of domains (Rabbani et al., 2013). Furthermore, it is 
also established that domain III melts prior to domain II (Sudlow et al., 1975), so TT 
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may correspond to the domain III while T, may correspond to the domain II. These 
domains might indicate two thermally induced inner unfolding steps during thermal 
denaturation of HSA. For a two-state process under equilibrium conditions, 
AH„H/A.H ai ratio equals to one. If one or more intermediate states are populated in the 
overall process, the ratio of L\H H/AHi will be lower than I during unfolding, 
whereas if the ratio of AH„H/tHcaI is greater than 1, self-association is clearly 
indicated (Johnson, 2013). Therefore, the values of tHv ji /IHcai ratio showed lower 
stability of peroxynitrite-modified HSA compared to the native counterpart. 
High performance liquid chromatography (HPLC) is considered as one of the 
most important techniques to detect the changes in proteins. Native and peroxynitrite-
modified HSA were subjected to _HPLC examination to analyze the formation of 3-
nitrotyrsoine using standard 3-nitrotyrosine as a reference. Pronase digested samples 
were used for the analysis. In contrast to the native protein, the formation of 3-
nitrotyrosine was observed in peroxynitrite-modified HSA which coincided with the 
retention time of standard 3-nitrotyrosine when subjected to the HPLC analysis in the 
same experimental conditions. The HPLC result showed that the formation of 3-
nitrotyrosine takes place when protein is projected to the nitration causing property of 
peroxynitrite. 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has 
become a widespread analytical tool for getting the accurate information about the 
post translational modifications in proteins. Therefore, the formation of 3-
nitrotyrosine in HSA after peroxynitrite treatment was analyzed by MALDI-MS 
spectra. Peroxynitrite-modified HSA showed mass at mlz 227, the characteristic m/z 
of 3-nitrotyrosine, contrary to the native protein. The result confirmed the formation 
of 3-nitrotyrosine when HSA gets exposed to the nitration causing property of 
peroxynitrite. This result along with the result of HPLC confirms that peroxynitrite 
reaction with HSA leads to the formation of 3-nitrotyrosine. 
The significant antioxidant activity of serum albumin has been evident by certain 
studies. Practically it is considered as a major and' predominant circulating antioxidant 
in plasma that is continuously exposed to oxidative stress (Soriani et al., 1994; Cha 
and Kim, 1996). Therefore, albumin has been categorized as an important component 
that plays a role in the efficient antioxidant defense against oxidative attack that 
143 
organisms have developed to protect themselves (Halliwell, 1996). Thus, we can say 
that structural alterations may lead to the alteration/loss of biological properties. 
The antioxidant properties of native and peroxynitrite-modified HSA were 
checked by free radical induced hemolysis test which measures the susceptibility of 
erythrocytes to free radicals. The basis of this test is that AAPH i.e,, generator of 
oxidants, mimic the in vivo condition of oxidative stress. The oxidant produce by 
AAPH may decrease erythrocyte deformations leading to reduce survival of 
erythrocyte and circulatory impairments (Halliwell & Gutteridge, 1990). As expected, 
the antioxidant property of native HSA protected hemolysis up to the maximum 
extent, as compared to peroxynitrite-modified protein, from the deleterious effect of 
AAPH. In wrapping up, we can say that the protective antioxidant property of the 
native HSA got significantly decreased upon peroxynitrite treatment. But it can also 
be said that a complete loss in the antioxidant property of modified HSA was not 
observed; indicating that some antioxidant action was still preserved in spite of being 
projected to the damaging effect of peroxynitrite. 
Immune tolerance covers the variety of physiological mechanisms by which the 
body diminishes or eliminates an immune response to particular agents. The term is 
used to explain the phenomenon underlying discrimination of self from non-self. 
Central tolerance, which falls under the heading of immune tolerance, is defined as 
the tolerance conventional by deleting autoreactive lymphocyte clones before they 
develop into fully immunocompetent cells. It takes place at some stage in lymphocyte 
development in the thymus (Sprent and Kishimoto, 2001; Hogquist et al., 2005) 
and bone marrow for T and B lymphocytes, respectively. Usually, a majority of 
endogenous antigens are non-immunogenic due to the phenomenon of immunological 
tolerance but it has been shown that under certain pathophysiological conditions, post 
translational modifications in proteins make them immunogenic (Ohmori and 
Kanayama, 2005). In that condition, the modified proteins may stimulate T-cells and / 
or B-cells leading to collapse or circumventing of immunological tolerance (Ohmori 
and Kanayama, 2005). Various studies so far have been done to know the effect of 
peroxynitrite on different biomolecules. It has been proved that when H2A histone is 
projected to peroxynitrite, the protein becomes immunogenic, elicits immune 
response and thus production of anti-peroxynitrite-modified-H2A histone antibodies 
in experimental animal takes place (Khan et al., 2009). In another study, it was shown 
that human placental DNA, which is non-immunogenic in its native form, acquires the 
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ability to elicit immune response in experimental animal when exposed to 
peroxynitrite (Habib et al., 2005). That means the non-immunogenic native DNA 
becomes immunogenic when it is modified by peroxynitrite. There are few other 
researchers who prove the in vivo damaging role of peroxynitrite towards different 
biomolecules. 
In second part of the present study, i.e., immunological part, experimental animals 
were used•to induce antibodies against native and peroxynitrite-modified HSA. After 
six booster doses, antibody titre was checked through direct binding ELISA and it was 
found that peroxynitrite-modified HSA was extremely potent antigen that induced 
high titre antibodies in experimental animals, compared to the native HSA that 
exhibited moderate antigenic response. The result clearly indicated that modification 
of HSA by peroxynitrite made the protein an even more potent immunogen which 
might be due to the generation of neo-epitopes on the protein molecule. Preimmune 
serum when used as control showed negligible binding with either immunogen under 
identical experimental conditions. Furthermore, anti-peroxynitrite-modified HSA 
antibodies were also scrutinized for their binding to denatured HSA to ensure the 
specificity of these antibodies towards HSA structure. Very weak binding of these 
antibodies to denatured HSA confirmed their specificity towards the tertiary structure 
of protein. 
Thereafter, competition ELISA was performed to see the antigenic specificity of 
experimentally produced antibodies against peroxynitrite-modified HSA. A higher 
inhibition in the binding of anti-peroxynitrite-modified-HSA IgG to peroxynitrite-
modified HSA was observed when peroxynitrite-modified HSA was used as an 
inhibitor while inhibition was moderate in the case of native HSA when used as an 
inhibitor. The enhanced immunogenicity of HSA after peroxynitrite modification is 
probably the result of the generation of neo-epitopes on HSA molecule consequent to 
modification. The generation of these neo-epitopes might be the result of nitration and 
oxidation of HSA. Therefore, it appears that two types of antibodies were induced; 
one recognized neo-epitopes while the other recognized old epitopes. Band shift assay 
further confirmed the specificity of induced anti-peroxynitrite-modified-HSA IgG 
towards peroxynitrite-modified HSA compared to its native counterpart. Compared to 
the native HSA, when peroxynitrite-modified HSA was used as an antigen for anti-
peroxynitrite-modified-HSA IgG, the formation of high molecular mass immune 
complexes was observed indicating a decrease in free antigen intensity showing its 
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greater involvement in the formation of immune complexes. This confirms the 
specificity of anti-peroxynitrite-modified-HSA IgG. The results indicate that while 
native HSA binds to the anti-peroxynitrite-modified-HSA IgG to some extent due to 
the presence of old epitopes, the binding is more prominent with modified 
counterpart. This shows that modified HSA has got both the epitopes, i.e., old and 
neo-epitopes formed by peroxynitrite modification. Therefore, immunization with 
peroxynitrite-modified HSA may produce polyspecific antibodies which can 
recognize both old and neo-epitopes. The polyspecificity of the induced antibodies 
was further confirmed by cross-reactivity study of anti-peroxynitrite-modified-HSA 
IgG with different inhibitors i.e., native and their peroxynitrite-modified counterpart 
proteins and amino acids. The anti-peroxynitrite-modified-HSA IgG showed 
significant recognition for peroxynitrite modified forms compared to their native 
analogues. That means peroxynitrite modified proteins and amino acids showed 
appreciable inhibition in the activities of anti-peroxynitrite-modified-HSA IgG, 
compared to their native counterparts. The results proved that the induced antibodies 
against peroxynitrite-modified HSA were found to be polyspecific in nature and cross 
react with a range of inhibitors sharing common antigenic determinants. 
The role of free radicals in different diseases is a well established fact. They are 
produced in vivo by normal physiological processes including aerobic metabolism and 
inflammatory responses that is why they are considered as ubiquitous in nature. Their 
levels remain in check by the delicately balanced antioxidant systems of our body. 
But an imbalance in the generation of oxidants and antioxidants may lead to different 
diseases. One of the diseases about which the evidences are growing up is cancer. 
Free radicals can alter the processes and pathways that are crucial for the normal 
tissue homeostasis failing which lead to carcinogenesis. The major targets of free 
radical modifications are DNA, RNA, proteins and lipids. Free radical effects on 
DNA may lead to mutations while post translational modifications in proteins by 
nitration, nitrosation, phosphorylation, acetylation, etc., lead to structural and/or 
functional alterations/loss of the proteins. These are the major deleterious effects of 
free radicals that may increase the cancer risk. There are a large number of scientists 
working in the area of cancer biology who have hypothesized by their in vitro studies 
the role of free radicals in altering the structures and functions of DNA and proteins 
leading to carcinogenesis. 
According to Hussain and co-workers, NO' and its derivatives are not only the key 
players that damage DNA, but they also alter the structure and function of proteins 
that are concerned in the safeguarding of cellular integrity and that encourage 
angiogenesis (Hussain et al., 2003). The role of peroxynitrite, which can diffuse 
within the cells (Radi, 1998), is of particular interest in cancer biology. It has been 
increasingly considered as a crucial mechanism contributing to the development of 
many chronic diseases, including cancer, and neurodegenerative diseases 
(Ischiropoulos and Beckman, 2003; Deliconstantinos et al_, 1995; Fraszczak et ai., 
2010; Rachmilewitz et al., 1993). A number of biomolecules such as proteins, 
phospholipids and DNA are the major targets of peroxynitrite reactivity that may 
result in various covalent adducts formation , leading to the propagation and 
amplification of human cancer (Ischiropoulos and Beckman, 2003). 
In view of the abundance of HSA in plasma, its proneness to various oxidizing 
and nitrating agents, and deleterious effects of peroxynitrite on different biomolecules 
in vivo, the present work was a thought of interest to investigate the possible role of 
peroxynitrite-modified HSA in relation to carcinogenesis. The presence of 
peroxynitrite-modified HSA was probed by different assays. The screening of cancer 
sera was done to detect the presence of autoantibodies against native and 
peroxynitrite-modified HSA. Binding reactions of-circulating cancer autoantibodies to 
native and peroxynitrite-modified HSA was probed by direct binding and inhibition 
ELISA which reiterated the specificity of cancer autoantibodies. The pattern of 
binding of peroxynitrite-modified HSA with cancer autoantibodies was quite 
enlightening. The results clearly indicated that in almost all cases (but maximally in 
the case of lung cancer) the naturally occurring cancer autoantibodies preferentially 
recognized the epitopes present on peroxynitrite-modified HSA, compared to the 
native analog. A significantly higher level of nitrated proteins in serum of the lung 
cancer patients has been observed by some researchers indicating the presence of 
oxidative and nitrosative stress in those, patients (Gole et al., 2000; Pignatelli et al., 
2001). Smoking can be considered as one of the most important reasons of lung 
cancer development as it releases complex proneoplastic agents which act by inducing 
chronic inflammatory situations by the delivery' of genotoxic carcinogens such as 
nitrosamines, peroxides and many potent oxidants into the lungs (Hoffinann and 
Hoffipann, 1997). It has been analyzed that inflammation-derived free radicals are 
powerful endogenous mediators for cancer development which is in support of the 
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inflammation hypothesis (Okada, 2002) which says that that chronic inflammation at 
a site may lead to cancer development (Balkwill and Mantovani, 2001). In the lung 
epithelial lining fluids, numerous antioxidants are present including reduced 
glutathione, ascorbic acid, taurine, uric acid, a-tocopherol, ceruloplasmin, antioxidant 
enzymes, albumin, and proteins. However, sometimes ROS/RNS are overproduced 
leading to oxidative stress. Numerous studies have been done to demonstrate the role 
of different antioxidants in protection/prevention of cancer (Cooper et al., 1999; 
Khan, 2000). However, the correlation between cancer prevention and antioxidants is 
not well established. The enhanced generation of ROS/RNS in lungs induces some of 
the major pulmonary diseases such as chronic obstructive pulmonary disease (COPD), 
asbestosis, silicosis, and cancer (Azad et ai., 2008). 
Strength to the result was further provided by band shift assay which again 
showed the preferential recognition of peroxynitrite-modified HSA over native 
counterpart by the purified cancer IgG. The result indicated decreased intensity of free 
antigen (peroxynitrite-modified HSA) due to its more and more involvement in the 
formation of high molecular weight species. Moreover, the isolated HSA from the 
blood of cancer patients showed enhanced binding to the experimentally induced anti-
peroxynitrite-modified HSA IgG, indicating towards the contribution of neo-epitopes 
in the generation of autoantibodies in cancer patients. In contrast to this, we observed 
less binding of HSA isolated from healthy individuals to anti-peroxynitrite-modified 
HSA IgG. Appreciably higher binding of in vitro modified HSA and HSA isolated 
from cancer patients with experimentally induced anti-peroxynitrite-modified HSA 
IgG is pointing towards the possible indication of epitope sharing between in vitro 
peroxynitrite-modified HSA and the HSA isolated from the cancer patients. It can be 
said here that exposure of HSA to peroxynitrite in vivo creates neo-epitopes on HSA 
that are recognized as non-self by the immune system and hence, an antigen for 
autoantibody production in cancer patients. 
Conclusion 
Human serum albumin is one of the most important plasma proteins with multiple 
functions in human body. Therefore, its structural stability becomes the main factor to 
carry out all its functions properly. The results clearly demonstrate that in vitro 
modification of HSA with peroxynitrite brings about biophysical and biochemical 
alterations in this protein, which was confirmed by the generation of highly specific 
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antibodies in experimental animal. Antibodies against modified/damaged HSA have 
been reported in various diseases like diabetes mellitus, systemic lupus erythernatosus 
(SLE), etc. The results suggest that structurally perturbed HSA exhibits neo-epitopes 
which are not ordinarily present on the native molecule. It is proposed that these 
epitopes project the physiologic protein as `alien' for the immune system leading to 
antibody generation in various diseases. The present study revealed greater binding of 
circulating cancer autoantibodies with peroxynitrite-modified HSA, compared to its 
native form, indicating that peroxynitrite induced modifications in HSA molecule Iead 
to structural loss and generation of neo-epitopes on the protein. These neo-epitopes 
made this protein antigenic, due to the fact that 'self proteins become 
immunologically vigorous if their structure is distorted. Such altered immunogens 
might be responsible for autoimmune response by exciting T cells (especially Thl 
cells) and inducing a speedy autoantibody response in the body. In the same manner 
autoantibodies may be produced in cancer patients against peroxynitrite-modified 
HSA. Furthermore, drop in the antioxidant property of the HSA molecule, as 
indicated by the free radical induced hemolysis test, confirms that not only the 
structural loss but functional alterations too occur when the native HSA is exposed to 
the damaging effects of peroxynitrite. It is also proposed that reduction in the 
antioxidant property of peroxynitrite-modified HSA greatly hampers the physiological 
concentration of the unaltered native HSA which in turn leads to a decrease in the 
overall antioxidant level of the blood plasma. As HSA represents major and 
predominant circulating antioxidant in plasma, a decline in this function may allow 
different free radicals to easily damage other important biomolecules of the system, 
like DNA and some other proteins, and hence affects the onset/progression to cancer. 
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1. Introduction 
A major and aggressive reaction of nitric oxide (NO•) is with 
superoxide anion (Oz~) to form peroxynitrite (ONOO-) which has 
a physiological half-life of approximately 1 s, as it decomposes 
spontaneously to give nitrate [ii. 
Of- +N0'-+ ON00-  
The possible biological significance of this reaction was first 
realized by Beckman and co-workers who pointed out that per-
oxynitrite may be formed under pathophysiological conditions, 
where both NOS  and 0f are produced at high rates by phagocytic 
cells such as macrophages, and that ONOO-  is a potent oxidant 
with the potential to destroy critical cellular components [2]. Per- 
oxynitrite can alter a variety of biomolecules but possesses high 
affinity for tyrosine residues in proteins, and 3-nitrotyrosine is 
a relatively specific marker of peroxynitrite-mediated damage to 
proteins [3]. Reaction of peroxynitrite with tyrosine residues is a 
covalent modification that results in attachment of a nitro (—NO2) 
group on the aromatic ring of tyrosine residues [4]. Nitrotyrosine 
formation is considered as a marker of nitrosative stress. More 
than 60 human disorders are now known to be associated with 
protein nitration. Indeed, the formation of protein 3-nitrotyrosine 
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in vivo has been shown in a number of inflammatory conditions 
in human and experimental animals [5]. Peroxynitrite also causes 
oxidation of sulfhydryls [6]. Being an oxidizing agent, peroxyni-
trite also causes protein oxidation; the most prominent marker 
of protein oxidation is increase in the carbonyl content of pro-
teins which is the outcome of oxidative modifications of the side 
chains oflysine, proline, arginine and threonine [7]. Increase in pro-
tein carbonyls has been observed in many diseases like diabetes, 
Alzheimer's, systemic lupus erythematosus, rheumatoid arthritis, 
sepsis, chronic renal failure, cancer, etc. [8]. Local pH and microen-
vironment affect the reactions of peroxynitrite, with hydrophobic 
membrane compartments favouring nitration and aqueous envi-
ronments favouring oxidation. 
Human serum albumin (HSA) is the most abundant protein 
found in human plasma. It is a heart-shaped single polypeptide of 
66 kDa. It has 585 amino acid residues with eighteen tyrosines, six 
methionines, one tryptophan, seventeen disulfide bridges and only 
one free cysteine (Cys34). HSA carries out several clearly defined 
physiological functions like maintenance of colloidal osmotic pres-
sure, free radical scavenging, binding and transport of important 
solutes, etc. [9]. Several studies have shown that HSA is quite 
vulnerable to modification by reactive oxygen species and an ele-
vated level of oxidized albumin is found in various diseases [10]. It 
has been shown that peroxynitrite preferentially reacts with the 
cysteine residue of HSA and causes thiol oxidation ]11]. HSA is 
continuously exposed to oxidative stress conditions due to its abun-
dance in the plasma, leading to the conformational and functional 
alterations of the protein molecule. The altered HSA may con-
tribute to the progression of many diseases. In the present study, 
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we have investigated the quantitative and qualitative changes in 
the structure of HSA upon reaction with peroxynitrite causing the 
generation of neo-epitopes in protein which in turn induce the 
production of highly specific antibodies in experimental animals. 
2. Materials and methods 
2.1. Chemicals 
Human serum albumin, 3-nitrotyrosine. sodium nitrite, 1-
anilinonaphthalene-8-sulphonic (ANS) acid, tyrosine, tryptophan, 
phenylalanine. protein A-agarose affinity column, p-nitrophenyl 
phosphate, Tween-20. Freund's complete and incomplete adju-
vants. and 2,4-dinitrophenyl hydrazine (DNPH) were obtained 
from Sigma-Aldrich (St. Louis. MO). Hydrogen peroxide, sodium 
hydroxide, silver nitrate and guanidine hydrochloride were from 
Qualigens (Mumbai, India). Flat bottom polysorp ELISA modules 
were purchased from NUNC, Denmark. All other reagents were of 
the highest analytical grade available. 
2.2. Peroxynitrite-modlhcatian of HSA 
Peroxynitrite was synthesized by rapid quenched flow process 
using sodium nitrite and acidified hydrogen peroxide [12] and 
stored in 1.2 M NaOH at —20 C. Before each use, concentration of 
stored peroxynitrite was determined from absorbance at 302 nm 
using molar extinction coefficient of 1670M' cm-1. HSA, at a 
concentration of 5 p.M in phosphate buffered saline (PBS) (10 mM 
sodium phosphate buffer. 150mM NaCI, pH 7.4), was incubated 
with 60. 125. 250. 500 and 750µM peroxynitrite at 37oC for 3 h. 
The reaction volume was made up to 3 ml with PBS. After incuba-
tion, the solutions were extensively dialyzed against PBS to remove 
excess peroxynitrite. To maintain the same condition for the con-
trol, unmodified HSA was also dialyzed in the same manner. The 
HSA concentration in both the cases was determined spectrophoto-
metrically using a molar extinction coefficient of 35,219 M-1 cm-1  
at 280 nm [13]. 
2.3. Absorbance spectroscopy 
The absorption profiles of native and peroxynitrite-modified 
samples were recorded on Shirnadzu UV-1 700 spectrophotometer 
in the 200-400 nm wavelength range. 
2.4. Electrophoresis 
Native and peroxynitrite-modified HSA were analyzed by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) under non-reducing conditions on a 10% polyac-
rylamide gel, as described previously [14]. Electrophoresis was 
performed at 80V for 4h at room temperature and the protein 
bands in the gel were visualized by silver staining. 
2.5. Fluorescence studies 
Fluorescence spectra were recorded on Hitachi F-200 spec-
trofluorimeter at 25±0.1 C. Fluorescence of tyrosine residues in 
native and peroxynitrite-modified HSA was monitored after exci-
tation at 275 nm and recording the emission in the 300-400 nm 
range. Loss in fluorescence intensity (FI) was calculated from the 
following equation: 
% loss of Fl — (Flnative sample — Flmodifed sample 1 x 100 
Flnative sample 	J  
2.6. Effective protein hydrophobicity 
Binding of ANS to native and peroxynitrite-modified HSA was 
evaluated in terms of fluorescence. The ANS fluorescence is affected 
by exposure or masking of hydrophobic patches in proteins. A 
fresh stock solution of ANS was prepared in distilled water and 
its concentration was determined spectrophotometrically using 
a molar extinction coefficient of 5000M-1  cm-' at 350nm [15]. 
The molar ratio of protein and ANS was 1:10 and emission spec-
tra were recorded in the range of 400-600 nm using an excitation 
wavelength of 380 nm. Decrease in fluorescence intensity (FI) was 
calculated as follows: 
% loss of Fl — f Ff native sample — Flmodified sample } x 100 
4\ 	Flnativesample 	J 
2.7. Estimation of diryrosine 
The dityrosine content of peroxynitrite-modified HSA was 
determined spectrophotometrically using a molar extinction coef-
ficient of 4000 M-1  cm' at 330 nm [16]. Dityrosine formation was 
also confirmed by fluorescence spectra after excitation of native 
and peroxynitrite-modi fled HSA at330 nm and measuring emission 
in the 350-450 nm range. 
2.8. Nitrotyrosine determination 
The concentration of nitrotyrosine in peroxynitrite-modified 
HSA was determined by measuring the absorbance at 420 nm using 
a molar extinction coefficient of 4300 M-1  cm 1 [17]. 
2.9. Determination of protein-bound carbonyl groups 
Carbonyl content of native and peroxynitrite-modified HSA was 
determined after reaction with DNPH [18]. The final absorbance 
was read at 360 nm against appropriate blank. The carbonyl 
content was determined using a molar extinction coefficient of 
22,000 M-1  cm-1  and expressed as nmol/mg protein. 
2,10. Circular dichroism 
CD measurements were carried out on a Jasco spectropo-
larimeter Q-815) equipped with a jasco Peltier-type temperature 
controller (PTC-4245/15). The instrument was calibrated with D-
10-camphorsulphonic acid. Spectra were taken in a cell of 1 and 
10 mm path length and protein concentrations used were 4.5 and 
12 µM for far and near-UV CD. respectively. The results were 
expressed as mean residue ellipticity (MRE) in degcm2 dmol-t 
which is defined as: 
MRE — Oobs(m deg) 
1OxnxCxl 
where Bobs  is the CD in milli-degree, n is the number of amino acid 
residues (585 —1 = 584),1 is the path length of the cell, and C is the 
concentration of protein in moles/litre. Helical content was calcu-
lated from the MRE values at 222 nm using the following equation 
[19]: 
MRE222 nm — 2340 % ct-helix- 
- ( 	30,300 	x 100  
2.11. FT.R spectroscopy 
Native and peroxynitrite-modified HSA samples were first 
lyophilized and prepared as KBr pellets and then subjected to spec-
tral recording on a Tensor 37 FTIR spectrometer (Bruker). 
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2.12. ltnmunization schedule 
White New Zealand female rabbits were immunized with 
native and peroxynitrite-modified HSA as described previously 
1201. Briefly, rabbits (n = 4: two each for native and peroxynitrite-
modified HSA) were immunized intramuscularly at multiple sites 
with 100 p.g of antigen emulsified with an equal volume of Fre-
und's complete adjuvant. The booster doses were administered in 
Freund's incomplete adjuvant at weekly intervals for 6 weeks with 
the same amount of antigen. Test bleeds, performed 7 days post 
boost, gave significant antibody titre. The sera were heated at 56' C 
for 30 min to inactivate complement proteins and stored at -20°C 
with 0.1% sodium azide as preservative. This study had clearance 
from bioethical committee of the institution, 
2.13. Protein A-agarose affinity chromatography 
lgG from rabbit sera was isolated by affinity chromatography on 
Protein A-agarose affinity column 121]. Protein-A (from Staphylo-
coccus aureus) binds to lgG from most mammalian species through 
unique histidine residues present in F. region of the molecule. 
The column was pre-equilibrated with PBS and 0.3 ml serum was 
applied on it. The wash through was recycled 2-3 times and 
unbound material was removed by extensive washing with PBS. 
The bound lgG was eluted with 0.58% (v/v) acetic acid in 0.85% 
(wfv) sodium chloride and collected in tubes containing 1.0 ml of 
1.0 M Tris-HC!. pH 8.5. Three ml fractions were collected and their 
absorbance was read at 278 nm. The IgG concentration was deter-
mined considering 1.4 0D273 =1.0 mg lgG/ml. The homogeneity of 
isolated lgC was checked on 10% SDS-PAGE. The isolated IgG was 
dialyzed against PBS and stored at -20 C with 0.1% sodium azide. 
2.14. Enzyme linked immunosorbent assay 
ELISA was performed on flat bottom polystyrene plates as 
described earlier [22]. Polystyrene PolySorp immunoplates with 96 
wells were coated with 100 p.l of native or peroxynitrite-modified 
HSA(10 µgjrnl) in antigen coatingbuffer.The plates were incubated 
for 2 h at 37°C and overnight at 4°C. Each sample was assayed in 
duplicate and half of the plate, devoid of antigen coating, served as 
control. The wells of the test plates were washed three times with 
TBS-T (20 mM Tris, 2.68 mM KCI, 150 mM NaCl. pH 7.4, containing 
0.05% Tween-20) and unoccupied sites were blocked with 150 Al 
of 1.5-2.5% fat-free skimmed milk in TBS (10 mM Tris, 150 mM 
NaCI, pH 7.4) for 4-6h at 37°C. After incubation, the plates were 
washed 5-6 times with TBS-T. Test serum, serially diluted in TBS-
T, was added to each well (100 µl/well) and reincubated for 2 h at 
37C and then overnight at 4°C. After incubation, the plates were 
washed three times with TBS-T and bound antibodies were assayed 
with anti-rabbit alkaline phosphatase conjugate in TBS. After 2 h 
incubation, the plates were again washed three times with TBS-T 
and twice with distilled water and then coated with p-nitrophenyl 
phosphate (substrate). Absorbance (A) in each well was monitored 
at 405 nm on an automatic microplate reader. Each sample was run 
in duplicate. Results were expressed as mean of Atest -Acontro1. 
2.15. Competition ELISA 
The antigenic specificity of antibodies was determined by com-
petition ELISA [23]. The plates were coated with 100µ1 of antigen 
(native or peroxynitrite-modified HSA. 10 Ag/ml) for 2h at 37°C 
and overnight at 4°C. Varying amounts of inhibitors (0-20 Ag/ml) 
were mixed with a constant amount of antiserum or affinity puri-
fied lgG. The mixtures were incubated at 37°C for 2 h and overnight 
at 4°C. The immune complex thus formed was coated in the wells 
instead of serum. The remaining steps were the same as mentioned  
above in direct binding ELISA. Percent inhibition was calculated 
using the equation: 
Percent inhibition = 1 - ( r Ainhibited ' x 100 Auninhited f 
2.16. Band shift assay 
Band shift assay was performed for the visual detection of 
antigen-antibody interaction and immune complex formation [24]. 
Immune complex was prepared by incubating constant amount 
of native or peroxynitrite-modified HSA with varying amounts of 
affinity purified anti-peroxynitrite-modified HSA IgG in PBS for 
2h at 37°C and overnight at 4°C. The samples were then elec-
trophoresed on 10% SDS-PAGE for 4 hat 80 V and the protein bands 
were visualized by silver staining. 
2.17. Statistical analysis 
Data are presented as mean ± standard deviation (SD). Statisti-
cal significance of data was determined by Student's t test and a p 
value of <0.05 was considered as significant. 
3. Results and discussion 
During oxidative burst triggered by inflammation, the cells of 
immunoregulatory network produce both nitric oxide and super-
oxide. These two free radicals can combine to produce peroxynitrite 
which causes nitration of tyrosine residues and oxidation of pro-
teins. Tyrosine nitration can profoundly alter protein function 
indicating that this reaction maybe fundamentally related to oxida-
tive cell injury. Therefore, it is a subject of great interest to study 
tyrosine nitration of HSA because formation of 3-nitrotyrosine 
in vivo in various pathological conditions has been well established 
[25] and it is for this reason that 3-nitrotyrosine is considered to 
be a relatively specific marker of nitrosative damage mediated by 
peroxynitrite. In addition to nitration, peroxynitrite is also a potent 
oxidizing agent and can oxidize a variety of biomolecules includ-
ing proteins. Many studies have shown the potent role of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) in var-
ious human diseases including cancer development [26] which 
can be delayed/prevented by the use of anti-oxidants [27]. HSA 
is continuously exposed to oxidative stress, which can alter the 
conformation and function of this molecule, resulting in modifi-
cation of its biological properties and hence its contribution to 
the progression to different diseases. Therefore, characterization of 
peroxynitrite induced structural and immunological modification 
in HSA assumes significance. 
3.1. Physicochemical characterization of peroxynitrite-modified 
NSA 
Native HSA showed an absorbance peak at 278nm which 
exhibited hyperchromicities upon modification by different con-
centrations of peroxynitrite (Fig. 1). Repeated experiments 
exhibited little difference between the hyperchromicities induced 
by 500 and 750 AM peroxynitrite. Therefore, HSA modified with 
500 p.M peroxynitrite was used in further studies. Hyperchromic-
ities at 278nm could be attributed to peroxynitrite-induced 
denaturation due to oxidation and nitration of native HSA. The 
absorbance profile of peroxynitrite-modified HSA also showed 
peak at 420 nm, which is a characteristic of 3-nitrotyrosine (inset). 
Furthermore, the generation of yellow colour in samples of 
peroxynitrite-modified HSA (with absorption peak at 420 nm) also 
reflects the formation of nitrotyrosine. The nitrotyrosine content 
in modified HSA was calculated to be 29.6±2.3 nmol/mg protein. 
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Fig. 1. Absorbance spectra of native HSA (-r-) and HSA modified by 60 µM (-A-). 
125 µM (-I-), 250pM (-0-), 500µM•{-a-) and 750µM (-0-) peroxynitrite. Inset 
shows absorbance profile of standard 3-nitrotyrosine. The spectra are the average 
of three determinations. 
It is quite clear from the results that peroxynitrite-modification 
caused concentration dependent generation of nitrotyrosine and 
consequent alteration in the native structure of HSA. 
Native and peroxynitrite-modified HSA was subjected to non-
reducing polyacrylamide gel electrophoresis under denaturing 
conditions (Fig. 2). Native HSA moved as compact single band 
while HSA, modified with increasing concentrations of peroxy-
nitrite, showed thickening of bands as compared to the native 
protein. HSA modified with 500µM peroxynitrite (Fig. 2, lane 5) 
showed maximum band width. It is quite clear that peroxyni-
trite induced modification (nitration and oxidation) has produced 
significant structural changes in HSA. The gradual thickening of 
bands, as compared to the native HSA, may be due to the intra-
molecular cross-linking in the modified protein, which might lead 
to abnormal migration of the protein molecules. The cross-linking 
may be formed due to the interactions of one tyrosyl radical 
with another tyrosyl radical, generating 4,0'-dityrosine covalent 
2 	3 	4 	5 
Fig. 2. SDS-polyacrylamide gel electrophoresis of HSA under non-reducing con-
ditions. Protein samples (10p.g in each lane) were loaded on gel. Electrophoresis 
was performed an 10%5D5-PAGE for 4 hat 80 V. Lanes: (I) native HSA: (2-5) HSA 
modified wirh 60. 125.250 and 500 µM peroxynitrite. 
cross-links [28]. Cross-linking and oligonierization have also been 
reported during nitration of several other proteins [29]. 
The formation of dityrosine was confirmed from fluorescence 
spectra obtained when the samples were excited at 330nm. A 
prominent emission peak at 401 nm in case of peroxynitrite-
modified HSA was seen which was completely absent in the native 
protein (Fig. 3A). The dityrosine concentration of peroxynitrite-
modified HSA was found to be 112.7 ± 3.1 nmol/mg protein. This 
result, along with the SDS-PAGE analysis, confirmed the formation 
of0,0'-dityrosine upon peroxynitrite modification ofHSA.This may 
be the reaction of one tyrosyl radical generated by peroxynitrite 
with another tyrosyl radical of HSA molecule [16]. 
Peroxynitrite-modified HSA showed 79% loss in fluorescence 
intensity and a blue shift of 34nm as compared to its native form 
when excited at 275 nm (Fig. 36). The loss could be ascribed to the 
destruction oftyrosine residues and/or modification of the tyrosine 
micro-environment upon peroxynitrite modification. 
The conformational changes in HSA and measurement of its 
hydrophobic surface accessibility were studied by ANS binding 
experiment. ANS is an extrinsic probe which can bind to apolar 
sites on proteins. It gives high fluorescence emission upon binding 
to hydrophobic regions, but does not fluoresce when present free 
in solution or in denatured protein solution [30[. Compared to the 
native protein, peroxynitrite-modified HSA showed 88.2% loss in 
Fluorescence intensity indicating that native HSA possesses a num-
ber of hydrophobic patches on its surface which were disrupted 
upon treatment with peroxynitrite (Fig. 3C). The peroxynitrite 
induced structural perturbations in HSA molecule led to the loss 
of ANS binding sites [311. 
Carbonyl content is the most commonly used marker of pro-
tein oxidation and its accumulation has been observed in many 
human diseases [32]. The typical markers of protein oxidation are 
carbonyls of lysine. arginine, threonine and proline residues which 
are detected after their derivatization with 2,4-dinitrophenyl 
hydrazine. The reaction forms a stable 2,4-dinitrophenyl hydrazone 
which is measured spectrophotometrically at 360 nm.The carbonyl 
contents of native and peroxynitrite-modified HSA were found to 
be 3.1 ± 0.4 and 20.24 1.2 nmol/mg protein, respectively (Fig. 4). 
This corresponds to almost seven fold increase in carbonyl level 
as compared to native HSA. The result suggests that peroxynitrite 
induced oxidation of HSA may be responsible for alterations in its 
structural and biological properties. 
The secondary structure of HSA was monitored by far-UV CD 
experiment which showed a decrease in percent helicity of HSA 
upon peroxynitrite modification. The CD spectra of HSA exhibited 
two minima, at208 and222 nm, which is typical fora-helical struc-
ture (Fig. 5A). The a-helix content was 64% in native HSA and 45% 
in peroxynitrite-modified HSA. This change in secondary structure 
shows that HSA undergoes conformational changes in the presence 
of peroxynitrite. 
The tertiary structure of proteins is inferred by near-UV CD spec-
tra which are sensitive to the environment of aromatic side chains 
[33]. The native HSA showed a peak at around 275 nm, which is spe-
cific for tyrosine residues. However, this peak was less pronounced 
in peroxynitrite-modified HSA (Fig. 5B) which shows that tyrosine 
residue(s) is/are modified by peroxynitrite. The above modification 
in tyrosine residue(s) might be responsible in altering the tertiary 
structure of HSA and hence, may cause alterations in its physiolog-
ical functions. 
The changes in the secondary structure ofHSA were further con 
firmed by FTIR. in which bands originating due to amide I and amid 
11 vibrations were analyzed. The amide I band, which arises due t 
C=0 stretching, is particularly important in the secondary structur 
studies [34]. Upon peroxynitrite modification of HSA, the amid 
I band was shifted from 1656 to 1638 cm-1 while a shoulder c 
amide II band, which arises due to CN stretching and NH bendin: 
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Fig. 3. Fluorescence emission spectra of native (-A-) and peroxynitnte-modified 
HSA (-n-) at different excitation wavelengths: (A) at 330 nm for dityrosine. (0) at 
275 nm for tyrosine, and (C) at 380nm for ANS binding to native and peroxynitrite-
modified HSA. The spectra are the average of three determinations. 
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Fig. 4. Carbonyl content of native and peroxynitrite-modified HSA. The bars show 
average carbonyl content (1-51)) of three independent assays. 
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shifted from 1553 to 1546 cm 1  (Fig. 6). It is clear from these results 	
Wavelength (nm) 
that amide I is more sensitive than amide 11 towards peroxynitrite 	Fig. 5. Far-UV (A) and near-UV (B) CD spectra of native (-i-) and peroxynitrite- 
modification. The observed shifting in amide I and amide 11 bands 	modified HSA (-o-). The spectra are the average of three determinations. 
is a clear proof of secondary structure perturbation and fully sup-
ports the observations of far-UV CD spectra. The characterization 
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Fig. 6. FTMR spectra of (A) native and (8) peroxynitrite-modified HSA. The spectra 
are the average of three determinations. 
of native and peroxynitrite-modified HSA has been summarized in 
Table i. 
3.2. Immunogenicity of native and peroxynitrite-modified HSA 
The immunogenicity of peroxynitrite-modified HSA was evalu-
ated by inducing antibodies in female rabbits. The direct binding 
ELISA result showed antibody titre of >1:12,800 (Fig. 7B) as com-
pared to <1:6400 titre obtained in the case of native HSA (Fig. 7A), 
Table 7 
Characterization of native and peroxynitrile-modified HSA. 
Parameters 	 Native HSA Peroxynitrite-modified 
HSA 
Absorbance (at 278 nm) 0.164 0.235 
Fluorescence intensity. Fl 114.77 22.25 
°(x,R -275) 
ANS-binding, Fl 107.84 12.75 
-380) 
Carbonyl content (nmol/mgprotein) 3.1±0.4 20.24±1.2b 
Nitrotyrosine conc. (nmolfmgprotein) - 29.6±2.3° 
Dityrosine cone. (nmol/mgprotein) - 112.73.1` 
Far-UV CD 
dMRE222nm -21,606 -15.971 
°n-Helix(%) 64 45 
Near-UV CD 
dMRE275nm -1263 -1072 
Fu R. peak positions 
(Amide t, cm-1) 1656 1638 
(Amide II, cm-1) 1553 1546 
A: excitation wavelength. 
e p<0.001 versus native HSA. 
~ p<0.001. 
d M1tE value in degcm2 dinol-'. 
a-Helix (%) calculated by Chen et al. method.  
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Fig. 7. Level of induced antibodies against native and peroxynitrite-modified HSP 
Direct binding EUSA of (A) native HSA and (B) peroxynitrite-modified HSA wit 
pre-immune (-a-) and immune (-o-) sera. Microtitre plates were coated with th 
respective antigens (10 sgJml). 
This clearly indicates that peroxynitrite modification of HSA ha. 
made the protein an even more potent immunogen which migh 
be due to the generation of neo-epitopes on the protein molecule 
Preimmune serum when used as control showed negligible bindini 
with either immunogen under identical experimental conditions 
The induced anti-peroxynitrite-modified HSA antibodies were alsi 
examined for their binding to denatured HSA to check the speci 
ficity of these antibodies towards HSA structure. Very weakbindinj 
of these antibodies to denatured HSA confirmed their specificit, 
towards the tertiary structure of protein (data not shown). 
IgG were purified from preimmune and immune rabbit antis, 
era of native and peroxynitrite-modified HSA by Protein A-agarost 
affinity chromatography. The purified lgG eluted as a single sym 
metrical peak and its purity was confirmed by the presence of 
single homogeneous band by SDS-PAGE under non-reducing con 
ditions (data not shown). Anti-p eroxynitrite-modified-HSA IgG an 
anti-native-HSA IgG showed strong binding with their respective 
immunogens as determined by direct binding ELISA. However, pre. 
immune IgG showed negligible binding under identical condition: 
(data not shown). 
Competitive inhibition ELISA was done to detect the specificit! 
of experimentally produced antibodies against peroxynitrite 
modified HSA. An inhibition of 55.3% was observed when nativ+ 
HSA was used as inhibitor of anti-peroxynitrite-modified-HSA 1gC 
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Fig.8. Inhibition ELISA ofanti-peroxynitrite-modified-HSA IgG.The inhibitors were 
native HSA (-A-) and peroxynitrite-modified HSA (-A-). Microtitre plates were 
coated with peroxynitrite-modified HSA (10 sg/ml). 
while it was 83.2% when peroxynitrite-modified HSA was used 
as inhibitor (Fig. 8). Fifty percent inhibition was achieved at an 
inhibitor (peroxynitrite-modified HSA) concentration of 3.9.Lg/ml. 
The enhanced immunogenicity of HSA after peroxynitrite modi-
fication is probably the result of the generation of neo-epitopes 
on HSA molecule consequent to modification. The generation of 
these neo-epitopes might be the result of nitration and oxidation 
of HSA. Therefore, it appears that two types of antibodies were 
induced; one recognizes neo-epitopes while the other recognizes 
old epitopes. l urthermore, cross-reactivity of anti-peroxynitrite-
modified-HSA IgG with different inhibitors was checked to confirm 
that the induced antibodies were highly specific for peroxynitrite-
modified HSA. Results of cross-reactivity with different inhibitors 
have been summarized in Table 2. 
Band shift assay was performed to visualize the speci-
ficity of antibodies and to confirm the interaction of native 
and peroxynitrite-modified HSA with the isolated IgG. The 
antigen-antibody complexes were prepared by incubating a con-
stant amount of native and peroxynitrite-inodified HSA with 
increasing concentrations of anti-peroxynitrite-modified-HSA lgG 
and then electrophoresing these immune complexes on 10% 
SDS-PAGE. The gel pattern showed that with increasing amount 
of anti-peroxynitrite-modified-HSA IgG, there was corresponding 
increase in the formation of high molecular mass immune com-
plexes (Fig. 9). The free antigen intensity was decreased showing 
its greater involvement in the formation of immune complexes. 
However, there was slight shifting in the mobility when native HSA 
was used instead of peroxynitrite-modified HSA under identical 
Table 2 
Cross-reaction of anti-peroxynitrite-modified-HSA IgG with different inhibitors. 
Inhibitors 	 % Inhibition,,,u at 20 vglml 
Peroxynitrite-modified HSA 83.2 
Native HSA 553 
Peroxynitrite-modi fled lgG 64.4 
Native I6G 42.3 
Peroxynitrite-modified H2A histone 59.4 
Native H2A histone 37.2 
Peroxynitrite-modified tyrosine 65 
Native tyrosine 32.6 
Peroxynitrite-modified tryptophan 34A 
Native tryptophan 17 
Peroxynitrite-modified phenylalanine 22.6 
Native phenylalanine 15.2 
Fig.9. Band shift assayofanti-peroxynitrite-modified-HSAIgGbindingto(A) native 
HSA and (B) peroxynitrite-modified HSA. Electrophoresis was performed on 10% 
SOS-PAGE for 4 h at 80V. (A) Native HSA (10µg) was incubated with 0,10, 20.30. 
40 and 50µg anti-peroxynitrite-modified-HSA IgG. respectively (lanes 1-6) for 2 h 
at 37-C and overnight at4 C. (B) Peroxynirrite-modified H5A (I Ogg) was incubated 
with 0. 10. 20, 30.40 and 50 .rg anti-peroxynitrite-modified-HSA JgG respectively 
(lanes 1-6) under identical cnnditinns. 
experimental conditions. These results indicate that while native 
HSA binds to the anti-peroxynitrite-modified-HSA lgG to some 
extent due to the presence of old epitopes. the binding is more 
prominent with modified protein. This shows that modified HSA 
has got both the epitopes, i.e., old and neo-epitopes formed by 
peroxynitrite modification. This confirms the specificity of anti-
peroxynitrite-modified-HSA IgG. 
Since HSA is one of the most important plasma proteins with 
multiple functions, therefore, its structural stability becomes the 
main factor to carry out all its functions properly. Our results clearly 
demonstrate that in vitro modification of HSA with peroxynitrite 
brings about biophysical and biochemical alterations in the protein, 
which was confirmed by the generation of highly specific antibod-
ies in experimental animal. Antibodies against modified/damaged 
HSA have been reported in various diseases like diabetes mel-
litus, systemic lupus erythematosus (SLE), cancer, etc. [35,36). 
Our results suggest that structurally perturbed HSA exhibits neo-
epitopes which are not ordinarily present on the native molecule. 
We propose that these epitopes project the physiologic protein as 
.alien' for the immune system leading to antibody generation in 
various diseases. 
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